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Abstract
High throughput screening technologies have generated a huge amount of biological data
in the last ten years. With the easy availability of array technology, researchers started to
investigate biological mechanisms using experiments with more sophisticated designs that
pose novel challenges to statistical analysis. We provide theory for robust statistical tests in
three flexible models. In the first model, we consider the hypothesis testing problems when
there are a large number of variables observed repeatedly over time. A potential application
is in tumor genomics where an array comparative genome hybridization (aCGH) study will
be used to detect progressive DNA copy number changes in tumor development. In the
second model, we consider hypothesis testing theory in a longitudinal microarray study
when there are multiple treatments or experimental conditions. The tests developed can be
used to detect treatment effects for a large group of genes and discover genes that respond to
treatment over time. In the third model, we address a hypothesis testing problem that could
arise when array data from different sources are to be integrated. We perform statistical tests
by assuming a nested design. In all models, robust test statistics were constructed based on
moment methods allowing unbalanced design and arbitrary heteroscedasticity. The limiting
distributions were derived under the nonclassical setting when the number of probes is large.
The test statistics are not targeted at a single probe. Instead, we are interested in testing
for a selected set of probes simultaneously. Simulation studies were carried out to compare
the proposed methods with some traditional tests using linear mixed-effects models and
generalized estimating equations. Interesting results obtained with the proposed theory in
two cancer genomic studies suggest that the new methods are promising for a wide range
of biological applications with longitudinal arrays.
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Chapter 1
Introduction and motivation
Advances in high through-put technologies have shifted the focus of scientists from mRNA
arrays with known genes to DNA arrays that can scan the entire genome of an organism.
This also enabled the transition from study of individual genes to examination of regions
of a chromosome. One of such techniques is array Comparative Genomic Hybridization
(aCGH), in which the whole genome DNA information of an organism can be scanned onto
a chip with high resolution. The unit on the chip is referred as a probe. A probe can contain
mutations such as a singular nucleotide polymorphism (SNP), or contain a long sequence
of DNA such as BAC clone. There may be multiple probes for a single gene. Though the
goals of their specific biological investigations may be different, biologists all need statistical
tools to identify DNA segments or regions that exhibit differences for the sample of interest
compared with a reference sample. Some examples are identification of DNA regions that
show DNA copy number variations for disease versus normal sample, searching for enriched
DNA fragments using microarray intensity from chromatin immunoprecipitation (ChIP-
chip) to find transcription factor (TF)-binding sites.
Currently, many statistical methods have been used to identify the regions of aberration
when the signal intensities on different chips are from independent samples. These include
hidden Markov models (Fridlyand et al. 2004; Li et al. 2005; Du et al. 2006), change
point analysis (Olshen et al. 2004), local smoothing (Hupe et al. 2004; Zheng et al. 2007),
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Bayesian maximum a posteriori probabilities (Daruwala et al. 2004), hierarchical clustering
(Wang et al. 2005), regression (Reiss et al. 2007), EM algorithm based edge filtering (Myers
et al. 2004) and Bayesian hierarchical model (Gottardo et al. 2008). Most of these methods
assume independence or Gaussian distribution with piecewise constant variance for the (log
ratio of) intensities of the probes. Even though such assumptions in distribution can simplify
the modeling, they may be unrealistic for the complex DNA genomic data and therefore
the accuracy of these methods in practice can be a problem. For example, Lai et al. (2005)
compared several methods and found that hidden Markov models did not detect any of the
three amplified regions in a glioma aCGH data even though they detected smaller regions
in their simulated data. On the other hand, the EM algorithm based edge filtering method
(Myers et al. 2004) found all three regions in the glioma data to be significant but did not
detect the presence of aberrations in their simulated data.
Though many methods are available for independent samples, there are rarely any publi-
cations providing methods for identification of the event regions when the experiments have
longitudinal aCGH arrays. Recently, research with aCGH arrays for multiple time points
have been under development to study the genetic basis of cell development and tumor
progression. In these studies, the dynamic behavior of genomic DNA is monitored through
multiple chips at different cell growth stages. For instance, time course aCGH studies of in
vivo lymphoma and leukemia as well as in vitro tumor cell lines are under investigation for
progressive DNA copy number changes in Abbott Laboratories. The examples below justify
the significance of methods for longitudinal study using aCGH data.
Example. About 15% of children with Wilms tumor suffer from relapse with nearly half
dying of their disease despite aggressive second line treatment regimens. To determine the
molecular genetic changes associated with the progression or relapse of Wilms tumor, aCGHs
were obtained on ten patients at initial diagnosis and recurrence (Natrajan et al. 2007).
Using real-time reverse-transcription polymerase chain reaction (RT-PCR), the authors ob-
served the acquisition of a number of additional molecular alterations between the time of
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diagnosis and subsequent relapse, such as a small deletion at 14q12 in four cases, loss of the
entire X chromosome, and gain of the whole of 15q and chromosome 5. Unfortunately, the
paired t-test they applied did not find any significant recurrent changes in copy number after
correction for multiple testing. There were, however, acquired alterations which occurred
in more than one relapsed tumor including gain of 5p, 8p12, 15q, 16p, and 20q, as well as
the loss of 17p between the time of diagnosis and subsequent relapse. This example makes
it clear that methods for detection of event regions using longitudinal aCGH arrays remain
to be an important topic to be investigated.
Additional examples can be seen from the research of members in the K-State Ecological
Genomics Institute who study how organisms respond to changing environments over long
and shorter evolutionary time scales. These include microarray experiments done to study
the environmental stresses (such as drought and nitrogen changes) on big bluestem tall
grass; expression profiling to examine cellular and molecular responses of aquatic organisms
to various environmental stressors including pesticides, heavy metals, nutrients, and oxygen
depletion; cellular mechanisms of tomato plants in defensive response to a viral pathogen
(tomato spotted wilt virus) and an arthropod herbivore (two-spotted spider mite); genetic
responses of soil nematode to changes in soil chemistry caused by nitrogen addition and fire,
etc. With all these data produced that require matching statistical tools to decipher the
information from biological and pathological processes, statistical methodology for analysis
of longitudinal arrays needs to be developed.
The temporal component in the examples above is an inherent part of the study for
discovery of important genes or transcriptional activity over developmental stages. Repeated
measurements over time on the same subject induce correlations that need to taken into
account. Due to the high cost of array experiments, a large sample size assumption is
usually impractical. This, together with the high dimensionality, makes the likelihood based
optimal test procedures unmanageable or not applicable. See Wahba (1990), Brumback
and Rice (1998), Fan and Lin (1998), Huang and Lu (2000, 2001), and Wang (2002) for
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examples of innovative models for designs with high-dimensional data. While such models
have had considerable impact in theory and applications, their applications in genomic data
are hindered due to the distributional assumptions that are restrictive or can not be justified
with small sample sizes. For example, many of the models in aforementioned references
assume normality or require large sample sizes. But it has been established that such data
do not follow a normal distribution (Daruwala et al. 2004; Sidorov et al. 2002; Zhao et al.
2004). Therefore, these methods have limited application in genomic studies.
In many aCGH data, the disease sample and reference sample were hybridized on the
same chip. Then the ratio or log ratio of the intensities of the disease and reference samples
are used as the observations. In this case, no additional fixed factors are necessary in the
model. In other cases, additional fixed factors are necessary to account for the effect of
multiple experimental conditions. In this thesis, nonparametric models are developed for
longitudinal high dimensional data with or without additional fixed factors. Test procedures
for the common hypotheses of interest under each of the models based on original observa-
tions are then constructed. The asymptotic distributions of the test statistics are obtained
under the non-classical setting in which the number of variables is large while the number of
replicates is small. Simulation studies were conducted to evaluate the new test procedures.
Applications of the new theory on genomic data from cancer studies are presented. The
methods in this thesis are based on a general model set up that allows robust inference in
presence of temporal correlations for heteroscedastic high dimensional low sample size data.
They provide flexible tools for nonparametric hypothesis testing and can be applied by a
wide range of scientists to accelerate novel gene discovery such as identification of biomarkers
to control tumor progression, important genes in pest and plant/animal/human interactions,
crucial genes for plants, animals or human to acquire tolerance to environmental stresses,
etc.
The rest of the thesis is organized as follows. Chapter 2 is devoted to nonparametric tests
for high dimensional longitudinal arrays when no additional fixed factors are in the model.
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We will focus our discussion in the setting of time course aCGH study to detect DNA copy
number variations. Chapter 3 gives the testing procedures for longitudinal arrays when
multiple experimental conditions exist. Chapter 4 presents the theory for rank tests for
nested design in high dimensional data. Summaries and future research topics are described
in Chapter 5. A short introduction about Affymetrix SNP array technology and the R code
for the tests are given in Appendices.
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Chapter 2
Non-parametric tests for longitudinal
array CGH data
Tumor cells usually undergo dramatic chromosome changes resulting in gain or loss of DNA
copy numbers. High throughput technologies have made it possible to simultaneously exam-
ine DNA copy numbers at thousands or millions of sites of a genome. A time course array
study enables discovery of DNA copy number variation during tumor development. In this
chapter, we present robust new statistical tests for detecting the DNA regions with copy
number variation. Simulation studies show that the proposed methods are robust against
non-normality and have higher power than linear mixed-effects models (LME) and general-
ized estimating equations (GEE). The theory is applied to a longitudinal array study with
tumor samples collected from Wilms’ patients at both diagnosis and relapse.
2.1 Introduction
The complete genomic information is conveyed by twenty-three pairs of chromosomes in nor-
mal human tissue. Enormous efforts have been dedicated to investigating the association of
DNA copy number alterations with disease. For normal tissues, each DNA segment has two
copies. However, tumor cells undergo complicated pathological progression. Their DNA is
often subject to translocation, amplification, and deletion, which leads to DNA copy number
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abnormality (Fig. 2.1). DNA amplification may cause over-expression of the encoded genes,
and DNA deletion may cause under-expression of the genes. Tumor biomarkers have been
intensively investigated in both academy and pharmaceutical industry. They are potentially
to be used in various stages of clinical management decisions, such as risk assessment, diag-
nostic testing, prognostic stratification, and chemotherapy selection (Forozan et al. (2000)).
Chromosome alterations associated with tumor progression are promising biomarker can-
didates. With the encouragement of FDA, the DNA copy number signature of a cancer
patient is likely to eventually serve as a basis for considering personalized medicine/therapy.
Figure 2.1: Demography of human chromosome in normal and tumor cells. The left panel shows the
normal complete genome for a male, 22 pairs of autosomal chromosomes plus 2 sex chromosomes, X and
Y. Different chromosomes are drawn with distinct colors. The right panel shows the genome from a breast
cancer cell line. The colors display the rearrangement of chromosome segments from the normal cell to the
tumor cell.
The molecular-cytogenetic method used to detect DNA copy number changes is called
comparative genomic hybridization (CGH). Fluorescent in situ hybridization (FISH) and
quantitative PCR (qPCR) have been widely used to detect chromosome aberration. How-
ever, these traditional techniques are low in resolution, slow in production, and labor inten-
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sive. With the rapid advance of high throughput technology, array based technology has
been increasingly used in CGH research today (Pinkel and Albertson (2005a)). Array CGH
(aCGH) is a microarray-alike technique which detects hundreds of thousands of chromosome
sites simultaneously with specific DNA sequences (probes). CGH array detects chromosome
DNA copy number, whereas mRNA microarray detects the amount of messenger RNA.
In comparison, aCGH reflects genome features, and microarray represents gene expression.
Because RNA is a volatile macromolecule which has a very short half life cycle and DNA is
relatively stable, aCGH signal is much more stable than microarray. In statistical analysis,
aCGH data have less noise and yield more reliable results. Figure 2.2 shows the typical
signal of a sequence of aCGH probes. The probe of aCGH is mainly of two types: BAC
(Bacterial Artificial Chromosome) clone and DNA oligonucleotide. BAC clones provides
the resolution on the order of 1 Mb (Greshock et al. 2004; Pinkel and Albertson 2005b).
In the last few years, DNA oligonucleotide arrays have become popular for CGH because
they can offer much higher resolution (Brennan et al. 2004). An example of oligonucleotide
probe is to use singular nucleotide polymorphism (SNP) to design DNA marker. A chip
based on SNP is referred to as a SNP array (Kennedy et al. (2003)). For examples, there
are four versions of widely-used SNP arrays manufactured by Affymetrix, each consisting
of 100K, 250K, 500K, and 1M SNPs, respectively. Another company, Agilent, provides a
250K SNPs array. Compared to microarray, which usually contain 5,000-50,000 probe sets,
aCGH data analysis is more suitable for novel gene discovery but also raises challenge for
statistical methodology, computational cost and memory usage. In section 2.2, we give a
detailed introduction of copy number generation from Affymetrix SNP array.
In aCGH study, we are often interested in copy number variations for large genomic
segments. For example, each chromosome has two arms, p and q, that are connected by a
centromere. Chromosome rearrangement often causes one arm to be translocated, dupli-
cated or lost. The copy number changes of a chromosome arm will affect thousands of SNPs
located in it. A number of statistical tools have been developed to detect gain or loss of
8
Figure 2.2: Screenshot of Affymetrix Genotyping Analysis software that generates DNA copy numbers
from aCGH intensity data. GSACN are Gaussian smoothed copy numbers that are used for further data
analysis.
DNA segment. Fridlyand et al. (2004) and Zhao et al. (2004) used hidden Markov models
(HMM) to estimate probe copy numbers; Olshen et al. (2004) proposed a circular binary
segmentation (CBS) algorithm to detect the break points of DNA segments; Daruwala et al.
(2004) and Sabatti and Lange (2008) fitted copy number variation with Bayesian models;
Hsu et al. (2005) smoothed aCGH signal with wavelet; Zou and Hastie (2005), Reiss et al.
(2007), Tibshirani and Wang (2008) selected important genomic regions by constraining
the regression parameters with L1 or L2 Norm. Most of these methods assume a specific
distribution for the (log ratio of) intensities of the probes such as normal, log-normal or
Poisson distribution. Despite the large amount of efforts made to justify those distributions
(Sidorov et al. 2002; Hoyle et al. 2002), it has been vigorously argued as to whether the
fitting of real image data with a well-defined distribution is adequate (Kerr et al. 2000;
Konishi 2004). Low convergence rates and slow computations are another problem with
some of high-computation oriented techniques. Based on our experiments, it affects the
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Bayesian-based models and regression-based models such as LASSO and elastic net. The
computational difficulty makes those methods impossible to be applied to dense SNP ar-
rays. Because of high dimensional and noisy nature of aCGH data, many of these methods
could not provide reliable and consistent results. Lai et al. (2005) discussed the strengths
and limitations of 11 methods. For examples, HMM was sensitive to detect small abnormal
regions in simulated data, but failed to detect any of the three amplified regions in a glioma
aCGH data; CBS successfully detected all three amplifications of glioma data but blurred
the break points.
In a cancer study, one of the central goals is to understand tumor development and
progression. Studies are designed to monitor the dynamic behavior of genomic DNA. For
instances, chromosomal instability during neoplastic progression was investigated for Bar-
rett’s esophagus patients with Affymetrix 100K SNP arrays (Lai et al. 2007), and relapse of
Wilms’ tumor was investigated with BAC clone CGH array (Natrajan et al. 2007). In these
studies, researchers are interested in identifying a genome signature consisting of DNA aber-
ration regions that is associated with a disease outcome and a drug response. As patients
are repeatedly measured, a proper within-subject correlation should be considered for any
reasonable statistical interpretations. Technically, the within-subject correlation over time
is the same as within-cluster correlation such as genomes within a family. An example of
within-family correlation can be found in the Framingham Heart Study directed by the Na-
tional Heart, Lung, and Blood Institute (Kottgen et al. 2008). They studied the genotypes
of original and Offspring cardiovascular disease patients with Affymetrix 100K SNP array.
The goal of the study is to identify the genetic factors underlying cardiovascular disease and
other disorders. Any methodology developed for longitudinal aCGH data should be able to
be applied to such within-cluster correlation data.
Most data analyses for an longitudinal microarray are based on statistical tests for indi-
vidual gene that is adjusted for multiple tests by using false discovery rate (FDR) procedure.
Linear mixed-effects models and generalized estimating equations (GEE) are widely used
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for longitudinal data analysis (Liang and Zeger (1986); Diggle et al. (2002)). While they
have proven to be useful tools for repeated measures with large sample size, the adequacy
of model fitting is of concern for high dimensional data analysis (Fan and Zhang (2000)).
Park et al. (2003) used a two-stage ANOVA model to calculate the P values for each gene.
At the first stage, a time effect is tested. The residuals of time effects are then used in a
permutation test. For their analysis, the study need to be balanced and the within-subject
correlation cannot be strong to achieve sufficient statistical power. Guo et al. (2003) pro-
posed a modified Wald statistic to test the differential expression of each gene over time. The
Wald statistic converges to a χ2 distribution under the null hypothesis when the number of
subjects is sufficiently large. Each gene is assigned a gene-specific score that is calculated by
the Wald statistic that accounts for within-subject correlation. A permutation test is then
performed to compute the false discovery rate (FDR) for each gene. Storey et al. (2005)
used a mixed model with a polynomial mean function to detect significant genes across
time points between treatment and control groups. Under the null hypothesis of no differ-
ential expression, the two groups are assumed to have the same population average time
curve. The population mean curve is modeled for the profile of each gene, and an F statistic
is then calculated based on it. P values are adjusted by FDR to determine significantly
differentiated genes.
All the above methods are based on univariate test for an individual gene by taking
into account of its within-subject correlation. Despite their wide applications in expression
microarray studies, their usage for aCGH study is limited because a FDR adjustment is not
sensitive enough in detecting small copy number variation, which is often important (Storey
and Tibshirani (2003)). Analysis of aCGH data is usually based on segmented probes for
chromosome rearrangement affecting a large number of probes located within the genomic
region. A rich class of techniques such as HMM and CBS as discussed earlier have been pro-
posed to segment DNA for independent samples. For dependent aCGH samples, researchers
are currently short of robust techniques. Tsai and Qu (2008) performed hypothesis testing
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for a set of genes by applying a non-parametric time-varying coefficient model. The within-
subject correlation was taken into account by a quadratic inference function (QIF). A QIF
derived from GEE is asymptotically χ2 distributed when the number of replications goes to
∞.
Due to the high cost of array experiments, a large sample size is usually not desired.
Therefore, methods based on large sample size have limited application in aCGH study. In
addition, the computational cost is substantially higher for time course analysis than for the
static experiments. The goal of this chapter is to provide a series of test statistics for detect
copy number variation of a DNA segment in a longitudinal aCGH study. The test statistics
should be robust to non-normality. They can also be used for other high dimensional low
replicated data with within-subject correlation. The proposed test statistics are applied to
unbalanced designs and heteroscedastic covariance structures as well. The method can be
used to identify genomic signatures with a test-based clustering algorithm.
In aCGH study, DNA copy number can be inferred by log2 ratio of the disease and
reference samples when both samples are hybridized onto the same chip. A positive log2
ratio indicates gain in copy number and a negative value indicates loss in copy number.
Due to experimental and biological factors such as purity of a sample, the log2 ratio does
not appear as the magnitude of copy numbers. For example, a frequent phenomenon in
the analysis of primary tumors is normal cell contamination caused by imperfect dissection.
Generally, pathologists make sure that each tumor sample contains no more than 50%
(or 30%) of normal cells. The purity of the tumor sample increases as the contamination
proportion decreases. Another factor that affects the copy number estimation is that not
all tumor cells may have acquired a given aberration. These factors make estimation of a
true copy number impossible. Here we aim at testing whether DNA sections within a DNA
region have common copy numbers. The test then can be used to partition the chromosome
into sets of the same copy number segment.
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The outline of this chapter is as follows. Section 2.2 presents the processes of copy number
generation illustrated with Affymetrix 100K SNP array. In section 2.3, we describe the study
design and the model specification. Test statistics are provided in section 2.4. Details of
asymptotic theories for original observations and the corresponding proofs are provided in
section 2.5. Simulation study is presented in section 2.6. Type I error rates were estimated
under various distributions in simulations, and power analysis was compared to LME and
GEE with bootstrap data. In section 2.7, we apply our methods to a Wilms’ tumor study.
2.2 Data generation from Affymetrix SNP arrays
In this section, we give an introduction of the array CGH technology. Array designs vary
manufacturer to manufacturer, and sometimes even vary version-to-version of the same
manufuacturer. For simplicity, we base our discussion on Affymetrix 100K SNP array.
SNPs are sequence changes that arose once during evolution. Public efforts have so
far identified over two million common human SNPs. Affymetrix designed the 100K SNP
array consisting of more than 110K SNPs distributed across a human genome. The SNP
arrays can be used for genetic linkage analyses, genotyping calling, and DNA copy number
variation study (Kennedy et al. 2003).
Typically, only two of the four possible bases at an SNP are present in human. If we
denote the two alleles at an SNP by the letters a and b, then each person has one of three
possible genotypes a/a, a/b, or b/b.
In Affymetrix SNP array, each SNP is assessed by 40 probes, each 25 bases long. Of the
40 probes, 20 are match probes that perfectly hybridize with one of the two alleles, and 20
are mismatch probes intended to measure the level of cross-hybridization. Among the 20
match probes, 10 probes are complementary to allele a, and 10 probes are complementary to
allele b. Each set of 10 match probes is further subdivided into two subsets of 5 probes; one
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subset is complementary to the sense strand and the other subset to the antisense strand
of the DNA molecule. This leads to four probe subsets: sense (s) a, antisense (t) a, sense
b, and antisense b. Each mismatch probe subset is paired with one subset of match probes
and differs from it at the base in the central position of the oligonucleotide.
The sample genomic DNA is processed with the following steps: (1) The DNA is broken
into small fragments by restriction enzyme digestion, (2) the fragments are amplified by
the polymerase chain reaction (PCR), (3) fragment copies are labeled with dye molecules
to distinguish the two alleles, (4) labeled fragment copies are hybridized with the array,
and (5) the intensity of the fluorescent signal at each spot is measured. The DNA labeling
process is illustrated in Figure 2.3.
Numerous algorithms have been proposed to summarize and to analyze the raw fluores-
cent intensity data derived from labeling of the array (Yang et al. 2002; Irizarry et al. 2003).
Here we focus our discussion on the copy number algorithm recommended by Affymetrix
(Affymetrix 2006). The intensity data are first subjeted to probe/SNP filtering for quality
control. Users can exclude mismatch probes for subsequent analysis. Additionally, users
can exclude SNPs based on the length of the PCR fragment with which they hybridize. It
have been shown that the exclusion of SNPs on larger PCR fragment sizes improve analyt-
ical accuracy. Secondly, probe intensities are normalized across multichips with the goal to
reduce experimental noise due to chip-to-chip variation, background, and relative variation
in the performance of probes interrogating a given SNP. Various methods are available for
data normalization. For examples, median scaling, quantile normalization, and Gaussian
smoothing are a few widely used approaches (Quackenbush 2002).
If we use both perfectly matched and mismatched probes in the analysis, we need to
summarize the relative measure with a discrimination score (D). For the ith allele, let PMi
denote the average normalized intensity of the perfectly matched probes, and MMi for the
average of the mismatched probes. The discrimination score for the ith allele is
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Figure 2.3: A schematic of generation and labelling of probes for hybridization of Affymetrix SNP arrays.
Di =
PMi −MMi
PMi +MMi
.
The raw copy number (CN) estimation is based on the log2ratio between tumor sample
and a reference sample. In practice, we use 48 female normal samples provided by Affymetrix
as global references. The copy number is generated for every allele. λi is the raw CN for
the ith allele based on sample score Si and reference score Ri.
15
λi = log2
Si
Ri
,
where Si and Ri are the average intensities of perfectly matched probes if only perfectly
matched probes are used, or are discrimination scores if mismatched probes are included.
Then Total Copy Number (TCN) of SNP k can be estimated with sumLog formula by
summing both alleles.
TCNk = log2
SkA
RkA
+ log2
SkB
RkB
,
where
RkA, RkB: scores in the allele a, b for SNP k of the reference;
SkA, SkB: scores in the allele a, b for SNP k of the tumor sample.
Therefore, for each SNP k, three raw CN esimates are generated: TCN, CN for allele a
(λkA), and CN for allele b (λkB). For DNA copy number analysis discussed in this thesis,
TCN are the input data for our statistics. TCN are continuous numerical data. They can
be transformed to integer copy number using hidden Markov models (HMM) or mixture
Gaussian models (Hodgson et al. 2001; Fridlyand et al. 2004). We prefer using raw TCN
data to avoid possible systemtic errors incurred in the transformation.
2.3 Model specification
In this section, we consider statistical analysis of high dimensional data with each subject
repeatedly measured over time. We will focus our discussion on analyses applied to a time
course aCGH study.
Let Xijk be the jth measurement of the ith probe from subject k ( i = 1, ..., I;
j = 1, ..., J ; k = 1, ..., ni). The number of probes is large, whereas the number of time
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points and the number of subjects are fixed. The design is assumed to be either balanced
or unbalanced, in that the number of subjects may vary for different probes. For example,
if all aCGH data come from a same version of a SNP array, the design will be balanced.
However, to take advantage of limited sources, we often need to import aCGH data from
different sources. For example, if data from Affymetrix 100K and 250K arrays are to be
combined, the design will be unbalanced. In this case, the SNPs shared between 100K and
250K arrays have more samples than the SNPs that only exist in 250K arrays. The probe
copy numbers are modeled by
Xijk = µ+ αi + βj + γij + εijk, (2.3.1)
where
∑I
i=1 αi =
∑J
j=1 βj =
∑I
i=1 γij =
∑J
j=1 γij = 0, µ is the overall mean, αi represents
the effect of the ith probe, βj represents the effect of the jth time point, and γij represents
the interaction effect of probe and time. The error terms εijk have mean 0, and they are
correlated for repeated measures from the same subject and the same probe. In other words,
εijk and εi′j′k′ are independent if i 6= i′ or k 6= k′, and they are only dependent when i=i’,
j 6= j′, and k=k’. Note that normality is not assumed for εijk.
The dependence of repeated measurements within an individual was taken into account
in the model fitting procedure. The within-subject correlation structure is not necessarily
homogeneous, it could vary for different probes. The covariance of a probe over time is
possibly dependent on its copy number or its location in a chromosome. Furthermore,
experiments of biological time course study are often not evenly spaced in time. Therefore,
the same correlation structure may not be appropriate. We apply a heteroscedastic variance
structure to the model specified by Cov(εijk, εij′k) = σi,jj′ .
The tests can be written in terms of the parameters in the model. For aCGH study, the
null hypothesis of no copy number variation is equivalent to restricting all αi to be zero. The
test will applied to detect the local DNA copy number changes in a given genome region.
If the goal is to find the DNA segments whose copy numbers are altered by time points, we
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will test that all βj equal to zero. The null hypothesis of DNA copy number is the same
over all time points is equivalent to restricting all γij to zero. It will be used to detect the
genome regions that have the same time response.
At the end of the section, we present a summary of notations which will be used in the
rest of the manuscript.
X˜i·· = J−1
J∑
j=1
X ij·, X˜·j· = I−1
I∑
i=1
X ij·,
σi,jj1 = Cov(Xijk, Xij1k) for any k, (note σi,jj = V ar(Xijk) = σ
2
ij),
σi,jj1,j2j3 = Cov(XijkXij1k, Xij2kXij3k), (σi,jj1,jj1 = σ
2
i,jj1
).
2.4 Testing statistics
In this section, we will use a few modified Wald test statistics and modified F test statistics
to provide robust tests for main effects and interactions.
First, we consider to explore whether copy number variation exists in a given genomic
region. Statistically, it is a test of no main effect of probe. The test will be very useful in
DNA segmentation, by which we want to partition the whole genome into amplified, deleted,
and normal regions. Under the null hypothesis, there is no copy number difference within
the DNA segment of interest. The null hypothesis is
H0(A) : all αi = 0, for i = 1, ..., I.
where I is the total number of probes located in this DNA segment.
To test H0(A), we modified the F statistic used in mixed ANOVA model.
FX(A) =
MSTA
MSEA
, MSTA =
1
I − 1
I∑
i=1
J∑
j=1
(X˜i·· − X˜···)2, (2.4.1)
MSEA =
1
IJ
I∑
i=1
J∑
j,j1
1
ni(ni − 1)
ni∑
k=1
(Xijk −X ij.)(Xij1k −X ij1.). (2.4.2)
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where X˜i·· is the sample average of X ij· for j = 1, ..., J , and X˜··· is the sample average of X˜i··
for all i. The definition of MSTA slightly different from that of ANOVA in that unweighted
averages are used instead of weighted averages. The definition of MSEA is different from
that of the traditional MSE in that the within-subject correlation over time is taken into
account.
Secondly, we want to carry out a statistical test of time effect. In a longitudinal aCGH
study, researchers are often interested in identifying DNA segments whose copy number
varies over time. These are potential genomic signatures indicating tumor progression or
regression. The test of time effect is targeted on all probes in a selected genomic region.
The null hypothesis of no time effect is
H0(B) : all βj = 0, for j = 1, ..., J.
In order to test H0(B) of time effect, we also consider a more general hypothesis H0(BG) :
Lβ = 0 where L is a p× J contrast matrix with full row rank, β = (β1, ..., βJ)′, and 0 is a
p dimensional zero vector. A modified Wald-type test statistic is used for testing H0(BG).
WB = D
′
BL
′(LVˆBL′)−1LDB (2.4.3)
where DB = (X˜·1·, ..., X˜·J ·)′, and VˆB is the estimated J × J covariance matrix for DB, with
the value at the jth row and the j′th column be VˆB,jj′ = I−2
∑I
i=1(ni(ni−1))−1
∑ni
k=1(Xijk−
X ij·)(Xij′k −X ij′·).
Finally, the high throughput time course study is often targeted to identify the variables
that show time response, such as genes regulated by cell cycle, or genomic regions that reflect
progressive tumors. Note that DNA copy number variation implies the changes of expression
level for the encoded genes by the DNA segment. The hypothesis test of interaction between
probe and time will allow us to identify the candidate gene in the genome region where the
probe is located, and whose expression changes over time. The null hypothesis is
H0(AB) : all (αβ)ij = 0, for i = 1, ..., I, and j = 1, ..., J.
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Similar to the test for main effect of gene, the test statistic for no interaction is also
based on a modified F statistic
FX(AB) =
MSTAB
MSEAB
, (2.4.4)
where
MSTAB =
1
(I − 1)(J − 1)
∑
i,j
(X ij· − X˜i·· − X˜·j· + X˜···)2, (2.4.5)
MSEAB =
1
I(J − 1)
I∑
i=1
J∑
j
1
ni(ni − 1)
ni∑
k=1
(Xijk −X ij.)2 −
1
IJ(J − 1)
I∑
i=1
J∑
j,j1
1
ni(ni − 1)
ni∑
k=1
(Xijk −X ij.)(Xij1k −X ij1.).
The asymptotic distribution for each of the test statistics in (2.4.1), (2.4.3), (2.4.4) will
be derived in the following sections.
2.5 Main results based on original observations
This section is devoted to developing the asymptotic distribution of the test statistics which
are defined in the last section. For simplicity, we use notation eijk = Xijk − E[Xijk] in the
proof.
Theorem 2.5.1. For testing H0(A): all αi = 0, let FX(A) be the statistic given in (2.4.1).
If Xijk has finite fourth central moment, then under H0(A),
√
I(FX(A)− 1)
VA
d→ N(0, 1), as I →∞.
where
VA =
√
τA/σA, (2.5.1)
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with
τA =
1
IJ2
I∑
i=1
2
ni(ni − 1)
J∑
j,j1,j2,j3
σi,jj1σi,j2j3 , and σA =
1
IJ
I∑
i=1
J∑
j,j1
σi,jj1
ni
.
Lemma 2.5.2. Under the settings and assumptions of Theorem 2.5.1,
MSEA − σA p→ 0 as I →∞.
Proof:
For any j, j1 = 1, ..., J, note that
E
[
(Xijk −X ij.)(Xij1k −X ij1.)
]
= E [(eijk − eij.)(eij1k − eij1.)]
= E(eijkeij1k)− E(eij.eij1k)− E(eijkeij1.) + E(eij.eij1.)
= σi,jj1 −
1
ni
σi,jj1 −
1
ni
σi,jj1 +
1
n2i
ni∑
k,k1
E(eijkeij1k1)
=
ni − 1
ni
σi,jj1 .
Thus, we have
E(MSEA) =
1
IJ
I∑
i=1
J∑
j,j1
1
ni(ni − 1)
ni∑
k
E
[
(Xijk −X ij.)(Xij1k −X ij1.)
]
= σA.
The result will follow if we show V ar(MSEA)→ 0 as I →∞.
|V ar(MSEA)| = 1
I2J2
I∑
i=1
ni∑
k=1
1
n2i (ni − 1)2
∣∣∣∣∣Cov[
J∑
j,j1
(eijk − eij.)(eij1k − eij1.),
J∑
j2,j3
(eij2k − eij2.)(eij3k − eij3.)]
∣∣∣∣∣ .
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Note that
E
[
(Xijk −X ij.)(Xij1k −X ij1.)
]2
= E [(eijk − eij.)(eij1k − eij1.)]2
= E[eijkeij1k − eij.eij1k − eijkeij1. + eij.eij1.]2
≤ 4[E(eijkeij1k)2 + E(eij.eij1k)2 + E(eijkeij1.)2 + E(eij.eij1.)2]
= 4
[
E(e2ijke
2
ij1k
) +
1
n2i
E(e2ijke
2
ij1k
) +
1
n2i
E(e2ijke
2
ij1k
) +
1
n4i
ni∑
k=1
E(e2ijke
2
ij1k
)
]
=
4(n3i + 2ni + 1)
n3i
Cov(e2ijk, e
2
ij1k
)
< ∞,
where the last inequality holds because Xijk has the finite fourth central moment. The first
inequality follows from Ho¨lder’s inequality,∣∣∣∣∣
m∑
i=1
zi
∣∣∣∣∣
p
≤ mp−1
m∑
i=1
|zi|p, m ≥ 1, p > 1. (2.5.2)
We have∣∣∣∣∣Cov[
J∑
j,j1
(eijk − eij.)(eij1k − eij1.),
J∑
j2,j3
(eij2k − eij2.)(eij3k − eij3.)]
∣∣∣∣∣ (2.5.3)
≤
∣∣∣∣∣V ar[
J∑
j,j1
(eijk − eij.)(eij1k − eij1.)]V ar[
J∑
j2,j3
(eij2k − eij2.)(eij3k − eij3.)]
∣∣∣∣∣
1
2
≤
∣∣∣∣∣E[
J∑
j,j1
(eijk − eij.)(eij1k − eij1.)]2
∣∣∣∣∣
1
2
∣∣∣∣∣E[
J∑
j2,j3
(eij2k − eij2.)(eij3k − eij3.)]2
∣∣∣∣∣
1
2
≤
∣∣∣∣∣J2
J∑
j,j1
E[(eijk − eij.)(eij1k − eij1.)]2
∣∣∣∣∣
1
2
∣∣∣∣∣J2
J∑
j2,j3
E[(eij2k − eij2.)(eij3k − eij3.)]2
∣∣∣∣∣
1
2
= J2
∣∣∣∣∣
J∑
j,j1
E[(eijk − eij.)(eij1k − eij1.)]2
∣∣∣∣∣
1
2
∣∣∣∣∣
J∑
j2,j3
E[(eij2k − eij2.)(eij3k − eij3.)]2
∣∣∣∣∣
1
2
< ∞,
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where the inequalities follow from the properties of variance and Ho¨lder’s inequality, and the
last equality holds for the finiteness showed previously. Therefore, V ar(MSEA) = O(I
−1)
and MSEA − σ2A p→ 0 as I →∞.
Lemma 2.5.3. Under the settings and assumptions of Theorem 2.5.1 and under H0(A), we
have
√
I(MSTA − PA(e)) p→ 0 as I →∞,
where PA(e) =
J
I
∑I
i=1 e˜
2
i...
Proof:
Note that under H0(A),
MSTA =
1
I − 1
I∑
i=1
J∑
j=1
(e˜i.. − e˜...)2
=
J
I − 1
I∑
i=1
(e˜i.. − e˜...)2
=
J
I − 1
(
I − 1
I
I∑
i=1
e˜2i.. −
1
I
I∑
i6=i′
e˜i..e˜i′..
)
=
J
I
I∑
i=1
e˜2i.. −
J
I(I − 1)
I∑
i6=i′
e˜i..e˜i′...
Thus, we have
E[
√
I(MSTA − PA(e))] =
√
IJ
I(I − 1)
I∑
i6=i′
E [e˜i..e˜i′..] = 0,
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and
E[
√
I(MSTA − PA(e))]2 = IJ
2
I2(I − 1)2E
[
I∑
i6=i′
e˜i..e˜i′..
]2
=
J2
I(I − 1)2E
[
I∑
i 6=i1,i2 6=i3
e˜2i..e˜
2
i1..
e˜2i2..e˜
2
i3..
]
=
2J2
I(I − 1)2E
[
I∑
i6=i1
e˜2i..e˜
2
i1..
]
=
2J2
I(I − 1)2
I∑
i6=i1
E[e˜2i..]E[e˜
2
i1..
]
= O(I−1).
Therefore, under H0(A),
√
I(MSTA − PA(e)) p→ 0 as I →∞.
Proof of Theorem 2.5.1: By Lemmas 2.5.2 and 2.5.3, we need only to consider the
asymptotic distribution of QA(e) =
√
I(PA(e) − MSEA) under H0(A), where PA(e) =
J
I
∑I
i=1 e˜
2
i...
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We can write
QA(e) =
√
I
[
J
I
I∑
i=1
e˜2i.. −
1
IJ
I∑
i=1
J∑
j,j1
1
ni(ni − 1)
ni∑
k=1
(Xijk −X ij.)(Xij1k −X ij1.)
]
=
1
J
√
I
I∑
i=1
[
(
J∑
j
eij.)
2 −
J∑
j,j1
1
ni(ni − 1)
ni∑
k=1
(eijk − eij.)(eij1k − eij1.)
]
=
1
J
√
I
I∑
i=1
J∑
j,j1
[
eij.eij1. −
1
ni(ni − 1)
ni∑
k=1
(eijk − eij.)(eij1k − eij1.)
]
=
1
J
√
I
I∑
i=1
J∑
j,j1
[
ni − 2
ni − 1eij.eij1. −
1
ni(ni − 1)
ni∑
k=1
(eijkeij1k − eij1keij. − eijkeij1.)
]
=
1
J
√
I
I∑
i=1
J∑
j,j1
[
ni − 2
n2i (ni − 1)
ni∑
k,k1
eijkeij1k1 −
1
ni(ni − 1)
ni∑
k=1
eijkeij1k+
2
n2i (ni − 1)
ni∑
k,k1
eij1keijk1
]
=
1
J
√
I
I∑
i=1
J∑
j,j1
1
ni(ni − 1)
ni∑
k 6=k1
eijkeij1k1 .
Therefore, E[QA] = 0. It follows that
V ar(QA(e))
=
1
IJ2
I∑
i=1
1
n2i (ni − 1)2
V ar
[
J∑
j,j1
ni∑
k 6=k1
eijkeij1k1
]
=
1
IJ2
I∑
i=1
2
n2i (ni − 1)2
ni∑
k 6=k1
V ar
[
J∑
j,j1
eijkeij1k1
]
=
1
IJ2
I∑
i=1
2
n2i (ni − 1)2
ni∑
k 6=k1
J∑
j,j1,j2,j3
σi,jj1σi,j2j3
=
1
IJ2
I∑
i=1
2
ni(ni − 1)
J∑
j,j1,j2,j3
σi,jj1σi,j2j3 .
Since V ar(QA(e)) is bounded away from zero and infinity, Lyapunov’s condition will be
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satisfied if
LA(a) =
∑I
i=1E| 1J√I
∑J
j,j1
1
ni(ni−1)
∑ni
k 6=k1 eijkeij1k1|4 → 0.
We have
LA(a) =
1
I2J4
I∑
i=1
E
∣∣∣∣∣
J∑
j,j1
1
ni(ni − 1)
ni∑
k 6=k1
eijkeij1k1
∣∣∣∣∣
4
≤ J
6
I2J4
I∑
i=1
J∑
j,j1
E
∣∣∣∣∣ 1ni(ni − 1)
ni∑
k 6=k1
eijkeij1k1
∣∣∣∣∣
4
=
J2
I2
I∑
i=1
J∑
j,j1
1
n4i (ni − 1)4
E
∣∣∣∣∣
ni∑
k 6=k1
eijkeij1k1
∣∣∣∣∣
4
≤ J
2
I2
I∑
i=1
J∑
j,j1
n3i (ni − 1)3
n4i (ni − 1)4
ni∑
k 6=k1
E|eijkeij1k1|4
=
J2
I2
I∑
i=1
J∑
j,j1
1
ni(ni − 1)
ni∑
k 6=k1
E[e4ijk]E[e
4
ij1k1
]
= O(I−1), if the fourth moment of eijk exists for any i, j, and k.
where the two inequalities follow Ho¨lder’s inequality (2.5.2). This completes the proof.
Theorem 2.5.4. For testing H0(BG): Lβ = 0 where L is a J × p contrast matrix, β =
(β1, ..., βJ)
′, and 0 is a p dimensional zero vector, let WB be the statistic given in (2.4.3).
If Xijk has finite second and fourth moments, then under H0(BG),
WB
d→ χ2p
holds for all ni ≥ 2, i=1, ..., I.
Proof of Theorem 2.5.4: Under H0(BG), LE[D(B)] = 0, then LD(B) = L(D(B) −
E[D(B)]). Let V (B) = V ar[D(B)]. V(B) is a J × J matrix, where the value of j1th row
and j2th column is defined as
Cov(X˜·j1·, X˜·j2·) = η(B)j1j2 =
1
I2
I∑
i
σi,j1j2
ni
.
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If j1 = j2 = j, it is the variance of X˜·j·, and it is denoted as
η(B)j =
1
I2
I∑
i
σ2i,j
ni
.
The result will follow from the Continuous Mapping and Slutsky’s Theorems, by showing
√
N(D(B)− E[D(B)]) d→ NJ(0, NV (B)) as I →∞, where N =
∑I
i=1 ni. It is sufficient to
show for any finite constants a = (a1, ..., aJ)
′,
√
Na′(D(B)− E[D(B)]) =
J∑
j=1
aj
√
N(X˜·j· − E(X˜·j·)) d→ N(0, Na′V (B)a).
where Na′V (B)a = N
∑I
i=1
∑J
j,j1
ajaj1σi,jj1/niI
2 converges if (
∑I
i
1
ni
)(
∑I
i ni)/I
2 converges,
which holds since ni are finite.
J∑
j=1
aj
√
N [X˜·j· − E(X˜·j·)]
=
√
N
I
I∑
i
J∑
j=1
aj[X ij· − E(X ij·)]
=
I∑
i
(√
N
I
J∑
j
ajeij·
)
.
The asymptotic normality can be shown by Lyapounov’s Theorem. The Lyapounov condi-
tion will be satisfied if
L(B) =
I∑
i
(√
N
I
)4
E
(
J∑
j
ajeij·
)4
→ 0.
Note that
L(B) =
I∑
i
(√
N
I
)4
E
(
J∑
j
ajeij·
)4
≤
I∑
i
N2
I4
J3
J∑
j
E(I4j e
4
ij·)
=
I∑
i
N2
I4
J3
J∑
j
I4j
1
n4i
E
(
ni∑
k
eijk
)4
≤
I∑
i
N2
I4
J3
J∑
j
I4j
n4i
B4
[
ni∑
k
E(e2ijk)
]2
=
I∑
i
N2
I4
J3
J∑
j
I4j
n4i
B4n
2
i [E(e
2
ij1)]
2 = O
(
I∑
i
N2
I4n2i
)
= O(I−1),
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where the first inequality follows Ho¨lder’s inequality (2.5.2), and the last equality holds if
ni are finite. The second inequality follows from the Khintchine inequality:
Let {zn}Nn=1 be i.i.d random variables with zero mean. Let 0 < p <∞, then(
E|
N∑
n=1
zn|p
)1/p
≤ Bp
(
N∑
n=1
E|xn|2
)1/2
, (2.5.4)
for some constant Bp > 0 depending only on p (Newman 1975). This complete the proof.
Theorem 2.5.5. For testing H0(AB): all γij = 0, let FX(AB) be the statistic given in
(2.4.4) with Xij = Xij. If Xijk has the finite fourth moment, then under H0(AB),
√
I(FX(AB)− 1)
VAB
d→ N(0, 1), where VAB is defined in (2.5.5).
The variance component is calculated by
VAB =
√
τAB/σAB, (2.5.5)
where
τAB =
2
I(J − 1)2
I∑
i
[
1
ni(ni − 1)
J∑
j,j1
σ2i,jj1 +
1
J2ni(ni − 1)
J∑
j,j1,j2,j3
σi,jj1σi,j2j3−
2
Jni(ni − 1)
J∑
j,j1,j2
σi,jj1σi,jj2
]
,
σAB =
1
I(J − 1)
I∑
i=1
J∑
j
σ2i,j
ni
− 1
IJ(J − 1)
I∑
i=1
J∑
j,j1
σi,jj1
ni
.
Lemma 2.5.6. Under the settings and assumptions of Theorem 2.5.5,
MSEAB − σAB p→ 0 as I →∞.
Proof:
As shown in lemma 2.5.2,
E
[
(Xijk −X ij.)(Xij1k −X ij1.)
]
=
ni − 1
ni
σi,jj1 .
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Then
E(MSEAB) =
1
I(J − 1)
I∑
i=1
J∑
j
1
ni(ni − 1)
ni∑
k
E
[
(Xijk −X ij.)2
]−
1
IJ(J − 1)
I∑
i=1
J∑
j,j1
1
ni(ni − 1)
ni∑
k
E
[
(Xijk −X ij.)(Xij1k −X ij1.)
]
=
1
I(J − 1)
I∑
i=1
J∑
j
σ2i,j
ni
− 1
IJ(J − 1)
I∑
i=1
J∑
j,j1
σi,jj1
ni
= σAB.
And, we have,
V ar(MSEAB)
=
1
I2(J − 1)2
I∑
i=1
1
n2i (ni − 1)2
ni∑
k
{
V ar
[
J∑
j
(Xijk −X ij.)2
]
+
1
J2
V ar
[
J∑
j,j1
(Xijk −X ij.)(Xij1k −X ij1.)
]
−
2
J
Cov
[
J∑
j
(Xijk −X ij.)2,
J∑
j,j1
(Xijk −X ij.)(Xij1k −X ij1.)
]}
.
In the proof of lemma (2.5.2), we showed in formula (2.5.3) that∣∣∣∣∣Cov[
J∑
j,j1
(Xijk −X ij.)(Xij1k −X ij1.),
J∑
j2,j3
(Xij2k −X ij2.)(Xij3k −X ij3.)]
∣∣∣∣∣
=
∣∣∣∣∣Cov[
J∑
j,j1
(eijk − eij.)(eij1k − eij1.),
J∑
j2,j3
(eij2k − eij2.)(eij3k − eij3.)]
∣∣∣∣∣
< ∞.
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This follows from
V ar
[
J∑
j
(Xijk −X ij.)2
]
<∞,
V ar
[
J∑
j,j1
(Xijk −X ij.)(Xij1k −X ij1.)
]
<∞,
Cov
[
J∑
j
(Xijk −X ij.)2,
J∑
j,j1
(Xijk −X ij.)(Xij1k −X ij1.)
]
<∞.
Therefore, we have V ar(MSEAB) = O(I
−1) and it follows that MSEAB − σ2AB p→ 0 as
I →∞.
Lemma 2.5.7. Under the settings and assumptions of Theorem 2.5.5 and under H0(AB),
we have
√
I(MSTAB − PAB(e)) p→ 0 as I →∞,
where PAB(e) =
1
I(J−1)
∑I
i=1
∑J
j=1(eij. − e˜i..)2.
Proof:
Note that under H0(AB),
MSTAB
=
1
(I − 1)(J − 1)
I∑
i=1
J∑
j=1
[
(eij. − e˜i..)2 − 2
I
I∑
i1
(eij. − e˜i..)(ei1j. − e˜i1..) +
1
I2
I∑
i1
(ei1j. − e˜i1..)2
]
=
1
(I − 1)(J − 1)
J∑
j=1
[
I + 1
I
I∑
i=1
(eij. − e˜i..)2 − 2
I
I∑
i,i1
(eij. − e˜i..)(ei1j. − e˜i1..)
]
=
1
I(J − 1)
I∑
i=1
J∑
j=1
(eij. − e˜i..)2 − 2
I(I − 1)(J − 1)
I∑
i6=i1
J∑
j=1
(eij. − e˜i..)(ei1j. − e˜i1..).
Thus, we have
E[
√
I(MSTAB − PAB(e))] = 2
√
I
I(I − 1)(J − 1)
I∑
i6=i1
J∑
j=1
E [(eij. − e˜i..)(ei1j. − e˜i1..)] = 0.
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And
E[
√
I(MSTAB − PAB(e))]2
=
4I
I2(I − 1)2(J − 1)2E
[
I∑
i6=i1
J∑
j=1
(eij. − e˜i..)(ei1j. − e˜i1..)
]2
=
4I
I2(I − 1)2(J − 1)2E
2 I∑
(i=i2)6=(i1=i3)
(
J∑
j=1
(eij. − e˜i..)(ei1j. − e˜i1..)
)
(
J∑
j1=1
(ei2j1. − e˜i2..)(ei3j1. − e˜i3..)
)]
=
8I
I2(I − 1)2(J − 1)2E
[
I∑
i6=i1
J∑
j,j1
(eij. − e˜i..)(ei1j. − e˜i1..)(eij1. − e˜i..)(ei1j1. − e˜i1..)
]
=
8I
I2(I − 1)2(J − 1)2
I∑
i6=i1
J∑
j,j1
E[(eij. − e˜i..)(eij1. − e˜i..)]E[(ei1j. − e˜i1..)(ei1j1. − e˜i1..)]
= O(I−1).
Therefore under H0(AB),
√
I(MSTAB − PAB(e)) p→ 0 as I →∞.
Proof of Theorem 2.5.5: By Lemma 2.5.6 and Lemma 2.5.7, we need only to consider
the asymptotic distribution of QAB(e) =
√
I(PAB(e)−MSEAB) under H0(AB).
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With some simple algebra, we have
QAB(e)
=
√
I
[
1
I(J − 1)
I∑
i
J∑
j
(eij· − e˜i··)2 − 1
I(J − 1)
I∑
i
J∑
j
1
ni(ni − 1)
ni∑
k
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1
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i
J∑
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1
ni(ni − 1)
ni∑
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]
=
1√
I(J − 1)
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i
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1
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ni∑
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J∑
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1
Jni(ni − 1)
ni∑
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]
=
1√
I(J − 1)
I∑
i
[
(
J∑
j
e2ij· −
1
J
J∑
j,j1
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J∑
j
1
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ni∑
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J∑
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1
Jni(ni − 1)
ni∑
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]
=
1√
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I∑
i
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(
1
n2i
J∑
j
ni∑
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eijkeijk1 −
1
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J∑
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ni∑
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eijkeij1k1)−
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1
ni(ni − 1)
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j
ni∑
k
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1
n2i (ni − 1)
J∑
j
ni∑
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eijkeijk1) +
(
1
Jni(ni − 1)
J∑
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ni∑
k
eijkeij1k −
1
Jn2i (ni − 1)
J∑
j,j1
ni∑
k,k1
eijkeij1k1)
]
=
1√
I(J − 1)
I∑
i
[
1
ni(ni − 1)
J∑
j
ni∑
k 6=k1
eijkeijk1 −
1
Jni(ni − 1)
J∑
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ni∑
k 6=k1
eijkeij1k1
]
.
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Therefore, E[QAB(e)] = 0. It follows that
V ar(QAB(e))
=
1
I(J − 1)2
I∑
i
V ar
[
1
ni(ni − 1)
J∑
j
ni∑
k 6=k1
eijkeijk1 −
1
Jni(ni − 1)
J∑
j,j1
ni∑
k 6=k1
eijkeij1k1
]
=
2
I(J − 1)2
I∑
i
ni∑
k 6=k1
[
V ar(
1
ni(ni − 1)
J∑
j
eijkeijk1) + V ar(
1
Jni(ni − 1)
J∑
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2Cov(
1
ni(ni − 1)
J∑
j
eijkeijk1 ,
1
Jni(ni − 1)
J∑
j,j1
eijkeij1k1)
]
=
2
I(J − 1)2
I∑
i
ni∑
k 6=k1
[
1
n2i (ni − 1)2
J∑
j,j1
E(eijkeij1k)E(eijk1eij1k1)+
1
J2n2i (ni − 1)2
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]
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2
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[
1
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σ2i,jj1 +
1
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2
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J∑
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]
.
Since V ar(QAB(e)) is bounded away from 0 and∞, Lyapounov’s condition will be satisfied if
LAB(a) =
I∑
i=1
E
∣∣∣∣∣ 1√I(J − 1)[( 1ni(ni − 1)
J∑
j
ni∑
k 6=k1
eijkeijk1 −
1
Jni(ni − 1)
J∑
j,j1
ni∑
k 6=k1
eijkeij1k1)]
∣∣∣∣∣
4
→ 0.
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We then have that
LAB(a) =
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I∑
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1
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J
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]
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J6
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=
8
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n3i (ni − 1)3
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4
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) + J2
J∑
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E(e4ijk)E(e
4
ij1k1
)
]
= O(I−1) if the fourth moment of eijk exist for any i, j, and k,
where the two inequalities follow Ho¨lder’s inequality (2.5.2). This completes the proof.
2.6 Simulation results
In order to evaluate the proposed non-parametric test statistics (NPT), we compare NPT
with linear mixed estimation model (LME) and generalized estimating equations (GEE) by
simulation studies. First, we performed simulation to calculate the type I error rates for
random numbers generated from various distributions and covariance structures. Secondly,
we generate bootstrap re-sampling data from real aCGH profiles. We then introduced
within-subject correlation to the data, and conducted power analysis to compare NPT,
LME, and GEE. All the data in this section were generated from the model specified in
(2.3.1)
Xijk = µ+ αi + βj + γij + εijk.
We used R programming to conduct all calculations and simulations. For calculations based
on LME and GEE methods, R packages nlme and geepack were used.
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2.6.1 Simulated data
In this subsection, simulations were used to estimate type I error rates for the proposed
method (NPT). The aCGH data were often modeled with log-normal or Poisson distribu-
tion (Sidorov et al. (2002); Zhao et al. (2004)). Nonetheless, such models have been shown
to be inappropriate because they skew data histograms or probability plots (Konishi 2004).
Therefore, we used normal, exponential, Poisson, or Cauchy distributions to generate ran-
dom samples. Proper within-subject correlation structures were introduced into the data as
well. All simulations were conducted using 1000 iterations.
As the copy number of normal chromosomes is 2, we used a mean of 2 for normal,
exponential,and Poisson distributions. The normal distribution had a standard deviation
equal to 1. The Cauchy distribution had a location parameter 0, and a scale parameter 1.
The within-subject correlation (over time points) were modeled either with an AR(1)
or an unstructured correlation structure. For AR(1) correlation, the covariance vector X
was conditioned by cov(Xijk, Xij1k) = .5
|j−j1|. The unstructured correlation structures were
obtained by generating a symmetric matrix that has random numbers uniformly distributed
between 0 and 1. The methods to introduce the correlation structures are described below.
First, we examined the proposed test statistic for H0(A) of no probe copy number vari-
ation. The probe copy numbers were randomly generated under null hypothesis of equal
numbers for distinct subjects at the same time point. For convenience, we used the same
mean for all probes at all time points. For the balanced design, the random numbers were
put in a matrix X of J rows and I × n columns. J is the number of time points, I is the
number of probes, and n is the number of replications. For unbalanced design, the number
of columns of X is the sum of the number of replications for all individual probes.
An AR(1) or unstructured correlation structure J × J matrix L was then generated as
described above. The Cholesky decomposition of L calculates the lower half triangle matrix
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h. Thus, we have the simulated data matrix Y = h · X that had the desired correlation
structure. The matrix Y had equal means across columns. Nonetheless, at different time
points (between rows), the copy numbers from the same probe could vary. It was then used
for analysis by our statistic defined in 2.4.1. There is an exception in the data generating
process for Poisson distribution. We intended to use Poisson distribution to generate integer
copy number data. Therefore, we first calculated the means matrix M for Y by multiplying
the half matrix h with a data matrix consisting of only copy number 2’s. Then the random
data matrix Y was generated by using Poisson distribution with mean M.
In the test of the probe effect, we considered both balanced and unbalanced designs.
Each sample have 5 replicates in the balanced design. The type I error rates with an AR(1)
correlation were shown in Table 2.1. Either 2 or 8 time points were simulated for each
dataset. The number of time points does not significantly affect the error rates. They had
similar error rates in all conditions. We increased the number of probes from 5 to 1000. At
the level α = 0.05, the error rate converges to 0.05 as the number of probes increases, and
they were close to 0.05 for normal, exponential and Poisson distributions when the number
of probes was 40 or above. The error rate for Cauchy distribution did not converge to 0.05
since Cauchy distribution does not have a finite mean.
For the unbalanced design, we created data by assigning four fifths of probes with 4
replications, and the remaining probes with 6 replications. The results of AR(1) and un-
structured correlation are shown in Table 2.2 and Table 2.3 separately. The conclusions
were similar to those of balanced designs (Table 2.3).
Secondly, we conducted hypothesis test for the time effect. Similar to that of the probe
effect, we first generate random copy numbers matrix X with equal means for all tested
distributions except for Poisson distribution. In order to maintain equal means across time
points (rows), we cannot use the Cholesky decomposition to introduce correlation structure.
Instead, we used a iterative algorithm. Suppose for probe i, the correlation between the jth
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no.time no.snp normal exponential Poisson Cauchy
5 0.107 0.117 0.118 0.190
10 0.091 0.076 0.096 0.173
20 0.085 0.073 0.066 0.147
30 0.074 0.063 0.059 0.135
2 40 0.063 0.060 0.048 0.132
50 0.050 0.055 0.053 0.128
100 0.053 0.051 0.053 0.107
200 0.051 0.046 0.060 0.123
500 0.054 0.053 0.056 0.111
1000 0.042 0.052 0.049 0.104
5 0.103 0.098 0.105 0.206
10 0.094 0.072 0.075 0.164
20 0.078 0.071 0.059 0.156
30 0.065 0.064 0.071 0.141
8 40 0.059 0.042 0.063 0.128
50 0.054 0.064 0.061 0.128
100 0.049 0.059 0.055 0.130
200 0.051 0.059 0.057 0.111
500 0.049 0.059 0.035 0.103
1000 0.051 0.051 0.063 0.085
Table 2.1: Estimated type I error estimate of the test of no probe effect at 0.05 level. The
data from the same probe follow AR(1) with correlation =0.5. There are 5 replications in
the design.
and (j+1)th time points is ρ. Given a copy number Xj for the jth time point, the random
copy number of the (j+1)th time point can be generated by
Xj+1 = ρXj + b,
where b is a random number with mean 2(1− ρ). Thus, the mean of Xj+1 is 2. For Poisson
distribution, similar to the process for the probe effect, we first generated the means with
desired correlation structure, and then used the means to generate random integer copy
numbers.
The type I error rates at alpha level 0.05 with an AR(1) correlation were shown in
Table 2.4. Two or eight time points were simulated for each experiment. For each dataset,
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no.snp normal exponential Poisson Cauchy
10 0.102 0.111 0.101 0.163
20 0.083 0.074 0.075 0.149
30 0.071 0.067 0.072 0.121
40 0.062 0.066 0.074 0.138
50 0.072 0.059 0.057 0.134
100 0.051 0.068 0.067 0.111
200 0.041 0.038 0.043 0.114
500 0.047 0.056 0.053 0.112
1000 0.052 0.053 0.048 0.087
Table 2.2: Estimated type I error of the test of no probe effect at 0.05 level. The data from
the same probe follow AR(1) with correlation =0.5. The number of time points is 2. For
each experiment, Four fifths of probes have 4 replications, and the remaining one fifth of
probes have 6 replications.
no.snp normal exponential Poisson Cauchy
10 0.089 0.091 0.100 0.156
20 0.077 0.072 0.075 0.133
30 0.060 0.072 0.054 0.117
40 0.071 0.069 0.048 0.120
50 0.070 0.071 0.043 0.116
100 0.054 0.074 0.051 0.121
200 0.055 0.057 0.048 0.121
500 0.050 0.055 0.057 0.108
1000 0.046 0.063 0.053 0.100
Table 2.3: Estimated type I error of the test of no probe effect at 0.05 level. The data from
the same probe follow unstructured correlation. The number of time points is 5. For each
experiment, Four fifths of probes have 4 replications, and the remaining one fifth of probes
have 6 replications.
four fifths of probes were assigned 4 replications, and the remaining one fifth of probes
were assigned 6 replications. As the number of time points increases, it needs more probes
to reach the expected error rate. Normal, exponential, and Poisson distributions showed
similar convergence rate. But as expected, the error rate for Cauchy distribution did not
converge to 0.05.
Table 2.5 showed the type I error rates for the unstructured correlation. The conclusions
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no.time no.snp normal exponential Poisson Cauchy
10 0.060 0.061 0.051 0.030
20 0.064 0.052 0.047 0.029
30 0.067 0.054 0.063 0.025
2 40 0.053 0.050 0.052 0.024
50 0.053 0.054 0.058 0.011
100 0.043 0.055 0.051 0.022
200 0.048 0.047 0.048 0.017
500 0.044 0.045 0.053 0.019
1000 0.058 0.037 0.052 0.016
5 0.373 0.404 0.349 0.319
10 0.192 0.207 0.176 0.106
20 0.113 0.125 0.106 0.052
30 0.092 0.090 0.077 0.033
8 40 0.075 0.075 0.088 0.024
50 0.065 0.082 0.074 0.027
100 0.048 0.059 0.049 0.017
200 0.052 0.044 0.055 0.011
500 0.052 0.053 0.042 0.015
1000 0.055 0.052 0.039 0.011
Table 2.4: Estimated type I error estimate of the test of no time effect at 0.05 level. The
data from the same probe follow AR(1) with correlation =0.5. For each probe, the number
of replications is either 4 or 6.
were similar to those of the balanced designs.
Thirdly, simulation was conducted to test the interaction of probe and time. The data
generating process was similar to that for test of time effect. Under null hypothesis, the copy
number for all probes at all time points are equal. We gave 8 time points in the experiment.
An unbalanced design was used such that four fifths of probes have 4 replications, and one
fifth of probes have 6 replications. The type I error rate at alpha level 0.05 were reported
in Table 2.6 and Table 2.7 for AR(1) and unstructured correlations, respectively. Normal,
exponential, and Poisson distributions showed similar convergence rate. Like other tests,
the error rate for Cauchy distribution did not converge.
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no.snp normal exponential Poisson Cauchy
10 0.114 0.121 0.103 0.052
20 0.084 0.074 0.086 0.027
30 0.070 0.093 0.058 0.023
40 0.065 0.069 0.077 0.026
50 0.065 0.074 0.060 0.019
100 0.038 0.054 0.047 0.016
200 0.052 0.051 0.048 0.015
500 0.038 0.039 0.041 0.018
1000 0.049 0.038 0.045 0.017
Table 2.5: Estimated type I error of the test of no time effect at 0.05 level. The data from
the same probe follow unstructured correlation. For each simulation, there are 8 time points.
For each probe, the number of replications is either 4 or 6.
no.snp normal exponential Poisson Cauchy
10 0.086 0.084 0.101 0.175
20 0.071 0.079 0.066 0.153
30 0.073 0.076 0.074 0.149
40 0.056 0.073 0.066 0.151
50 0.045 0.051 0.054 0.142
100 0.047 0.062 0.052 0.139
200 0.070 0.054 0.056 0.105
500 0.035 0.044 0.046 0.097
1000 0.062 0.047 0.055 0.095
Table 2.6: Estimated type I error rates of the test of no interaction of probe and time effects
at 0.05 level. The data from the same probe follow AR(1) with correlation =0.5. For each
probe, the number of replications is either 4 or 6.
2.6.2 Bootstrap data
In this subsection, we used power analysis to compare the proposed method (NPT) with
linear mixed-effects model (LME) and generalized estimating equations (GEE). To simulate
data as closely as possible to the real aCGH data, we used bootstrap to generate re-sampled
data based on an aCGH application.
It has been reported that amplification of chromosome 7q is associated with glioma
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no.snp normal exponential Poisson Cauchy
10 0.080 0.087 0.086 0.175
20 0.076 0.074 0.057 0.155
30 0.050 0.070 0.059 0.153
40 0.048 0.057 0.055 0.145
50 0.049 0.063 0.051 0.136
100 0.060 0.052 0.043 0.117
200 0.050 0.065 0.053 0.140
500 0.050 0.071 0.047 0.110
1000 0.061 0.062 0.040 0.099
Table 2.7: Estimated type I error rates of the test of no interaction of probe and time effects
at 0.05 level. The data from the same probe follow unstructured correlation with correlation
=0.5. For each probe, the number of replications is either 4 or 6.
tumor (Maher (2006)). We acquired the copy numbers of 3,000 SNPs in chromosome 7q
from Affymetrix 100K SNP arrays for both a healthy person and a glioma patient. From
Figure 2.4, we see that the glioma sample has 7q amplification. Its mean copy number is 4.4.
The normal sample has a mean of 2.05. In the simulation design, 100 SNPs were repeatedly
measured at 5 time points with either a balanced or unbalanced design. In each dataset,
the majority of data came from normal 7q sample (under H0), and they were contaminated
with a small proportion of glioma data (under Ha).
Figure 2.5 showed the power curves of testing SNP effects in the balanced design with an
AR(1) correlation structure. In each experiment, there were 5 time points, and 5 replications.
The contamination percentage of glioma SNPs varied from 0 to 2%. The re-sampling data
formed a data matrix X with 5 rows and 500 (5 × 100) columns. Each row represented
a time point, and each column represented a SNP. The 5 replications of each SNP were
in adjacent columns. The AR(1) correlation structure was introduced with the Cholesky
decomposition as described in the subsection 2.6.1. The proposed method (NPT) had
the fastest convergence rate to 1. The power was 100% when there were at least 0.9%
contamination. At 0.9% contamination, the power of LME was 54.5%, and that of GEE
was only 25.3%. GEE had the worst power among the three methods. It had a power of
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Figure 2.4: The plots of DNA copy numbers in chromosome 7q of normal and glioma samples. Red plots
denote the copy numbers of glioma SNPs, and blue plots denote the copy numbers of normal SNPs. The x
axis showed the genomic positions of each SNP on chromosome 7q.
96.9% for 2% contamination whereas the other two methods had 100% power.
We next considered unbalanced design and unstructured correlation for the bootstrap-
resampled data. Four fifths of SNPs were assigned 4 replications, whereas the remaining
one fifth of SNPs were assigned 6 replications. An unstructured correlation matrix were
introduced with the Cholesky decomposition such that the correlation between distinct time
points for the same SNP was random. Still, we considered 5 time points. The contamination
percentage of glioma SNPs in each dataset was in the range of 0 to 2%. The conclusion
was similar to that of the balanced design (Figure 2.6). The proposed method (NPT)
outperformed the other two methods. It reached 100% power when there was at least 1.3%
of contamination, whereas LME and GEE had 75% and 51% of powers, respectively. With
2% of contamination, LME had 97.3% of power, and GEE had 88.1% of power.
For the test of the time effect, bootstrap-resampled data were generated with 5 time
points. The design was unbalanced and the correlation structure was unstructured. The
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Figure 2.5: The power curves of balanced design with an AR(1) correlation.
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Figure 2.6: The power curves of unbalanced design with unstructured correlation.
correlation structure was incorporated via the interactive algorithm as described in the
previous subsection. Figure 2.7 showed the power curves for the three methods. With 2%
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of amplified copy number contamination, NPT had a power of 96.7%, LME of 71.8%, and
GEE of 62.2%.
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Figure 2.7: The power curves of unbalanced design with unstructured correlation
For the test of the interaction of SNP and time, we generated unbalanced unstructured
correlated data by bootstrap-resampling for 5 time points. Similarly, we used the interactive
algorithm to generate the unstructured correlation as discussed earlier. Figure 2.8 showed
the power curves for the three methods. The contamination of amplified SNPs were changed
from 0% to 4%. The three methods were not discriminable when the contamination is less
than 0.9%. Nonetheless, NPT had a higher power for more than 0.9% of contamination.
GEE performed better than LME in the interaction test, but not in the SNP and the time
effect tests. With 4% of contamination, NPT had a power of 96.8%, LME of 63.6%, and
GEE of 89.0%.
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Figure 2.8: The power curves of unbalanced design with unstructured correlation.
2.7 A longitudinal study
Wilms’ tumor typically occurs in children’s kidney. Although the percentage of patients
who survive at least five years is above 90%, 15% of patients will suffer from tumor relapse
(Kalapurakal et al. (2004)). A lot of recent work regarding Wilms’ tumor has been aimed
at discovering the genetic biomarkers for diagnosis, prognosis, and treatment management
(Eggert et al. (2001); Takahashi et al. (2002); Williams et al. (2004); Dome et al. (2005)).
Genetic aberrations such as loss of heterozygosity and chromosome copy number changes
have been found to be associated with the tumor relapse (Grundy et al. (2005); Yuan et al.
(2005); Natrajan et al. (2006)). However, few longitudinal studies have been conducted to
identify biomarkers that are responsible to tumor progression and recurrence.
Natrajan et al. (2007) carried out aCGH experiments for 10 Wilms’ patients with re-
lapse. The aCGH samples were conducted at both diagnosis and relapse for each patient.
They used Breakthrough Breast Cancer Human CGH 4.6K 1.1.2 arrays that consist of 4179
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Bacterial Artificial Chromosome (BAC) clones. The BAC clones serve as probes for measur-
ing the genomic DNA copy number. In their report, 29 chromosome regions were identified
to have copy number alterations responsible to Wilms’ tumor relapse. However, their con-
clusions were based on pairwise comparison of diagnosis and relapse for each patient. It is
not statistically justified to conduct hypothesis test without replications of subject. The
reproducibility of such analysis is expected to be low, and the claimed biomarkers are pos-
sibly not useful for predicting the potential relapse of new Wilms’ patients. In fact, only 6
of the 29 regions were found in 2 of the 10 patients according the their paper. Motivated by
the need to redo the analysis with rigorous statistical method, we acquired the raw aCGH
data and conducted analysis with the following steps.
We first performed quality control and normalization for the raw data. As female and
male people have different number of sex chromosomes, to avoid them confounding with the
analysis, we removed X and Y chromosomes from the data. The raw data were adjusted to
baseline by subtracting the median background signal. In the experiment, each probe was
labeled with two fluorescent dyes, Cy5 and Cy3. The fluorescent intensity ratio of Cy5/Cy3
were used as input data. The Cy5/Cy3 ratio were subject to quantile normalization across
all samples (Bolstad et al. (2003)). The processed data had a median copy number of 2 and
a standard deviation of 0.04 for each sample. They were used for subsequent analysis.
As discussed in section 2.1, a first goal of a CGH study is usually to detect the gain or loss
of a chromosome arm because it is often the unit of genomic mutation and translocation
activity. For instances, Hing et al. (2001) and Lu et al. (2002) found that the gain
of chromosome 1q is associated with relapse of Wilms’ tumor. We applied our proposed
methods to each chromosome arm for hypothesis tests of probe, time, and probe× time
effects. There were no probes for 5 of the 44 arms. They were 13p, 14p, 15p, 21p, and 22p.
For the other arms, the minimum number of probes was 84, and the maximum number was
699. Table 2.8 lists the chromosome arms that were statistically significant for the tests.
Totally 16 arms showed significant probe× time interaction. That implied the copy numbers
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of some of the probes in these arms varied between diagnosis and relapse. Of the remaining
chromosome arms, no time effects were detected, and two arms showed significant probe
effects.
p arm q arm
chromosome probe time probe×time probe time probe×time
1
2 2.552E−03 2.720E−03
3 6.697E−03 2.472E−04 0.014 0.010
4
5 5.070E−09 1.216E−11 2.382E−04 9.936E−05
6 0.034
7 2.426E−08 0.023 0.031
8 0.041
9 0.036 0.036
10
11 5.054E−08 4.350E−07
12 0.016
13
14
15 0.038
16 5.538E−05 6.836E−07
17 0.015
18 2.554E−14 1.776E−15
19
20
21 1.593E−03
22 0.013
Table 2.8: Summary of significant P values (< 0.05) calculated by NPT methods for each
chromosome arm.
We were most interested in the chromosome regions in which all probes had copy num-
ber gain or loss simultaneously and had no significant effect. From Table 2.8, 26 chro-
mosome arms were not detected for any effect. We calculated the mean value for each of
the arm. Unfortunately, none of these mean values was abnormally higher or lower than
2. Further analysis can be conducted by comparing to normal reference samples with the
non-parametric methods proposed by Wang and Akritas (2004). The desired biomarkers
for predicting relapse should show a consistent pattern between diagnosis and relapse. If
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a genetic event only occurs in either of the two measures, its association with tumor re-
currence is hard to be established. For the purpose of identifying prognostic biomarkers,
we were not interested in the chromosome arms with probe×time interaction. Nevertheless,
the interaction may indicate important genetic regulation mechanisms, and be worth further
biological studies.
We explored the chromosome 8p and 21q that showed only probe effect. Significant probe
effect suggests some regions in the two arms have gain or loss of DNA copies. By calculating
the mean value of each probe with the measures from both diagnosis and relapse, we found
four regions with abnormal copy numbers. The results were summarized in Table 2.9.
Chromosome region 8p21.3 was found to have a DNA deletion. Two genes are encoded in
this region. INTS10 is a subunit of RNA polymerase. Reduced expression level of RNA
polymerase could lead to abnormal expression of many other genes. Thus, it is a potential
oncogenesis gene. LPL is responsible for lipoprotein uptake, and it was reported to be
associated with prostate cancer (Narita et al. (2004)). Chromosome 21q11.1 and 21q11.3
loss may affect the expression of genes CR614803, NCAM2, and CYYR1. However, the gene
functions and their relevancy with cancer is not clear currently. The loss of 21q22.3 were
associated with functions of 3 genes, NX1, NX2, and TMPRSS2. NX1 is responsible for
anti-viral reaction; NX2 is a subunit of GTPase; TMPRSS2 belongs to the serine protease
family. Both GTPase and serine protease are involved in a number of fundamental gene
regulation pathways. The four selected regions overlapped with 2 copy number alterations
reported by Natrajan et al. (2007). Thus, out of their 29 selected regions, we were only
able to verify 2 potential biomarkers.
Longitudinal aCGH studies can provide unique insights into the genetic abnormalities
involved in disease development and progression. However, there are a lot of challenges
faced by statistical analysis. Researchers often use over-simplified analysis methods that
are not able to provide sufficient statistical power and justification. We provided a robust
tool based on non-parametric statistics that has potentially broad applications in this area.
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Genomic region Gene Function
8p21.3 INTS10 RNA transcription
LPL lipoprotein
21q21.1 CR614803 NA
NCAM2 NA
21q21.3 CYYR1 NA
21q22.3 NX1 anti-viral response
NX2 GTPase
TMPRSS2 Serine protease
Table 2.9: Summary of the copy number alterations detected for both primary and relapse
tumors.
49
Chapter 3
Statistical tests for time course
microarray data
Time course microarray experiments have been widely used to explore dynamic changes in
gene expression in varying biological conditions. In a longitudinal gene expression study,
each subject is repeatedly measured over time. Statistical models need to take within-subject
correlation into account. In this chapter, we provide robust test procedures to compare
groups of genes under multiple treatments or experimental conditions using expression data.
3.1 Introduction
Recent advances in high-throughput screening technology and in high-dimensional data anal-
ysis have made it possible for scientists to study more complex problems, such as measuring
dynamic response of organisms at the molecule level. For examples, time-course microarray
experiments have been conducted to investigate gene expression in the cell cycle, in the
Drosophila immune response, in the mouse cardiac development, in the human osteoblast
differentiation, in the inflammatory response of human blood leukocyte, and in the aging
of human kidney cortex tissue (Shedden and Cooper (2002); Gregorio et al. (2001); Qi
et al. (2003); Rodwell1 et al. (2004); Calvano et al. (2005)). Many time-course microarray
experiments are designed to repeatedly measure the gene expression from the same object
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over time. The following two examples highlight the structure of the data.
Example 1. A recent study was carried out on human (Calvano 2005) to study gene ex-
pression over time during acute inflammatory and immune response. Gene expression in
whole blood leukocytes was determined by microarray immediately before and at 2, 4, 6, 9
and 24 h after the intravenous administration of bacterial endotoxin to four healthy human
subjects. Four additional subjects were studied under identical conditions but without en-
dotoxin administration. The blood samples were taken from the same patient at different
time points were therefore correlated. Changes in blood leukocyte gene expression patterns
were analyzed. The study provide insight into the generic regulation of global leukocyte
activities.
Example 2. The Hessian fly (Mayetiola destructor) is one of the most destructive pests of
wheat in the U.S., Western Asia, and Northern Europe. Resistance (R) genes in wheat
have been the most effective means in controlling Hessian fly damages. The challenge for
using resistance genes is that the effectiveness of a R gene is short-lived, lasting from six
to eight years after its initial deployment Hatchett et al. (1987), Ratcliffe et al. (2000).
Consequently, new R genes need to be continuously identified and incorporated into wheat
cultivars for continued success. In addition, experiments at Kansas State University found
that rice is a nonhost plant for Hessian fly since 100% Hessian fly larvae died in rice during
the whole larval stage (Chen et al. 2008). To identify genes and pathways that were affected
in resistant wheat, suspectable wheat and rice leading to host and nonhost resistance, whole
genome arrays of wheat and rice were used at different time points (half-day, 1-day, 3-day
and 5-day) after Hessian fly attacks. The genes affected at an early time are likely involved
in regulations and signal transduction whereas the genes affected at a later time are likely
involved in direct chemical defense. Large amount of array data from this experiment
involving interactions of Hessian fly with wheat and rice over time remain to be analyzed
effectively to identify critical genes for genetic engineering.
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In the examples above, the temporal component is an inherent part of the study and
multiple treatments are involved for discovery of important genes or transcriptional activ-
ity over developmental stages. These poses novel challenges for statistical analysis since
effective methods need to take into account both curse of dimensionality and within-subject
correlations. A few statistical attempts have been made to analyze longitudinal microar-
ray data. Most of data analysis for longitudinal microarray is based on statistical test for
individual genes and then is adjusted for multiple tests by false discovery rate (FDR). Lin-
ear mixed-effects model (LME) and generalized estimating equation (GEE) are commonly
used for longitudinal data analysis (Liang and Zeger (1986); Diggle et al. (2002)). While
they have been proved to be useful tools for repeated measures with large sample size, the
adequacy of model fitting is of concern for high dimensional data analysis (Fan and Zhang
(2000)). Park et al. (2003) used a two-stage ANOVA model to calculate the P values for
each gene. At the first stage, the time effect is tested; the residuals of the time effect are
then used for permutation test. They require the study to be balanced and there is no strong
within-subject correlation. Guo et al. (2003) proposed a modified Wald statistic to test the
differential expression of each gene over time. The Wald statistic converges to a χ2 distribu-
tion under null hypothesis when the number of subjects is sufficiently large. Each gene was
assigned a gene-specific score that was calculated by the Wald statistic by accounting for
within-subject correlation. The gene-specific score was adjusted by a small positive number
to comprise small gene expression level. Permutation test was then performed to compute
the false discovery rate (FDR) for each gene. Storey et al. (2005) used a mixed model with
a polynomial mean function to detect significant genes across time between treatment and
control groups. Under the null hypothesis of no differential expression, the two groups were
assumed to have the same population average time curve. The population mean curve for
the profile of each gene was modeled, and it was used for calculating F statistic for the gene.
And then FDR was used to call significantly differentiated genes.
All methods above consider within-subject correlations, and they are targeted to test
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individual genes. However, the following FDR adjustment leads to a high P value for the
multiple tests at one hand, and FDR is so conservative that it excludes many positive signals
at the other hand (Storey and Tibshirani (2003)). It has become a current trend to test a
set of genes simultaneously instead of performing tests for individual genes. A set of genes,
selected from biological knowledge from pathway information or literature mining, are tested
for variation as a group. One of such knowledge-based approaches was recently reported
as Gene set enrichment (Subramanian et al. (2005); Efron and Tibshirani (2007)). Tsai
and Qu (2008) tested a subset of genes by applying non-parametric time-varying coefficient
model. The within-subject correlation was taken into account by the quadratic inference
function (QIF). QIF is derived from GEE and it is asymptotically χ2 distributed when the
number of replications goes to ∞.
Due to the high cost of microarray experiments, a large sample size is usually difficult
to obtain. Therefore, the methods based on large sample size have limited application in
array study. In addition, the large number of variables and multiple time points entail high
requirement for computation. Efficient computation algorithm need to be implemented for
methodology development. In microarray data analysis, the raw data are to be pre-processed
for quality control and data normalization. In many studies, it is convenient to make normal
or log-normal distribution assumption about the raw or processed data (Tseng et al. (2001);
Olshen and Jain (2002); Sidorov et al. (2002)). Hoyle et al. (2002) justified that microarray
data are in agreement with both Benford’s law and Zipf’s law, and suggested the lognormal
model to be a good candidate concerning the data distribution. However, there are a number
of arguments that the data are largely skewed, and the normal or log-normal distributions
does not provide a close fit to the data (Kerr et al. (2000); Konishi (2004)). Therefore, a
statistical method that has wide application in microarray data analysis should be robust
for multiple distribution assumptions and potential outliers.
For Affymetrix microarray chips, the raw microarray data are generated in a similar
way as aCGH data described in section 2.2. Both expression microarray and aCGH are
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based on fluorescent intensities, which are then transformed to discrimination scores by
summarizing the relative measures of perfectly matched mismatched probes. In contrast to
aCGH, microarray takes the discrimination scores as raw input data, instead of calculating
a ratio to a reference sample, and microarray does not summarize the allele information.
The goal of this chapter is to provide a series of hypothesis testing theory to compare the
expression levels for the effect of a set of probes or genes, the time effect and probe by time
interactions in a longitudinal microarray study. We would like to use a general model set up
so that the test statistics are robust with respect to non-normality. They can also be used for
other high dimensional low sample size data with within-subject correlations. The proposed
test statistics consider unbalanced designs and heteroscedastic covariance structures as well.
An unbalanced design is very common in current microarray data analysis. The data are
often collected from different sources such as multiple centers or online database. The
dataset often contain different versions or even different manufacturers of microarray. Thus,
the number of measurements varies between genes. Our proposed methods can be adapted to
various designs. Furthermore, they have the potential to be used with test-based clustering
to identify groups of genes with similar expression patterns, producing a gene expression
signature.
The outline of this chapter is as follows. In section (3.2), we describe the study design and
the model specification. Test statistics are provided in section (3.3). Details of asymptotic
theory for original observations and their proofs are provided in section (3.4). Section (3.5)
presents the simulation results on type I error estimates and power analysis for our proposed
methods. In section (3.6), we applied our method to a recent longitudinal microarray study
in which the gene expression profiles of murine T cells with or without interleukin-2 (IL-2)
stimulation were collected at 4 and 8 h. Sets of genes from different functional groups were
tested for IL-2 signaling over time.
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3.2 Model specification
We consider high dimensional longitudinal data in this manuscript. The subjects are ran-
domly assigned to different treatment groups, each subject has thousands of variables, and
they are repeatedly measured over time. We focus on the applications of analysis of biolog-
ical data, such as genomic, proteomics, and metabonomics data.
Let Xijkl be measurement of the k
th gene/probe from subject l in treatment group i at
time j (i = 1, ..., I; j = 1, ..., J ; k = 1, ..., K; l = 1, ..., nik). The number of probes is large,
whereas the number of time points and the number of replications are small. The design
is assumed to be either balanced or unbalanced, in that the number of replications may
vary for different treatment groups and for different probes. The measurement values are
modeled by
Xijkl = µ+ αi + βj + γk + (αβ)ij + (αγ)ik + (βγ)jk + εijkl (3.2.1)
where
∑I
i αi =
∑J
j βj =
∑K
k γk =
∑I
i (αβ)ij =
∑J
j (αβ)ij =
∑I
i (αγ)ik =
∑K
k (αγ)ik =∑J
j (βγ)jk =
∑K
k (βγ)jk = 0, µ is the overall mean measurement, αi represents the effect of
ith treatment, βj represents the effect of the j
th time point, and γk represents the effect of
the kth gene. The interaction effect of treatment and gene is denoted by (αγ)ik, and the
interaction effect of time and gene is denoted by (βγ)jk. The error terms εijkl are identically
distributed with mean 0. Assume that εijkl and εi′j′k′l′ are independent if i 6= i′ or k 6= k′
or l 6= l′. They are only dependent when they are observations at various time points for
the same gene from an individual, in this case, i=i’, j 6= j′, k=k’, and l=l’. The three-way
interaction of treatment, time, and response is not of biological interest, so it is not included
in the model. Note that normality is not assumed for εijkl. We only requires the existence
of the fourth moment.
The treatment effect αi accounts for differences between treatments averaged over the
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whole time period and over all genes. Such differences could arise if the mRNA transcription
of some genes is inhibited by the treatment. Similarly, the time effect βj accounts for the
differences between time points. The gene expression may have a trend over time. The
gene effect γk accounts for the average relative expression level of gene k. The term (αγ)ik
accounts for the effect of treatment i for gene k. An individual gene could have distinct
responses to different treatments. Nonzero treatment*gene interaction indicates differential
expression for some genes. The term (βγ)jk accounts for the effect of gene k at time point
j. Genes could have distinct expression trends over time.
The dependence of repeated measurements within an individual was taken into account
in the model fitting procedure. The within-subject correlation structure is not necessar-
ily homogeneous, but could vary for different genes. In microarray data, each individual
gene has its own transcription activity, therefore, each gene has its unique correlation struc-
ture. Biological time course experiments are often not evenly spaced in time. Thus, the
same correlation structure should not be assumed for different time point for the same
subject. Therefore a heteroscedastic variance structure is used for the model such that
Cov(εijkl, εij′kl) = σi,k,jj′ .
The tests can be written in terms of the parameters in the model. In microarray exper-
iments, the null hypothesis of no differential expression between treatments is equivalent to
restricting all αi to be zero. The test of the null hypothesis that the gene expression does
not vary over time is equivalent to testing all βj equal to zero. The null hypothesis of no
variation in gene expression levels between treatments is equivalent to restricting all (αγ)ik
to zero. The null hypothesis of gene expression independent of time points is equivalent to
restricting all (βγ)jk to zero. In order to identify differentially expressed genes, we will test
whether all γk equal to zero across all treatments and over the whole time period.
At the end of the section, we present a summary of notations which will be used in the
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rest of the manuscript.
X˜i·k· = J−1
J∑
j=1
X ijk·, X˜ij·· = K−1
K∑
k=1
X ijk·, X˜·jk· = I−1
I∑
i=1
X ijk·, X˜i··· = J−1
J∑
j=1
X˜ij··,
X˜·j·· = I−1
I∑
i=1
X˜ij··, σ2i,k,j = V ar(Xijkl), σi,k,jj1 = Cov(Xijkl, Xij1kl) ( note σi,k,jj = σ
2
i,k,j),
σ2i,k,jj1 = V ar(XijklXij1kl), σi,k,jj1,j2j3 = Cov(XijklXij1kl, Xij2klXij3kl), (σi,k,jj1,jj1 = σ
2
i,k,jj1
).
3.3 Test statistics
The analysis of variance (ANOVA) is often used for the model specified in last section (Kerr
2000). However, the asymptotic results for traditional ANOVA are not satisfied because the
sample size is small and the data may not be normally distributed. Here we will construct
new test statistics that are suitable when there is unknown within-subject correlation in
the presence of a large number of variables. In this section, we will use a few modified
Wald test statistics and modified F test statistics to provide robust tests for main effect and
interactions.
First, we will test the treatment main effect. One of the major purposes of a microar-
ray study is identifying changes in expression across various biological conditions, such as
different tissues, species, or drug response states. Under the null hypothesis for microarray
studies, there is no differential expression of genes between treatments. The null hypothesis
is
H0(A) : all αi = 0, for i = 1, ..., I.
In order to test H0(A) of the treatment effect, we consider a more general hypothesis
H0(AG) : Lα = 0 for a contrast among αi, where L is a p×I contrast matrix, α = (α1, ..., αI)′,
and 0 is a p dimensional zero vector. If we test the treatment effect for each individual gene,
a Wald-type test statistic with estimated correlation structure for the gene may be consid-
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ered (Kent 1982). The Wald statistic for the kth gene is
WA,k = D
′
A,kL
′(LV̂AkL
′)−1LDA,k
where DA,k = (X˜1·k·, ..., X˜I·k·)′, and V̂Ak is the estimated I × I variance matrix for vector
DA,k, which is a diagonal matrix for subjects are independent between treatment groups.
The purpose is to perform multivariate test for the treatment effect that takes into
account the large number of variables and the within-subject dependence. To adapt the
Wald statistic to high dimensional and non-normal data, we proposed a modified Wald-type
test statistic for null hypothesis H0(AG) that takes into account all genes.
WA = D
′
AL
′(LV̂AL′)−1LDA, (3.3.1)
where DA = (X˜1···, ..., X˜I···)′, and V̂A = diag(η̂A1, ..., η̂AI), which is the estimated covariance
matrix for DA. The term η̂Ai represents the estimation of variance of X˜i···, and it is defined
as
η̂Ai =
1
J2K2
J∑
j1,j2
K∑
k
1
nik(nik − 1)
nik∑
l
(Xij1kl −X ij1k·)(Xij2kl −X ij2k·). (3.3.2)
Secondly, we carry out a statistical test for the time effect. In a longitudinal microarray
study, researchers are often interested in genes whose expression changes over time, such as
cell cycle genes and HOX genes involved in tissue development. The test of the time effect
is only intended for a subset of genes of interest, selected from pathways or from a biological
database.
The null hypothesis of no time effect is
H0(B) : all βj = 0, for j = 1, ..., J.
Similar to testing H0(A), in order to test H0(B) of the time effect, we also consider a
more general hypothesis H0(BG) : Lβ = 0 where L is a p× J matrix, β = (β1, ..., βJ)′, and
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0 is a p dimensional zero vector. A modified Wald-type test statistic is used for testing
H0(BG).
WB = D
′
BL
′(LV̂BL′)−1LDB, (3.3.3)
where DB = (X˜·1··, ..., X˜·J ··)′, and V̂B is the estimated J × J covariance matrix for DB, with
the value at the j1th row and the j2th column being
η̂Bj1j2 =
1
I2K2
I∑
i
K∑
k
1
nik(nik − 1)
nik∑
l
(Xij1kl −X ij1k·)(Xij2kl −X ij2k·). (3.3.4)
A third hypothesis test is conducted for the main effect on the gene of interest. While the
expression levels vary greatly between genes, it is not desirable to compare the expressions
directly. To make comparisons between genes, the data should be adjusted to other data,
such as a reference or a control dataset, or an alternative dye intensity. In such cases,
we often use log-ratio to transform the original gene expression profile. We are interested
in detecting discordance of expression pattern between large groups of genes. The null
hypothesis is
H0(G) : all γk = 0, for k = 1, ..., K.
To test H0(G), similar to analysis of variance, a modified F test statistic is considered.
F (G) =
MSTG
MSEG
. (3.3.5)
But these versions of MST and MSE are slightly different from that of ANOVA, in that
MSTG =
IJ
K − 1
K∑
k=1
(X˜··k· − X˜····)2 (3.3.6)
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where X˜··k· is the sample average of all X˜i·k· for i=1, ..., I, and in the same way, X˜i·k· is the
sample average of X ijk· X˜···· is the sample average of all X˜··k·.
MSEG =
1
IJK
I∑
i=1
J∑
j,j1
K∑
k
1
nik(nik − 1)
nik∑
l=1
(Xijkl −X ijk.)(Xij1kl −X ij1k.). (3.3.7)
The definition of MSEG is different from that of the traditional MSE in that the within-
subject correlation over time is taken into account.
The fourth test statistic is for interaction effect of treatment and time. In such situation,
we want to identify the gene sets that are activated by treatment in only some specific time
points. The expression of genes are affected by treatment, but the effects are only observed
after a period of time.
The null hypothesis of no interaction of treatment and time is
H0(AB) : all (αβ)ij = 0, for i = 1, ..., I, and j = 1, ..., J.
Similar to test H0(B), in order to test H0(AB) of the time effect, we also consider a
more general hypothesis H0(ABG) : L(αβ) = 0 where L is matrix with p rows and I × J
columns, (αβ) is the vector of (αβ)ij with length I×J , and 0 is a p dimensional zero vector.
A modified Wald-type test statistic is used for testing H0(ABG).
WAB = D
′
ABL
′(LV̂ABL′)−1LDAB, (3.3.8)
where DAB = (X˜11··, X˜12··, ..., X˜ij··, ..., X˜IJ ··)′, and V̂AB is the estimated covariance matrix
for DAB. The estimated covariance of X˜ij·· and X˜i1j1·· is given at the ((i − 1)J + j)th row
and ((i1− 1)J + j1)th column of V̂AB. If i 6= i1, the value is zero. If i = i1, the value is given
by
η̂AB(ij)(ij1) =
1
K2
K∑
k
1
nik(nik − 1)
nik∑
l
(Xij1kl −X ij1k·)(Xij2kl −X ij2k·). (3.3.9)
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The next test is targeted to find the gene set that have some genes responsible to the
treatment. The gene set can be discovered via hypothesis test of the interaction of gene and
treatment effect. The null hypothesis is
H0(AG) : all (αγ)ik = 0, for i = 1, ..., I, and k = 1, ..., K.
Similar to the test statistic for main effect of gene, the test of interaction H0(AG) is also
based on a derivative of F statistic
F (AG) =
MSTAG
MSEAG
, (3.3.10)
where
MSTAG =
J
(I − 1)(K − 1)
I∑
i
K∑
k
(X˜i·k· − X˜i··· − X˜··k· + X˜····)2, (3.3.11)
MSEAG =
1
IJK
I∑
i
J∑
j,j1
K∑
k
1
nik(nik − 1)
nik∑
l
(Xijkl −X ijk.)(Xij1kl −X ij1k.).
The calculation of sample average is different from ANOVA model, and it is denoted by
X˜····).
Finally, the high throughput time course study is often targeted to identify the vari-
ables that show positive time response, such as genes regulated by cell cycle. We provide
hypothesis test for the interaction of variables and time. The null hypothesis is
H0(BG) : all (βγ)jk = 0, for j = 1, ..., J, and k = 1, ..., K.
Alike to the test statistic for main effect of gene, the test of interaction H0(BG) is also
based on a derivative of F statistic
F (BG) =
MSTBG
MSEBG
, (3.3.12)
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where
MSTBG =
I
(J − 1)(K − 1)
J∑
j
K∑
k
(X˜·jk· − X˜·j·· − X˜··k· + X˜····)2, (3.3.13)
MSEBG =
1
IK(J − 1)
I∑
i
J∑
j
K∑
k
1
nik(nik − 1)
nik∑
l
(Xijkl −X ijk.)2 −
1
IKJ(J − 1)
I∑
i
J∑
j,j1
K∑
k
1
nik(nik − 1)
nik∑
l
(Xijkl −X ijk.)(Xij1kl −X ij1k.).
The calculation of sample average is different from ANOVA model, and it is denoted by
X˜····.
The asymptotic distribution for each of the test statistic will be derived in the following
sections.
3.4 Main results based on original observations
This section is devoted to develop the asymptotic distribution of the test statistics which
are defined in the last section. The asymptotic properties are derived based on the original
observation under null hypotheses. For simplicity, we use the residual eijkl = Xijkl−E[Xijkl]
in this section.
Theorem 3.4.1. For testing H0(AG): Lα = 0 where L is a I × p contrast matrix, α =
(α1, ..., αI)
′, and 0 is a p dimensional zero vector, let WA be the statistic given in (3.3.1).
If Xijkl has a finite fourth moment, then under H0(AG),
WA
d→ χ2p as K →∞.
We will start the proof by first showing that the variance estimation in WA is consistent.
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Lemma 3.4.2. Let ηA,i = V ar(X˜i···) denote the variance of X˜i···, and let η̂A,i be the statistic
given in (3.3.2). Under the settings and assumptions of Theorem 3.4.1,
K(η̂A,i − ηA,i) p→ 0 as K →∞.
for i=1, ..., I.
Proof: By the independence of X˜i·k· for k=1, ..., K, we have
ηA,i = V ar(X˜i···) = V ar
(∑K
k=1 X˜i·k·
K
)
=
1
K2
K∑
k=1
V ar(X˜i·k·).
Let
η̂Ai,k =
1
J2nik(nik − 1)
J∑
j1,j2
nik∑
l
(Xij1kl −X ij1k·)(Xij2kl −X ij2k·).
We will show that η̂Ai,k is an unbiased estimator of ηA,i,k = V ar(X˜i·k·). First note that
E
[
(Xij1kl −X ij1k·)(Xij2kl −X ij2k·)
]
= E [(eij1kl − eij1k·)(eij2kl − eij2k·)]
= E(eij1kleij2kl)− E(eij1k·eij2kl)− E(eij1kleij2k·) + E(eij1k·eij2k·)
= σi,k,j1j2 −
1
nik
σi,k,j1j2 −
1
nik
σi,k,j1j2 +
1
n2ik
nik∑
l
E(eij1kleij2kl)
=
nik − 1
nik
σi,k,j1j2 .
We then have
E(η̂Ai,k) =
1
J2nik(nik − 1)
J∑
j1,j2
nik∑
l
E
[
(Xij1kl −X ij1k·)(Xij2kl −X ij2k·)
]
=
1
J2ni,k
J∑
j1j2
σi,k,j1j2
It is easy to show that
ηA,i,k =
1
J2ni,k
J∑
j1j2
σi,k,j1j2 .
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Therefore we have shown that E(η̂Ai,k) = ηA,i,k. The lemma will follow by showing that
1
K
∑K
k=1(η̂Ai,k − ηA,i,k)
p→ 0. The convergence is obtained by applying the Markov weak law
of large number. The Markov condition will be satisfied if 1
K2
∑K
k=1E(η̂Ai,k − ηA,i,k)2 → 0
as n→∞. It is sufficient to show that E(η̂Ai,k)2 is finite. By Ho¨lder’s inequality,
E(η̂Ai,k)
2
= E
[
1
J2nik(nik − 1)
J∑
j1,j2
nik∑
l
(eij1kl − eij1k·)(eij2kl − eij2k·)
]2
=
1
J4n2ik(nik − 1)2
E
[
J∑
j1J2
nik∑
l
(eij1kl − eij1k·)(eij2kl − eij2k·)
]2
≤ 1
J2nik(nik − 1)2
J∑
j1J2
nik∑
l
E [(eij1kl − eij1k·)(eij2kl − eij2k·)]2
=
1
J2nik(nik − 1)2
J∑
j1J2
nik∑
l
E [eij1kleij2kl − eij2kleij1k· − eij1kleij1k· + eij2k·eij2k·]2
≤ 4
J2nik(nik − 1)2
J∑
j1J2
nik∑
l
[
E(eij1kleij2kl)
2 + E(eij2kleij1k·)
2 + E(eij1kleij1k·)
2+
E(eij2k·eij2k·)
2
]
< ∞,
for fixed J and nik. The finite bound is obtained because the first four moments of Xijkl
exist. This completes the proof.
Proof of Theorem 3.4.1: Under H0(AG), LE[DA] = 0, where DA = (X˜1···, ..., X˜I···)′, we
have LDA = LDA−E[DA]). Let VA = V ar[DA] = diag(ηA,1, ..., ηA,I). From Lemma (3.4.2),
we have that V̂A is a consistent estimate of VA. Because of the independence of X˜1···’s,
the result will follow with the Continuous Mapping and Slutsky’s Theorems, by showing
(X˜i··· − E[X˜i···])/√ηA,i d→ N(0, 1) as K → ∞. Since X˜i·k·’s are independent for k=1, ...,K,
it is sufficient to show that
∑
k(X˜i·k· − E[X˜i·k·])/(K
√
ηA,i) =
∑
k e˜i·k·/(K
√
ηA,i)
d→ N(0, 1)
as K →∞. And the asymptotic normality of X˜i··· can be shown by Lyapounov’s Theorem.
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The Lyapounov condition will be satisfied if
LA =
∑K
k=1E|e˜i·k·|4
(
∑K
k=1 ηA,i,k)
2
→ 0
Because the first four moments of Xijkl exists, it is easy to show E|e˜i·k·|4 is finite for any k by
Ho¨lder’s theorem. Since ηA,i,k’s are non-zero constant, LA → 0 as a → ∞. This completes
the proof.
Theorem 3.4.3. For testing H0(BG): Lβ = 0 where L is a p × J contrast matrix, β =
(β1, ..., βJ)
′, and 0 is a p dimensional zero vector, let WB be the statistic given in (3.3.3).
If Xijkl has a finite fourth moment, then under H0(BG),
WB
d→ χ2p as K →∞.
Proof of Theorem 3.4.3: Under H0(BG), LE[DB] = 0, then LDB = L(DB − E[DB]).
Let VB = V ar[DB]. VB is a J × J matrix, where the value of j1th row and j2th column is
defined as
Cov(X˜·j1··, X˜·j2··) = ηB,j1j2 =
1
I2K2
I∑
i
K∑
k
σi,k,j1j2
nik
.
If j1 = j2 = j, it is the variance of X˜·j··, and it is denoted
ηB,j =
1
I2K2
I∑
i
K∑
k
σ2i,k,j
nik
.
The result will follow with the Continuous Mapping and Slutsky’s Theorems, by showing
√
N(DB − E[DB]) d→ NJ(0, limK→∞NVB) as K → ∞, where N =
∑I
i=1
∑K
k=1 nik. It is
sufficient to show for any finite constants a = (a1, ..., aJ)
′,
√
Na′(DB − E[DB]) =
J∑
j=1
aj
√
N(X˜·j·· − E(X˜·j··)) d→ N(0, lim
K→∞
Na′VBa),
where Na′VBa = N
∑I
i=1
∑J
j,j1
∑K
k ajaj1σi,k,jj1/(nikI
2K2) converges if
(
∑I
i
∑K
k n
−1
ik )(
∑I
i
∑K
k nik)/K
2 converges, which holds if maxnik/minnik = O(1).
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Note that
J∑
j=1
aj
√
N [X˜·j·· − E(X˜·j··)]
=
√
N
K
J∑
j=1
aj
K∑
k
[X˜·jk· − E(X˜·jk·)]
=
K∑
k
(√
N
K
J∑
j
aj e˜·jk·
)
.
Asymptotic normality is attained by applying Lyapounov’s Theorem. The Lyapounov
condition will be satisfied if
LB =
K∑
k
(√
N
K
)4
E
(
J∑
j
aj e˜·jk·
)4
→ 0.
To see this,
LB =
K∑
k
(√
N
K
)4
E
(
J∑
j
aj e˜·jk·
)4
≤
K∑
k
N2
K4
J3
J∑
j
E(a4j e˜
4
·jk·)
=
K∑
k
N2
K4
J3
J∑
j
a4j
I
E(
I∑
i
e4ijk·) ≤
K∑
k
N2
K4
J3
J∑
j
a4j
I
B4
[
I∑
i
E(e2ijk·)
]2
=
K∑
k
N2
K4
J3
J∑
j
a4j
I
B4
[
I∑
i
1
n2ik
E(
nik∑
l
eijkl)
2
]2
=
K∑
k
N2
K4
J3
J∑
j
a4j
I
B4
[
I∑
i
1
nik
σ2i,k,j)
]2
= O
(
K∑
k
N2
K4
I∑
i
1
n2ik
)
= O(K−1),
where the first inequality follows Ho¨lder’s inequality (2.5.2), and the last equality holds
if max{nik} = O(min{nik}). The second inequality follows from Khintchine’s inequality
(2.5.4). B4 is a constant with definition of B2m = ((2m)!/2
mm!)
1
2m .
66
This completes the proof.
Theorem 3.4.4. For null hypothesis H0(G): all γk = 0, let F (G) be the statistic given in
(3.3.5). If Xijkl has a finite fourth moment, then under H0(G), as K →∞,
√
K(F (G)− 1)
VG
d→ N(0, 1),
where VG is the asymptotic variance defined as
VG =
√
τG/σG. (3.4.1)
where
τG =
2
I2J2K
K∑
k=1
[
I∑
i 6=i1
J∑
j,j1,j2,j3
1
nikni1k
σi,k,jj1σi1,k,j2j3 +
I∑
i
J∑
j,j1,j2,j3
1
nik(nik − 1)σi,k,jj1σi,k,j2j3
]
,
σG =
1
IJK
I∑
i=1
J∑
j,j1
K∑
k
σi,k,jj1
nik
.
Lemma 3.4.5. Under the settings and assumptions of Theorem 3.4.4,
MSEG − σG p→ 0 as K →∞.
Proof:
First note that in the proof of Lemma (3.4.2) we have shown
E
[
(Xij1kl −X ij1k·)(Xij2kl −X ij2k·)
]
=
nik − 1
nik
σi,k,j1j2 .
Then,
E(MSEG) =
1
IJK
I∑
i=1
J∑
j,j1
∑
k
1
nik(nik − 1)
nik∑
l=1
E
[
(Xijkl −X ijk.)(Xij1kl −X ij1k.)
]
= σG.
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And we have
V ar(MSEG)
=
1
(IJK)2
I∑
i=1
J∑
j,j1
∑
k
1
n2ik(nik − 1)2
nik∑
l=1
nik∑
l2=1
Cov
[
b∑
j,j1
(Xijkl −X ij.)(Xij1kl −X ij1.),
b∑
j2,j3
(Xij2kl2 −X ij2.)(Xij3kl2 −X ij3.)
]
.
Note that
E
[
(Xijkl −X ijk.)(Xij1kl −X ij1k.)
]2
= E [(eijkl − eijk.)(eij1kl − eij1k.)]2
= E[eijkleij1kl − eijk.eij1kl − eijkleij1k. + eijk.eij1k.]2
≤ 4[E(eijkleij1kl)2 + E(eijk.eij1kl)2 + E(eijkleij1k.)2 + E(eijk.eij1k.)2]
= 4
[
E(e2ijkle
2
ij1kl
) +
1
n2ik
E(e2ijkle
2
ij1kl
) +
1
n2ik
E(e2ijkle
2
ij1kl
) +
n2ik
n4ik
nik∑
l=1
nik∑
l1=1
E(e2ijkle
2
ij1kl1
)
]
=
4(n2ik + 2 + nik)
n2ik
Cov(e2ijkl, e
2
ij1kl
) + 4σ2ijkσ
2
ij1k
< ∞,
where the first inequality follows Ho¨lder’s inequality (2.5.2), and the last inequality holds
because Xijk has the finite fourth moment.
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We have∣∣∣∣∣Cov
[
J∑
j,j1
(eijkl − eijk.)(eij1kl − eij1k.),
J∑
j2,j3
(eij2kl2 − eij2k.)(eij3kl2 − eij3k.)
]∣∣∣∣∣ (3.4.2)
≤
∣∣∣∣∣V ar
[
J∑
j,j1
(eijkl − eijk.)(eij1kl − eij1k.)
]
V ar
[
J∑
j2,j3
(eij2kl2 − eij2k.)(eij3kl2 − eij3k.)
]∣∣∣∣∣
1
2
≤
∣∣∣∣∣∣E
[
J∑
j,j1
(eijkl − eijk.)(eij1kl − eij1k.)
]2∣∣∣∣∣∣
1
2
∣∣∣∣∣∣E
[
J∑
j2,j3
(eij2kl2 − eij2k.)(eij3kl2 − eij3k.)
]2∣∣∣∣∣∣
1
2
≤
∣∣∣∣∣J2
J∑
j,j1
E [(eijkl − eijk.)(eij1kl − eij1k.)]2
∣∣∣∣∣
1
2
∣∣∣∣∣J2
J∑
j2,j3
E [(eij2kl2 − eij2k.)(eij3kl2 − eij3k.)]2
∣∣∣∣∣
1
2
= J2
∣∣∣∣∣
J∑
j,j1
E [(eijkl − eijk.)(eij1kl − eij1k.)]2
∣∣∣∣∣
1
2
∣∣∣∣∣
J∑
j2,j3
E [(eij2kl2 − eij2k.)(eij3kl2 − eij3k.)]2
∣∣∣∣∣
1
2
< ∞,
where the inequalities follow from the Cauchy Schwartz Inequality and Ho¨lder’s inequality,
and the last inequality holds due to the results previously shown.
Therefore,
V ar(MSEG) = O(K
−1)
It follows that MSEG − σG p→ 0 as K →∞.
Lemma 3.4.6. Under the settings and assumptions of Theorem 3.4.4 and under H0(G), we
have
√
K(MSTG − PG(e)) p→ 0 as K →∞,
where PG(e) =
IJ
K
∑K
k=1 e˜
2
··k·.
Proof:
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Note that under H0(G),
MSTG =
IJ
K − 1
K∑
k=1
(e˜··k· − e˜····)2
=
IJ
K − 1
(
K − 1
K
K∑
k=1
e˜2··k· −
1
K
K∑
k 6=k′
e˜··k·e˜··k′·
)
=
IJ
K
K∑
k=1
e˜2··k· −
IJ
K(K − 1)
K∑
k 6=k′
e˜··k·e˜··k·.
Thus, we have
E[
√
K(MSTG − PG(e))] =
√
KIJ
K(K − 1)
K∑
k 6=k′
E [e˜··k·e˜··k·] = 0.
Furthermore,
E[
√
K(MSTG − PG(e))]2
=
KI2J2
K2(K − 1)2
(
K∑
k 6=k′
E [e˜··k·e˜··k·]
)2
=
I2J2
K(K − 1)2E
[
K∑
k 6=k1,k2 6=k3
e˜2··k·e˜
2
··k1·e˜
2
··k2·e˜
2
··k3·
]
=
2I2J2
K(K − 1)2E
[
K∑
k 6=k1
e˜2··k·e˜
2
··k1·
]
=
2I2J2
K(K − 1)2
K∑
k 6=k1
E[e˜2··k·]E[e˜
2
··k1·]
= O(K−1).
Therefore, under H0(G),
√
K(MSTG − PG(e)) p→ 0 as K →∞.
Proof of Theorem 3.4.4: From Lemmas 3.4.5 and 3.4.6, we need only to consider the
asymptotic distribution of QG(e) =
√
K(PG(e) − MSEG) under H0(G), where PG(e) =
IJ
K
∑K
k=1 e˜
2
··k·.
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Using some simple algebra, we have
QG(e)
=
√
K
[
IJ
K
K∑
k=1
e˜2··k· −
1
IJK
I∑
i=1
J∑
j,j1
∑
k
1
nik(nik − 1)
nik∑
l=1
(Xijkl −X ijk.)(Xij1kl −X ij1k.)
]
=
1
IJ
√
K
K∑
k=1
[
(
I∑
i
J∑
j
nik∑
l
eijkl
nik
)2 −
I∑
i=1
J∑
j,j1
1
nik(nik − 1)
nik∑
l=1
(eijkl − eijk.)(eij1kl − eij1k.)
]
=
1
IJ
√
K
J∑
j,j1
K∑
k=1
[
I∑
i,i1
nik∑
l
ni1k∑
l1
eijklei1j1kl1
nikni1k
−
I∑
i=1
1
nik(nik − 1)
nik∑
l=1
(eijkleij1kl − eij1kleijk.
−eijkleijk. + eijk.eij1k.) ]
=
1
IJ
√
K
J∑
j,j1
K∑
k=1
[
I∑
i6=i1
nik∑
l
ni1k∑
l1
eijklei1j1kl1
nikni1k
+
I∑
i=1
1
nik(nik − 1)
nik∑
l 6=l1
eijkleij1kl1
]
.
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Therefore, E[QG] = 0. It follows that
V ar(QG(e))
= E
(
1
IJ
√
K
J∑
j,j1
K∑
k=1
[
I∑
i6=i1
nik∑
l
ni1k∑
l1
eijklei1j1kl1
nikni1k
+
I∑
i=1
1
nik(nik − 1)
nik∑
l 6=l1
eijkleij1kl1
])2
=
1
I2J2K
K∑
k=1
E
(
J∑
j,j1
[
I∑
i6=i1
nik∑
l
ni1k∑
l1
eijklei1j1kl1
nikni1k
+
I∑
i=1
1
nik(nik − 1)
nik∑
l 6=l1
eijkleij1kl1
])2
=
1
I2J2K
K∑
k=1
[
E(
I∑
i6=i1
J∑
j,j1
nik∑
l
ni1k∑
l1
eijklei1j1kl1
nikni1k
)2 + E(
I∑
i=1
J∑
j,j1
1
nik(nik − 1)
nik∑
l 6=l1
eijkleij1kl1)
2
]
=
2
I2J2K
K∑
k=1
[
I∑
i6=i1
1
n2ikn
2
i1k
E(
J∑
j,j1
nik∑
l
ni1k∑
l1
eijklei1j1kl1)
2 +
nik∑
l 6=l1
E(
I∑
i=1
J∑
j,j1
1
nik(nik − 1)eijkleij1kl1)
2
]
=
2
I2J2K
K∑
k=1
[
I∑
i6=i1
J∑
j,j1,j2,j3
nik∑
l
ni1k∑
l1
1
n2ikn
2
i1k
E(eijkleij1klei1j2kl1ei1j3kl1)
+
I∑
i
J∑
j,j1,j2,j3
nik∑
l 6=l1
1
n2ik(nik − 1)2
E(eijkleij1kleij2kl1eij3kl1)
]
=
2
I2J2K
K∑
k=1
[
I∑
i6=i1
J∑
j,j1,j2,j3
nik∑
l
ni1k∑
l1
1
n2ikn
2
i1k
E(eijkleij1kl)E(ei1j2kl1ei1j3kl1)
+
I∑
i
J∑
j,j1,j2,j3
nik∑
l 6=l1
1
n2ik(nik − 1)2
E(eijkleij1kl)E(eij2kl1eij3kl1)
]
=
2
I2J2K
K∑
k=1
[
I∑
i6=i1
J∑
j,j1,j2,j3
1
nikni1k
σi,k,jj1σi1,k,j2j3 +
I∑
i
J∑
j,j1,j2,j3
1
nik(nik − 1)σi,k,jj1σi,k,j2j3
]
= τG.
Since V ar(QG(e)) is bounded, Lyapunov’s condition will be satisfied if
LG =
K∑
k=1
E
∣∣∣∣∣ 1IJ√K
J∑
j,j1
[
I∑
i6=i1
nik∑
l
ni1k∑
l1
eijklei1j1kl1
nikni1k
+
I∑
i=1
1
nik(nik − 1)
nik∑
l 6=l1
eijkleij1kl1 ]
∣∣∣∣∣
4
→ 0.
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We have
LG =
1
I4J4K2
K∑
k=1
E
∣∣∣∣∣
J∑
j,j1
[
I∑
i6=i1
nik∑
l
ni1k∑
l1
eijklei1j1kl1
nikni1k
+
I∑
i=1
1
nik(nik − 1)
nik∑
l 6=l1
eijkleij1kl1 ]
∣∣∣∣∣
4
≤ J
6
I4J4K2
J∑
j,j1
K∑
k=1
E
∣∣∣∣∣
I∑
i 6=i1
nik∑
l
ni1k∑
l1
eijklei1j1kl1
nikni1k
+
I∑
i=1
1
nik(nik − 1)
nik∑
l 6=l1
eijkleij1kl1
∣∣∣∣∣
4
≤ 8J
2
I4K2
J∑
j,j1
K∑
k=1
[
E|
I∑
i 6=i1
nik∑
l
ni1k∑
l1
eijklei1j1kl1
nikni1k
|4 + E|
I∑
i=1
1
nik(nik − 1)
nik∑
l 6=l1
eijkleij1kl1|4
]
≤ 8J
2
I4K2
J∑
j,j1
K∑
k=1
[
I∑
i6=i1
nik∑
l
ni1k∑
l1
I3(I − 1)3n3ikn3i1k
n4ikn
4
i1k
E|eijklei1j1kl1|4
+
I∑
i=1
nik∑
l 6=l1
I3n3ik(nik − 1)3
n4ik(nik − 1)4
E|eijkleij1kl1|4
]
=
8J2
IK2
J∑
j,j1
K∑
k=1
[
I∑
i6=i1
nik∑
l
ni1k∑
l1
(I − 1)3
nikni1k
E(eijkl)
4E(ei1j1kl1)
4
+
I∑
i=1
nik∑
l 6=l1
1
nik(nik − 1)E(eijkl)
4E(eij1kl1)
4
]
= O(K−1),
if the fourth moment of eijk exists for any i, j, and k. The inequalities follow from Ho¨lder’s
inequality, and the last equation results from the finite fourth central moment of Xijkl. This
completes the proof.
Theorem 3.4.7. For testing H0(ABG): L(αβ) = 0 where L is a contrast matrix with p
rows and I × J columns, (αβ) is the vector of (αβ)ij, and 0 is a p dimensional zero vector,
let WAB be the statistic given in (3.3.8). If Xijkl has a finite fourth moment, then under
H0(ABG),
WAB
d→ χ2p as K →∞.
Proof of Theorem 3.4.7: Under H0(ABG), LE[DAB] = 0, then LDAB = L(DAB −
E[DAB]). Let VAB = V ar[DAB]. VAB is a (IJ)× (IJ) matrix, and the estimated covariance
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of X˜ij·· and X˜i1j1·· is given at the ((i− 1)J + j)th row and ((i1− 1)J + j1)th column of V̂AB.
If i 6= i1, the value is zero. If i = i1, the value is given by
η̂AB(ij)(ij1) =
1
K2
K∑
k
1
nik(nik − 1)
nik∑
l
(Xij1kl −X ij1k·)(Xij2kl −X ij2k·). (3.4.3)
The result will follow with the Continuous Mapping and Slutsky’s Theorems, by showing
√
N(DAB −E[DAB]) d→ NJ(0, limK→∞NVAB) as K →∞, where N =
∑I
i=1
∑K
k=1 nik. It is
sufficient to show for any finite constants a = (a11, a12, ..., aij, ..., aIJ)
′,
√
Na′(DAB − E[DAB]) =
I∑
i=1
J∑
j=1
aij
√
N(X˜ij·· − E(X˜ij··)) d→ N(0, lim
K→∞
Na′VABa),
where Na′VABa = N
∑I
i=1
∑J
j,j1
∑K
k aijaij1σi,k,jj1/(nikK
2) converges if
(
∑I
i
∑K
k n
−1
ik )(
∑I
i
∑K
k nik)/K
2 converges, which holds if maxnik/minnik = O(1).
I∑
i=1
J∑
j=1
aij
√
N(X˜ij·· − E(X˜ij··))
=
√
N
K
I∑
i=1
J∑
j=1
aij
K∑
k
(X ijk· − E(X ijk·))
=
K∑
k
(√
N
K
I∑
i=1
J∑
j=1
aijeijk·
)
.
The asymptotic normality can be shown by Lyapounov’s Theorem. The Lyapounov condi-
tion will be satisfied if
LAB =
K∑
k
(√
N
K
)4
E
(
I∑
i=1
J∑
j=1
aijeijk·
)4
→ 0.
Note that
LAB =
K∑
k
(√
N
K
)4
E
(
I∑
i=1
J∑
j=1
aijeijk·
)4
≤
K∑
k
N2I3
K4
I∑
i
E
(
J∑
j=1
aijeijk·
)4
≤
K∑
k
N2I3J3
K4
I∑
i
J∑
j=1
E(a4ije
4
ijk·) =
K∑
k
N2I3J3
K4
I∑
i
J∑
j=1
a4ij
n4ik
E
(
nik∑
l
eijkl
)4
≤
K∑
k
N2I3J3
K4
I∑
i
J∑
j=1
a4ij
nik
E(e4ijkl) = O(K
−1),
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where the inequalities follow from Ho¨lder’s inequality (2.5.2), and the last equality holds if
the fourth moment exists. This completes the proof.
Theorem 3.4.8. For null hypothesis H0(AG): all (αγ)jk = 0 for j=1, ...,J, and k=1, ...,K,
let F(AG) be the statistic given in (3.3.10). If Xijkl has a finite fourth moment, then under
H0(AG),
√
K(F (AG)− 1)
VAG
d→ N(0, 1) as K →∞,
VAG =
√
τAG/σAG, (3.4.4)
with
τAG =
2
I2J2K
J∑
j,j1,j2,j3
K∑
k
[
I∑
i
1
nik(nik − 1)σi,k,jj1σi,k,j2j3+
1
(I − 1)2
I∑
i6=i1
1
nikni1k
σi,k,jj1σi1,k,j2j3
]
,
σAG =
1
IJK
I∑
i=1
J∑
j,j1
K∑
k
σi,k,jj1
nik
.
Lemma 3.4.9. Under the settings and assumptions of Theorem 3.4.8,
MSEAG − σAG p→ 0 as K →∞.
Proof:
As shown in lemma 3.4.2,
E
[
(Xijkl −X ijk.)(Xij1kl −X ij1k.)
]
=
nik − 1
nik
σi,k,jj1 .
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Then
E(MSEAG)
=
1
IJK
I∑
i
J∑
j,j1
K∑
k
1
nik(nik − 1)
nik∑
l
E[(Xijkl −X ijk.)(Xij1kl −X ij1k.)]
=
1
IJK
I∑
i
J∑
j,j1
K∑
k
σi,k,jj1
nik
= σAG.
Therefore,
V ar(MSEAG)
=
1
I2J2K2
I∑
i
K∑
k
1
n2ik(nik − 1)2
nik∑
l
V ar
[
J∑
j,j1
(Xijkl −X ijk.)(Xij1kl −X ij1k.)
]
.
From formula (3.4.2), we have∣∣∣∣∣Cov
[
J∑
j,j1
(Xijkl −X ijk.)(Xij1kl −X ij1k.),
J∑
j2,j3
(Xij2kl −X ij2k.)(Xij3kl −X ij3k.)
]∣∣∣∣∣
=
∣∣∣∣∣Cov
[
J∑
j,j1
(eijkl − eijk.)(eij1kl − eij1k.),
J∑
j2,j3
(eij2kl − eij2k.)(eij3kl − eij3k.)
]∣∣∣∣∣
< ∞.
Therefore, we have
V ar
[
J∑
j,j1
(Xijkl −X ijk.)(Xij1kl −X ij1k.)
]
<∞.
It follows that
V ar(MSEAG)→ 0
as K →∞. Thus we proved MSEAG − σ2AG p→ 0 as K →∞.
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Lemma 3.4.10. Under the settings and assumptions of Theorem 3.4.8 and under H0(AG),
we have
√
K(MSTAG − PAG(e)) p→ 0 as K →∞,
where PAG(e) =
J
K(I−1)
∑I
i=1
∑K
k=1(e˜i.k. − e˜..k.)2.
Proof:
Note that under H0(AG),
MSTAG
=
J
(I − 1)(K − 1)
I∑
i=1
K∑
k=1
(e˜i.k. − e˜i... − e˜..k. + e˜....)2
=
J
(I − 1)(K − 1)
I∑
i=1
K∑
k=1
[
(e˜i.k. − e˜..k.)2 − 2
K
K∑
k1
(e˜i.k. − e˜..k.)(e˜i.k1. − e˜..k1.)+
1
K2
K∑
k1
(e˜i.k1. − e˜..k1.)2
]
=
J
(I − 1)(K − 1)
I∑
i=1
[
K + 1
K
K∑
k=1
(e˜i.k. − e˜..k.)2 − 2
K
K∑
k,k1
(e˜i.k. − e˜..k.)(e˜i.k1. − e˜..k1.)
]
=
J
K(I − 1)
I∑
i=1
K∑
k=1
(e˜i.k. − e˜..k.)2 − 2J
K(I − 1)(K − 1)
I∑
i=1
K∑
k 6=k1
(e˜i.k. − e˜..k.)(e˜i.k1. − e˜..k1.).
Thus, we have
E[
√
K(MSTAG − PAG(e))] = 2J
√
K
K(I − 1)(K − 1)
I∑
i=1
K∑
k 6=k1
E[(e˜i.k. − e˜..k.)(e˜i.k1. − e˜..k1.)] = 0.
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And
E[
√
K(MSTAG − PAG(e))]2
=
4J2K
K2(I − 1)2(K − 1)2E
[
I∑
i=1
K∑
k 6=k1
(e˜i.k. − e˜..k.)(e˜i.k1. − e˜..k1.)
]2
=
8J2
K(I − 1)2(K − 1)2E
 K∑
(k=k1)6=(k2=k3)
(
I∑
i=1
(e˜i.k. − e˜..k.)(e˜i.k2. − e˜..k2.)
)
(
I∑
i=1
(e˜i.k1. − e˜..k1.)(e˜i.k3. − e˜..k3.)
)]
=
8J2
K(I − 1)2(K − 1)2E
[
K∑
k 6=k1
I∑
i
(e˜i.k. − e˜..k.)(e˜i.k1. − e˜..k1.)(e˜i.k. − e˜..k.)(e˜i.k1. − e˜..k1.)
)
=
8J2
K(I − 1)2(K − 1)2
I∑
i
K∑
k 6=k1
E[(e˜i.k. − e˜..k.)(e˜i.k. − e˜..k.)]E[(e˜i.k1. − e˜..k1.)(e˜i.k1. − e˜..k1.)]
= O(K−1).
The last equation holds if Xijkl has the finite fourth moment. Therefore under H0(AG),
√
K(MSTAG − PAG(e)) p→ 0 as K →∞.
Proof of Theorem 3.4.8: From Lemma 3.4.9 and Lemma 3.4.10, we need only to consider
the asymptotic distribution of QAG(e) =
√
K(PAG(e)−MSEAG) under H0(AG).
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With some simple algebra, we have
QAG(e)
=
√
K
[
J
K(I − 1)
I∑
i=1
K∑
k=1
(e˜i.k. − e˜..k.)2 − 1
IJK
I∑
i
J∑
j,j1
K∑
k
1
nik(nik − 1)
nik∑
l
(eijkl − eijk·)(eij1kl − eij1k·)
]
=
√
K
[
1
JK(I − 1)
I∑
i=1
K∑
k=1
J∑
j,j1
(eijk. − e˜.jk.)(eij1k. − e˜.j1k.)−
1
IJK
I∑
i
J∑
j,j1
K∑
k
1
nik(nik − 1)
nik∑
l
(eijkl − eijk·)(eij1kl − eij1k·)
]
=
1
J(I − 1)√K
I∑
i
J∑
j,j1
K∑
k
(eijk. − e˜.jk.)(eij1k. − e˜.j1k.)−
1
IJ
√
K
I∑
i
J∑
j,j1
K∑
k
1
nik(nik − 1)
nik∑
l
(eijkl − eijk·)(eij1kl − eij1k·)
=
1
J(I − 1)√K
I∑
i
J∑
j,j1
K∑
k
(eijk.eij1k. − eij1k.e˜.jk. − eijk.e˜.j1k. + e˜.jk.e˜.j1k.)−
1
IJ
√
K
I∑
i
J∑
j,j1
K∑
k
1
nik(nik − 1)
nik∑
l
(eijkleij1kl − eij1kleijk· − eijkleij1k· − eijk·eij1k·)
=
1
J(I − 1)√K
J∑
j,j1
K∑
k
(
I∑
i
eijk.eij1k. −
1
I
I∑
i,i1
eijk.ei1j1k.
)
−
1
IJ
√
K
I∑
i
J∑
j,j1
K∑
k
1
nik(nik − 1)
(
nik∑
l
eijkleij1kl −
1
nik
nik∑
l,l1
eijkleij1kl1
)
=
1
J(I − 1)√K
J∑
j,j1
K∑
k
(
I∑
i
nik∑
l,l1
I − 1
In2ik
eijkleij1kl1 −
I∑
i6=i1
nik∑
l
ni1k∑
l1
1
Inikni1k
eijklei1j1kl1
)
−
1
IJ
√
K
I∑
i
J∑
j,j1
K∑
k
1
nik(nik − 1)
(
nik − 1
nik
nik∑
l
eijkleij1kl −
1
nik
nik∑
l 6=l1
eijkleij1kl1
)
=
1
IJ
√
K
J∑
j,j1
K∑
k
(
I∑
i
nik∑
l 6=l1
1
nik(nik − 1)eijkleij1kl1 −
1
I − 1
I∑
i6=i1
nik∑
l
ni1k∑
l1
1
nikni1k
eijklei1j1kl1
)
.
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Therefore, E[QAG(e)] = 0. It follows that
V ar(QAG(e))
=
1
I2J2K
K∑
k
V ar
[
J∑
j,j1
(
I∑
i
nik∑
l 6=l1
1
nik(nik − 1)eijkleij1kl1 −
1
I − 1
I∑
i6=i1
nik∑
l
ni1k∑
l1
1
nikni1k
eijklei1j1kl1
)]
=
1
I2J2K
K∑
k
[
V ar
(
I∑
i
J∑
j,j1
nik∑
l 6=l1
1
nik(nik − 1)eijkleij1kl1
)
+
V ar
(
I∑
i6=i1
J∑
j,j1
nik∑
l
ni1k∑
l1
1
(I − 1)nikni1k
eijklei1j1kl1
)]
=
1
I2J2K
K∑
k
[
2
I∑
i
nik∑
l 6=l1
V ar
(
J∑
j,j1
1
nik(nik − 1)eijkleij1kl1
)
+
2
(I − 1)2
I∑
i 6=i1
(
nik∑
l
V ar
(
J∑
j
1
nik
eijkl
))(ni1k∑
l1
V ar
(
J∑
j1
1
ni1k
ei1j1kl1
))]
=
2
I2J2K
K∑
k
[
I∑
i
nik∑
l 6=l1
1
n2ik(nik − 1)2
J∑
j,j1,j2,j3
E(eijkleij2kl)E(eij1kl1eij3kl1)+
1
(I − 1)2
I∑
i 6=i1
(
nik∑
l
1
n2ik
J∑
j,j1
E(eijkleij1kl)
)(ni1k∑
l1
1
n2i1k
J∑
j,j1
E(ei1jkl1ei1j1kl1)
)]
=
2
I2J2K
K∑
k
[
I∑
i
1
nik(nik − 1)
J∑
j,j1,j2,j3
σi,k,jj1σi,k,j2j3+
1
(I − 1)2
I∑
i 6=i1
(
1
nik
J∑
j,j1
σi,k,jj1
)(
1
ni1k
J∑
j,j1
σi1,k,jj1
)]
=
2
I2J2K
K∑
k
[
I∑
i
1
nik(nik − 1)
J∑
j,j1,j2,j3
σi,k,jj1σi,k,j2j3+
1
(I − 1)2
I∑
i 6=i1
1
nikni1k
J∑
j,j1,j2,j3
σi,k,jj1σi1,k,j2j3
]
.
Since V ar(QAG(e)) is bounded, Lyapunov’s condition will be satisfied if
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LAG(K) =
K∑
k
E
∣∣∣∣∣ 1IJ√K
J∑
j,j1
(
I∑
i
nik∑
l 6=l1
1
nik(nik − 1)eijkleij1kl1−
1
I − 1
I∑
i6=i1
nik∑
l
ni1k∑
l1
1
nikni1k
eijklei1j1kl1
)∣∣∣∣∣
4
→ 0.
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We have
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= O(K−1) if the fourth moment of eijkl exist for any i, j, k, and l.
where the two inequalities follow from Ho¨lder’s inequality (2.5.2). This completes the proof.
Theorem 3.4.11. For null hypothesis H0(BG): all (βγ)jk = 0 for j=1, ...,J, and k=1,
...,K, let F(BG) be the statistic given in (3.3.12). If Xijkl has a finite fourth moment, then
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under H0(BG),√
K(F (BG)− 1)
VBG
d→ N(0, 1) asK →∞,where VBG is defined in (3.4.5).
The variance component is calculated by
VBG =
√
τBG/σBG (3.4.5)
where
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I∑
i
K∑
k
[
1
nik(nik − 1)
J∑
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.
Lemma 3.4.12. Under the settings and assumptions of Theorem 3.4.11,
MSEBG − σBG p→ 0 as K →∞.
Proof:
As shown in lemma 3.4.2,
E
[
(Xijkl −X ijk.)(Xij1kl −X ij1k.)
]
=
nik − 1
nik
σi,k,jj1 .
Then
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= σBG.
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Therefore,
V ar(MSEBG)
=
1
I2K2(J − 1)2
I∑
i
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.
From formula (3.4.2), we have∣∣∣∣∣Cov
[
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< ∞.
It follows that
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Therefore,
V ar(MSEBG)→ 0
as K →∞. It follows that MSEBG − σ2BG p→ 0 as K →∞.
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Lemma 3.4.13. Under the settings and assumptions of Theorem 3.4.11 and under H0(BG),
we have
√
K(MSTBG − PBG(e)) p→ 0 as K →∞,
where PBG(e) =
1
IK(J−1)
∑I
i=1
∑J
j=1
∑K
k=1(eijk. − e˜i.k.)2.
Proof:
Note that under H0(BG),
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E(eijk. − e˜i.k.)2
= E[PBG(e)].
Thus, we have
E[
√
K(MSTBG − PBG(e))] = 2I
√
K
K(J − 1)(K − 1)
J∑
j=1
K∑
k 6=k1
E[(e˜.jk. − e˜..k.)(e˜.jk1. − e˜..k1.)] = 0.
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And,
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= O(K−1).
Therefore under H0(BG),
√
K(MSTBG − PBG(e)) p→ 0 as K →∞.
Proof of Theorem 3.4.11: From Lemma 3.4.12 and Lemma 3.4.13, we need only to
consider the asymptotic distribution of QBG(e) =
√
K(PBG(e)−MSEBG) under H0(BG).
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With some simple algebra, we have
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Therefore, E[QBG(e)] = 0. It follows that
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Since V ar(QBG(e)) is bounded, Lyapunov’s condition will be satisfied if
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We have
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= O(K−1) if the fourth moment of eijkl exist for any i, j, k, and l,
where the two inequalities follow from Ho¨lder’s inequality (2.5.2). This completes the proof.
3.5 Simulation results
Simulation study was carried out to evaluate the proposed nonparametric test statistics
(NPT) in various conditions. First, we looked at their type I error rates under null hypoth-
esis. To test the robustness of the proposed statistics, we generated random numbers from
various distributions and covariance structures. Secondly, power analysis were conducted
to compare NPT statistics to linear mixed-effects model (LME) and generalized estimat-
ing equations (GEE). In order to generate random numbers as close as to real microarray
data, we use bootstrap to re-sample data from a two-treatment microarray experiment.
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Proper within-subject correlation was then incorporated to the data, and power curves were
produced for each of NPT, LME, and GEE methods.
All the data in this section were generated from the model specified in (3.2.1)
Xijkl = µ+ αi + βj + γk + (αβ)ij + (αγ)ik + (βγ)jk + εijkl.
Throughout the manuscript, all calculations and simulations were completed with R pro-
gramming. LME and GEE methods were implemented by using gls and geese functions
from R packages nlme and geepack , respectively ((Pinheiro and Bates (2000)); (Yan and
Fine (2004)).
3.5.1 Type I error rate analysis with simulated data
In this section, we measured the specificity of our proposed model (NPT) based on type I
error rates for simulated data from various distributions. In most of microarray applications,
the researchers are interested in identifying gene expression changed by treatment comparing
to a control group. In the simulation, we will focused on two treatment groups. The number
of time points we simulated is either 2 or 5. As balanced design is only a special form of
unbalanced design, here we only consider unbalanced design in that four fifths of genes
having 4 replications and the remaining one fifth of genes having 6 replications.
The gene expression microarray data were often modeled with log-normal or normal
distribution (Sidorov et al. (2002); Hoyle et al. (2002)). Nonetheless, there are a number
of arguments that the real gene profile does not closely fit these distributions, and to model
the distribution is still an hot research field with big challenge (Kerr et al. (2000); Konishi
(2004)). To allow a wide variety of data types, normal, exponential, Poisson, and Cauchy
distributions were used to generate random samples. Appropriate within-subject correlation
structures were introduced into the data with the methods described for each experiment.
Throughout the manuscript, all simulations were performed using 1000 iterations.
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For normal, exponential, and Poisson distributions, the mean of random numbers was set
to 2. The normal distribution was given a standard deviation of 1. The Cauchy distribution
had a location value of 0, and a scale value of 1. The within-subject correlation (over
time points) were modeled either with AR(1) or unstructured correlation structure. For
AR(1) correlation, the covariance vector X was conditioned with cov(Xijk, Xij1k) = .5
|j−j1|.
The unstructured correlation structures were obtained by generating correlation symmetric
matrix that has random numbers uniformly distributed between 0 and 1.
First, we examined the proposed test statistic for H0(A) of no gene expression variations
across treatments. A data matrix X of J rows and n columns were were randomly generated
with each row representing a time point and each column representing a gene. J is the
number of time points, and n is the sum of the number of replications for all genes across all
treatment groups. The data matrix were generated under null hypothesis such that there
were no expression changes across columns. An AR(1) or unstructured correlation structure
matrix L with J rows and J columns were then generated as described above. We used
the Cholesky decomposition to produce the lower triangle half matrix h for the correlation
matrix L. The Cholesky decomposition is conducted via R function chol. Thus the data
matrix Y=h*X has the desired correlation structure and it would be used for subsequent
data analysis. The matrix Y had equal means across columns. Nonetheless, at different
time points (across rows), the values from the same gene could be varied. Random data
generation from Poisson distribution was performed slightly differently. We aimed to use
Poisson distribution to generate integer data that simulate specific image data, such as DNA
copy number and cell count. Therefore, we first calculated the means matrix M of the same
dimensions as Y. The matrix M was generated by incorporating the correlation structure to
a matrix with identical elements of value 2. Then the random data matrix Y was obtained
by generate random numbers from Poisson distribution with mean M.
The results of Type I error rate at alpha level 0.05 were given in Table 3.1. Subjects were
assumed to be repeatedly measured at 5 time points with AR(1) within-subject correlation
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structure. As the number of genes increases, the error rate converges to 0.05 for normal,
exponential, and Poisson distribution. They were close to 0.05 with at least 30 genes.
However, the error rate for Cauchy distribution did never go to 0.05 because it does not
have a finite mean.
no.gene normal exponential Poisson Cauchy
5 0.051 0.071 0.075 0.035
10 0.056 0.067 0.062 0.026
20 0.037 0.058 0.053 0.023
30 0.049 0.053 0.055 0.023
40 0.053 0.057 0.054 0.020
50 0.057 0.053 0.052 0.026
100 0.041 0.055 0.051 0.025
200 0.049 0.056 0.054 0.020
500 0.051 0.049 0.047 0.021
1000 0.051 0.051 0.051 0.020
Table 3.1: Estimated type I error estimate of the test of no treatment effect at 0.05 level in
unbalanced design. The data from the same gene follows AR(1) with correlation =0.5.
Table 3.2 showed the type I error rates for unstructured correlation. Either 2 or 5 time
points were simulated for each dataset. For normal, exponential, and Poisson distributions,
the error rates for at least 5 genes and 2 or 5 time points were in high agreement with the
expected level alpha = 0.05. The error rate for Cauchy distribution failed to converge to
0.05.
Secondly, we conducted hypothesis test for the time effect with simulated data. The
random numbers were generated as described above. As correlation introduction via the
Cholesky decomposition does not maintain equal means across time points (rows), we used
an iterative algorithm to generate the AR(1) or unstructured correlation. Suppose for gene
i, the correlation between the jth and (j+1)th time points is ρ that was given based on
AR(1) or unstructured correlation. Given the value Xj of gene i at the jth time point, the
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no.time no.gene normal exponential Poisson Cauchy
5 0.060 0.053 0.063 0.021
10 0.047 0.052 0.048 0.024
20 0.053 0.046 0.054 0.026
2 30 0.048 0.063 0.058 0.019
40 0.044 0.052 0.053 0.021
50 0.043 0.052 0.057 0.020
100 0.040 0.050 0.042 0.020
5 0.056 0.052 0.059 0.032
10 0.053 0.055 0.057 0.025
20 0.047 0.045 0.066 0.020
5 30 0.060 0.058 0.050 0.014
40 0.050 0.049 0.047 0.018
50 0.044 0.041 0.041 0.016
100 0.062 0.047 0.050 0.023
Table 3.2: Estimated type I error estimate of the test of no treatment effect at 0.05 level in
unbalanced design. The data from the same gene have unstructured correlation.
random copy number of the (j+1)th time point can be obtained by
Xj+1 = ρXj + b,
where b is a random number with the mean of 2(1− ρ). Thus the mean of Xj+1 is 2, which
is the same as that of Xj. For Poisson distribution, we first generated the mean values with
the iterative algorithm, and then used the means to generate random integer numbers.
The type I error rates at alpha level 0.05 with unstructured correlation structure were
shown in Table 3.3. Two time points were simulated for each experiment. The error rates
were close to 0.05 for normal, exponential, and Poisson distributions when there were at
least 50 genes in the dataset. The error rate for Cauchy distribution did not converge to
0.05.
Thirdly, simulation was conducted to test the gene effect. Under null hypothesis of no
gene log-ratio variation, the data generating process was the same to that for test of the
treatment effect. An unstructured correlation was introduced to the repeated measures for
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no.gene normal exponential Poisson Cauchy
5 0.049 0.058 0.061 0.025
10 0.062 0.050 0.041 0.016
20 0.055 0.055 0.045 0.018
30 0.074 0.057 0.058 0.020
40 0.062 0.040 0.051 0.018
50 0.047 0.052 0.054 0.022
100 0.042 0.040 0.044 0.017
200 0.044 0.046 0.045 0.021
500 0.053 0.043 0.041 0.017
1000 0.056 0.046 0.037 0.017
Table 3.3: Estimated type I error of the test of no time effect at 0.05 level. The data from the
same gene followed unstructured correlation. For each simulation, there are 2 time points.
either 2 or 5 time points for each gene. The type I error rates at alpha level 0.05 were
shown in Table 3.4. Normal, exponential, and Poisson distributions with both 2 and 5 time
points had similar convergence rate. They converged to 0.05 with at least 40 genes. Cauchy
distribution did not converge to 0.05 as expected.
The next test was concerned with the interaction of treatment and time effect. Under
null hypothesis of no interaction, we generate random data with the same process as to
that for test of the time effect. An unstructured correlation was introduced to the repeated
measures of two time points for each gene. The type I error rates at alpha level 0.05 were
shown in Table 3.5. Normal, exponential, and Poisson distributions had error rates close to
0.05 when the number of genes was above 50. Cauchy distribution did not converge to 0.05.
The fifth test was conducted for the interaction of treatment and the gene effect. Under
null hypothesis of no interaction, the data were simulated in the same way as to that for test
of the gene effect. An unstructured correlation was introduced to the repeated measures
of two time points for each gene. The type I error rates at alpha level 0.05 were shown
in Table 3.6. Normal, exponential, and Poisson distributions had error rates converging to
0.05 with at least 50 genes. Cauchy distribution did not converge to 0.05.
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no.time no.gene normal exponential Poisson Cauchy
5 0.076 0.093 0.097 0.184
10 0.063 0.067 0.058 0.145
20 0.062 0.069 0.055 0.141
30 0.055 0.063 0.053 0.177
2 40 0.067 0.055 0.054 0.138
50 0.059 0.057 0.053 0.135
100 0.052 0.040 0.049 0.158
200 0.049 0.052 0.044 0.141
500 0.060 0.058 0.052 0.137
1000 0.037 0.055 0.048 0.141
5 0.073 0.096 0.072 0.189
10 0.080 0.068 0.074 0.179
20 0.062 0.062 0.065 0.135
30 0.067 0.064 0.070 0.148
5 40 0.051 0.060 0.046 0.140
50 0.043 0.050 0.047 0.159
100 0.053 0.056 0.038 0.143
200 0.046 0.046 0.047 0.146
500 0.041 0.057 0.041 0.113
1000 0.060 0.063 0.027 0.142
Table 3.4: Estimated type I error rates of the test of no gene effect at 0.05 level. The data
from the same gene follow unstructured correlation. There were either 2 or 5 time points
for repeated measures.
Our last attempt was for the interaction test of time and gene effect. Under null hypoth-
esis of no interaction, the random samples were generated in the same way as described for
test of time effect. An unstructured correlation was introduced to the repeated measures
for either 2 or 5 time points for each gene. The number of time points did not play an
important role to affect the error rate. The type I error rates at alpha level 0.05 were shown
in Table 3.7. Normal, exponential, and Poisson distributions had error rates converging to
0.05 with at least 40 genes. Cauchy distribution did not converge to 0.05.
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no.gene normal exponential Poisson Cauchy
5 0.087 0.103 0.099 0.046
10 0.074 0.082 0.064 0.035
20 0.061 0.063 0.050 0.024
30 0.070 0.071 0.063 0.019
40 0.071 0.060 0.065 0.019
50 0.064 0.052 0.056 0.011
100 0.037 0.051 0.048 0.012
200 0.043 0.050 0.052 0.018
500 0.048 0.040 0.051 0.022
1000 0.057 0.046 0.048 0.013
Table 3.5: Estimated type I error of the test of no treatment*time interaction at 0.05 level.
The data from the same gene followed unstructured correlation. For each simulation, there
are 2 time points.
no.gene normal exponential Poisson Cauchy
5 0.088 0.083 0.089 0.195
10 0.072 0.076 0.064 0.173
20 0.070 0.072 0.059 0.186
30 0.053 0.063 0.049 0.167
40 0.053 0.066 0.050 0.138
50 0.058 0.059 0.056 0.163
100 0.057 0.064 0.043 0.140
200 0.054 0.053 0.049 0.139
500 0.055 0.050 0.052 0.147
1000 0.044 0.049 0.051 0.139
Table 3.6: Estimated type I error of the test of no treatment*gene interaction at 0.05 level.
The data from the same gene followed unstructured correlation. For each simulation, there
are 2 time points.
3.5.2 Power analysis with bootstrap data and simulated data
In this sub-section, power analysis was conducted to compare the proposed method (NPT)
with linear mixed model (LME) and generalized estimating equations (GEE) . Since the
distribution fitting for microarray data is not satisfactory as discussed in section 3.1, we
primarily used bootstrap to produce data samples based on real microarray data. As the
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no.time no.gene normal exponential Poisson Cauchy
5 0.083 0.099 0.107 0.261
10 0.055 0.068 0.090 0.254
20 0.056 0.053 0.068 0.248
30 0.051 0.069 0.073 0.242
2 40 0.047 0.050 0.050 0.238
50 0.049 0.039 0.068 0.251
100 0.042 0.037 0.057 0.242
200 0.032 0.034 0.037 0.270
500 0.031 0.033 0.039 0.254
1000 0.034 0.034 0.028 0.249
5 0.090 0.088 0.097 0.261
10 0.049 0.072 0.074 0.267
20 0.047 0.043 0.049 0.252
30 0.053 0.050 0.039 0.242
5 40 0.045 0.054 0.034 0.246
50 0.034 0.037 0.039 0.245
100 0.039 0.037 0.048 0.258
200 0.055 0.045 0.032 0.259
500 0.038 0.038 0.029 0.249
1000 0.028 0.037 0.041 0.239
Table 3.7: Estimated type I error rates of the test of no time*gene effect at 0.05 level. The
data from the same gene follow unstructured correlation. There were either 2 or 5 time
points for repeated measures.
simulation study for type I error rates, we only used unstructured correlation matrix for it is
a general form. The correlation was then introduced to bootstrap samples with the iterative
algorithm described in the previous sub-section. In each experiment, we only consider 2
time points for it is common in a longitudinal microarray experiment design. Based on
our simulation study for type I error rates, 50 genes is sufficient large to achieve expected
error rates. So we used 50 genes for all power analysis experiments. Similar to type I error
simulation, the design was unbalanced with four fifths of genes having 4 replications and one
fifth of genes having 6 replications. Two treatment groups were considered in this bootstrap
study. As a comparison, we also used random number generated from normal distributions
for power analysis. The results were shown at the end of the section for two hypothesis
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tests.
We acquired the data of two microarray samples for IL-2 response experiment in murine
T cell (Zhang et al. (2007)). One sample were stimulated with IL-2 for 4 hours, and the
other was a control without IL-2 treatment. The detail of the experiment design and data
preprocession was described in the next section (3.6). We used the following procedure to
determine the gene list under H0 and under Ha. For each gene, we calculated its log-ratio
expressions of the IL-2 treatment to the control. If the log-ratio was between ±0.1, we
regarded the gene is normal (under H0). If the log-ratio was above 1.3, we regarded the
gene to be abnormal (under Ha) for it was activated by IL-2 by more than 3.5 fold change.
In such an arbitrary definition, we had 3652 genes in the normal list, and 1409 genes in
the abnormal list. The power analysis was conducted by contaminating a bootstrap sample
of normal genes with a small proportion of a bootstrap sample of abnormal genes. For
different tests, we bootstrapped either the original gene expressions (log transformed) or
the log ratios of the two samples. We will discuss which type of data should be used for
each experiment.
LME analysis was carried out by gls function available in contributed R package nlme
(Pinheiro and Bates (2000)). Unstructured within-subject correlation structure was assumed
to the model. Since random effect was not considered, we used generalized least squares
were used to fit the LME model (Carroll and Ruppert (1988)). GEE analysis was carried
out by geese function available in contributed R package geepack (Yan and Fine (2004)).
Unstructured correlation was assumed to the model. The Gaussian family was assumed for
the error distribution.
First, we conducted power analysis for the treatment effect. We considered log ratio data
in this test to simulate the data of two-channel microarray (two dyes) or the data comparing
to a reference sample. In the simulation, for one treatment group, all data came from the
normal gene lists. For the other treatment group, the normal genes were contaminated a
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small percentage of abnormal genes. Both normal and abnormal data were bootstrapped
from the previously defined gene lists. The contamination percentage in each dataset varied
from 0 to 1%. The unstructured correlation structure was introduced to the bootstrap data
by the Cholesky decomposition as described in the previous sub-section. The three power
curves for NPT, LME, and GEE were shown in Figure 3.1. When the contamination was
less than 0.7%, GEE had a higher power than the other two methods, but its power did not
monotonously increase with percentage of contaminations. NPT outperformed LME and
GEE when there was at least 0.7% contamination, and it was the method that first reached
80% power. Therefore, NPT had a better performance in this situation.
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Figure 3.1: The power curves of testing the treatment effect for unbalanced design with unstructured
correlation correlation. There were 2 time points in the experiment.
To illustrate how the number of genes affects statistical power, we displayed power curves
with varying number of genes. The contamination percentage was fixed at 0.5%. As the
number of genes increased, the power of NPT approached to 100% (Figure 3.2). It was the
only method whose power significantly increased with the number of genes. GEE increased
slightly. The power of LME stayed close to zero for the whole range of number of genes.
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Figure 3.2: The power curves of testing the treatment effect with 0.5% contamination. The design was
assumed to be unbalanced with unstructured correlation correlation. There were 2 time points in the experi-
ment.
Our next test was for time effect. We used the log expression values for bootstrap. Since
we only considered two time points, we bootstrapped the gene IDs, and let the data from
IL-2 sample form one time point, and let the data from the control sample form the other
time point. As discussed in the previous subsection, we had to use the iterative algorithm to
incorporate the unstructured correlation. All three methods were very sensitive in detecting
gene expression variation over time. At 2% contamination, all reached a power of 100%
(Figure 3.3). Nonetheless, NPT performed the best because it was the first method to reach
100% power.
Thirdly, we explored the sensitivity of testing the gene effect with the three methods.
As described in section 3.3, log ratio is commonly used to identify differentially expressed
genes. So we calculated the log ratio for this hypothesis test. Both treatment groups were
contaminated with the same percentage (≤ 1%) of abnormal genes. From Figure 3.4, NPT
showed much higher power than LME and GEE with minimal contamination. With 0.5%
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Figure 3.3: The power curves of testing time effect with up to 2% contamination. The design was assumed
to be unbalanced with unstructured correlation correlation. There were 2 time points in the experiment.
contamination, NPT has 89.2% power, whereas LME and GEE have powers of 31.4% and
24.3%, respectively.
Fourthly, we conducted power simulation analysis for treatment and time interaction.
The data generation is similar to that for time effect except that only one treatment group
was contaminated with abnormal genes in this study. We ran simulation up to 1.5% contam-
ination to illustrate how the three power curves approached to 100%. As shown in Figure
3.5, the power curves of the three methods were very close thought NPT reached 80% and
100% powers first.
The fifth test was for treatment and gene interaction. Bootstrap data were generated
in a similar way to that for test of the gene effect. The only exception is that we only
contaminated one treatment group with up to 2% of abnormal genes. The performance of
NPT was obviously higher than the other two methods (Figure 3.6). The power of NPT
went to above 90% at 1% contamination, whereas the powers of GEE and LME reached
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Figure 3.4: The power curves of testing time effect with up to 1% contamination. The design was assumed
to be unbalanced with unstructured correlation correlation. There were 2 time points in the experiment.
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Figure 3.5: The power curves of testing time effect with up to 1.5% contamination. The design was assumed
to be unbalanced with unstructured correlation correlation. There were 2 time points in the experiment.
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90% at close to 2% contamination.
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Figure 3.6: The power curves of testing time effect with up to 2% contamination. The design was assumed
to be unbalanced with unstructured correlation correlation. There were 2 time points in the experiment.
Our sixth test was conducted for time and gene interaction. We used the same data-
generating process as for test of time effect. We ran the simulation up to 1.5% contamination
with two time points. As the other bootstrap studies, NPT performed the best in the
power analysis (Figure 3.6). Its power curve increased sharply above 90% at about 0.5%
contamination. GEE and LME achieved above 90% power with at least 1% contamination.
To evaluate the effects of real microarray data on the statistical powers of these methods,
we generated Gaussian distributed random numbers for power analysis. We want to know
the behaviors of the three methods in such an ideal condition.
The simulations were only conducted for the time effect and the time*gene interaction.
For the test of the time effect, the data for one time point were generated from a normal
distribution with mean 0 and standard deviation 1. The data for the other time point were
based on a normal distribution with a mean varying from 0 to 0.4. Its standard deviation
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Figure 3.7: The power curves of testing time effect with up to 1.5% contamination. The design was assumed
to be unbalanced with unstructured correlation correlation. There were 2 time points in the experiment.
was still 1. For the test of time*gene interaction, the data for the majority of genes came
from a normal distribution with mean 0 and standard deviation 1. The remaining gene
expressions had a mean of 2 and a standard deviation of 1. As shown in Figures 3.8 and
3.9, the three methods behaved equivalently well for the normality assumption.
Of all the bootstrap simulations, NPT were constantly the first method to reach a high
power (> 90%). In most of the conditions, especially for those tests for the gene effect or
its interaction, it performed significantly better than LME and GEE. As shown in Figure
3.2, whereas the large number of genes may have a negative effect on the performance of
LME and GEE, we expected the performance of NPT increases with the number of genes.
NPT is a robust method as well. It performed as good as LME and GEE for Gaussian
distributed data. For the noisy intensity data, it maintains a high sensitivity to detect
a very low contamination (usually < 1% contamination) with above 80% power. As we
used real microarray data for bootstrap, we expect NPT have similar high performance in
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Figure 3.8: The power curves of testing time effect with up to 1.5% contamination. The design was assumed
to be unbalanced with unstructured correlation correlation. There were 2 time points in the experiment.
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Figure 3.9: The power curves of testing time effect with up to 1.5% contamination. The design was assumed
to be unbalanced with unstructured correlation correlation. There were 2 time points in the experiment.
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microarray applications.
3.6 Real data analysis
Cytotoxic T lymphocyte (T cells) is of key importance in cell-mediated immune response.
They destroy virally infected cells, tumor cells, and other disease cells. The effective im-
mune response to a foreign antigen depends on rapid activation and proliferation of T cells.
Interleukin-2 (IL-2) cytokine plays an important role in stimulating the growth, differenti-
ation and survival of antigen-selected cytotoxic T cells via the activation of the expression
of specific genes (Beadling et al. (1993)). A number of studies have been conducted to
illustrate the gene expression profile with IL-2 stimulation and approximately 3000 IL-2-
regulated genes were identified in human T cells (Beadling and Smith (2002); Kovanen
et al. (2005); Mzali et al. (2005); Gatzka et al. (2006); Kovanen et al. (2008)).
Time course microarray study was recently carried out in Sandia National Laboratories
to explore the expression profiles of IL-2 regulated genes during T cell proliferation and
differentiation (Zhang et al. (2007)). The murine T cell line CTLL-2 was cultured in the
presence or in the absence (control) of IL-2 stimulation. There were 3 independent cell
cultures for either treatment group. For each culture, cells were harvested at time points 4
h and 8 h. Harvested cell samples were applied to microarray experiment with one array
per sample. The Affymetrix Mouse Genome 430 2.0 Array were used. It comprises 45,000
probes representing approximately 30,000 mouse genes. We calculated the gene expression
profile for each array by averaging the multiple probes of the gene. The gene profiles were
log-transformed, and were then normalized with quantile-normalization method (Bolstad
et al. (2003)). The normalized data were analyzed by gene set enrichment approach with
the proposed statistics.
We used the C2 collection of gene sets from the Molecular Signature Database (MSigDB)
of Broad Institute. C2 collection are curated gene sets that came from various sources such as
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online pathway database, biomedical literature, and knowledge of domain experts (Newman
and Weiner (2005)). The collection contains 1892 gene sets. The previous simulation studies
have shown that a gene set consisting at least 50 genes would achieve sufficient statistical
power and satisfactory type I error rate. Of the 1892 gene sets, 548 sets consist at least 50
genes. The distribution of the number of genes from the 548 gene sets was shown in Figure
3.10. The majority of gene sets (> 300) have between 50 and 100 genes. The largest gene
set consists of 1601 genes. They are the genes enriched in mouse neural stem cell comparing
to differentiated brain and marrow cells (Ramalho-Santos et al. (2002)).
In order to identify the gene sets that are regulated by IL-2, we used NPT to perform
hypotheses testing for two effects, the interactions of treatment and time, and the main effect
of IL-2 treatment. It is tempting to carry out test for the interaction of treatment and gene,
for it would detect the gene sets that have a subset of genes differentially expressed between
treatment groups. However, gene set enrichment analysis is only concerned with detecting
expression alteration for the whole gene set, because a subset of genes would overlap with
other gene sets and it does not convey all genetic information for an independent biological
function. Therefore, we were not interested in such kind of gene sets. The P value of each
test was converted to false discovery rate (FDR) with Storey’s positive FDR method (Storey
(2002)). The FDR was calculated by R package fdrtool (Strimmer (2008)).
With FDR cut off value at 5%, 285 out of 548 gene sets showed significant treatment*time
interaction. In other words, they had differential expression between two treatment groups
at 4 or 8 or both hours after IL-2 stimulation, but their expression patterns were distinct
between the two time points. The biological analysis of the 285 gene sets need to be further
explored. Of the remaining 263 gene sets, statistical tests for the treatment effect were
performed, and 20 sets were identified to be significantly differentially expressed. Thus, all
together we have 283 gene sets that are responsible to IL-2. The 20 selected gene sets for
the treatment effect were reported in Table (3.8). Their FDR values were displayed as well.
There were 1,760 distinct genes involved in the 20 gene sets.
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Figure 3.10: The histogram showed the distribution of the size of the 548 gene sets used for data analysis.
In order to illustrate how the gene expression in a selected gene set were uniformly
altered by IL-2 over time period, we calculated ratio score by the formula: ratio score =
(log(G11)− log(G12))− (log(G21)− log(G22)), where Gij is the gene expression value at the
ith treatment group, and at the jth time point. We expected that the ratio scores in the
20 selected gene sets to be close to zero. The ratio scores for each gene sets were plotted in
Figures 3.11 and 3.12. They were distributed around the horizontal line at y=0, implying
NPT selected the desired gene sets.
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Gene Set FDR
ROSS CBF 0.020
PEART HISTONE UP 0.047
ROME INSULIN 2F UP 0.038
HIVNEFPATHWAY 0.025
CELL ADHESION 0.041
HADDAD HSC CD7 UP 0.010
FLECHNER KIDNEY TRANSPLANT REJECTION PBL UP 0.009
SHEPARD POS REG OF CELL PROLIFERATION 0.029
HADDAD CD45CD7 PLUS VS MINUS UP 0.010
HSIAO LIVER SPECIFIC GENES 0.031
TAKEDA NUP8 HOXA9 3D UP 0.030
CROMER HYPOPHARYNGEAL MET VS NON DN 0.028
VANASSE BCL2 TARGETS 0.006
GAMMA UNIQUE FIBRO DN 0.018
TNFALPHA ADIP DN 0.026
GN CAMP GRANULOSA DN 0.041
AGED MOUSE NEOCORTEX UP 0.026
ADIP DIFF UP 0.006
HSA04370 VEGF SIGNALING PATHWAY 0.016
HSA04520 ADHERENS JUNCTION 0.008
Table 3.8: The IL-2 regulated gene sets.
T lymphocyte activation with IL-2 culminates many cellular processes, including blas-
togenesis, cell cycle progression, DNA replication and Mitosis (Beadling and Smith (2002)).
Many of the selected gene sets are responsible such complicated biological functions. The
gene set, VANASSE BCL2 TARGETS, consists of genes differentially expressed in murine
CD19+ B cells overexpressing Bcl-2, a key gene regulating apoptosis. IL-2 is known to have
antiapoptotic effects that proliferate T cells (Lenardo et al. (1999)). The other gene sets
having similar functions of cell proliferation and aging are SHEPARD POS REG OF CELL
PROLIFERATION, GAMMA UNIQUE FIBRO DN, and AGED MOUSE NEOCORTEX
UP. Some selected gene sets, such as FLECHNER KIDNEY TRANSPLANT REJECTION
PBL UP and HSIAO LIVER SPECIFIC GENES, are involved in the immune response of T
cell. The gene sets, HADDAD HSC CD7 UP and HADDAD CD45CD7 PLUS VS MINUS
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Figure 3.11: The plots of log odds ratio for the first 10 selected gene sets.
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Figure 3.12: The plots of log odds ratio for the second 10 selected gene sets.
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UP, are involved in T cell development. The gene sets, CELL ADHESION and HSA04520
ADHERENS JUNCTION, are responsible to the interaction of T cell with foreign cell, the
core function of T cell mediated cytotoxicity. Insulin 2F related gene set, ROME INSULIN
2F UP, plays multiple roles in many gene regulating pathways including cell proliferation.
The gene set HSA04370 VEGF SIGNALING PATHWAY often functions in tumor agiogen-
esis. The relationship of these gene sets with IL-2 stimulation is worth further investigation.
Most microarray data analyses in biological literature employ univariate analysis for each
individual gene or probe. A list of genes is selected by FDR, and pathway analysis is then
conducted for the candidate genes. On one hand, such analysis suffers low statistical power
of detecting desired genes. On the other hand, the reported pathways are often misleading
because they are based on one or very few selected genes, and those genes are most likely
involved in many pathways. The proposed NPT methods via gene set enrichment analysis
provides a promising alternative for biological functional analysis. The reported gene sets
are highly relevant to the key functions of IL-2. It suggests high performance of the proposed
methods in longitudinal microarray analysis.
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Chapter 4
Rank-based Hypothesis Testing in
Unbalanced Heteroscedastic Nested
Design
In this chapter, we consider statistical testing for high dimensional data from a nested
design when the number of lower-level factors is large. The proposed methods have potential
applications in biological and meterological studies.
4.1 Model specification
Consider the nested design model:
Xijk = µ + αi+ βij + eijk, i = 1, . . . , a; j = 1, . . . , bi; k = 1, . . . , cij,
where α and β are fixed effects due to factor A and B, respectively. eijk is the error term
with mean zero and variance σij <∞. And we assume E(eijk4) = δij < ∞. We consider the
case that a and cij are fixed and bi → ∞.
Let
Xijk ∼ Fij, i = 1, . . . , a; j = 1, . . . , bi; k = 1, . . . , cij
We have the decomposition
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Fij = M + Ai + Bij,
where
a∑
i=1
Ai =
a∑
i=1
Bij
bi∑
j=1
Bij = 0
We use the following notations in this chapter. X∗ denotes a monotone transformation of
X. X˜ denotes the average of X ij·’s.
4.2 Test statistics
To test the hypothesis that there is no main effect for A factor, i.e. H0(A): Ai = 0 for all i,
we use a Wald-type test statistics
Qx∗(A) = W
′C ′A(CAVˆ C
′
A)
−1CAW, (4.2.1)
where W = (X˜
∗
1··, ..., X˜
∗
a··)
′, CA = (1a−1j − Ia−1), Vˆ = diag(ηˆ1, ..., ηˆa), and
ηˆi =
1
b2i
bi∑
j=1
S2ij,X∗
cij
,
with
S2ij,X∗ = (cij − 1)−1
cij∑
k=1
(X
∗
ijk − X¯
∗
ij·)
2.
To test H0(B): Bij = 0 for all i and j, we use a modified F test.
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FX∗(B) =
MSTB
MSE
,
where
MSTB =
1
a∑
i=1
bi − a
a∑
i=1
bi∑
j=1
(X˜∗ij· − X˜∗i··)2,
MSE =
1
a
a∑
i=1
1
bi
bi∑
j=1
1
cij(cij − 1)
cij∑
k=1
(X∗ijk − X¯∗ij·)2 =
1
a
a∑
i=1
1
bi
bi∑
j=1
S2ij,x
cij
,
and n is the total number of samples.
4.3 Main results based on original observations
First, we consider the balanced case such that bi = b for all i. We have
MSTB =
1
ab− a
a∑
i=1
b∑
j=1
(X˜ij· − X˜i··)2,
and
MSE =
1
ab
a∑
i=1
b∑
j=1
1
cij(cij − 1)
cij∑
k=1
(Xijk − X¯ij·)2 = 1
ab
a∑
i=1
b∑
j=1
S2ij,x
cij
.
Theorem 4.3.1. For testing H0(A): Ai = 0 for i=1,...,a, let QX(A) be the statistic given
in (4.2.1). If Xijk has the finite fourth moment, then under H0(A),
QX(A)
d→ χ2a−1
holds for all ni ≥ 2, i=1, ..., I.
The proof is similar to that of theorem 3.2.1 in Wang (2004).
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Theorem 4.3.2. For testing H0(B), suppose Xijk have finite variance σ
2
ij and
lim sup(ab)−1
a∑
i=1
b∑
j=1
1
cij
E[Xijk − E(Xijk)]4 <∞.
Set
τB =
2
ab
a∑
i=1
b∑
j=1
σ4ij
cij(cij − 1) ,
and
σ2 =
1
ab
a∑
i=1
b∑
j=1
σ2ij
cij
As b → ∞,
√
ab(Fx(B)− 1)√
τB/σ2
d→ N(0, 1)
holds when cij >3 stay fixed.
Proof: By Lemma A.1 And A.2, we only need to consider the asymptotic distribution of
TB(e) = n(a, b)
√
ab(PB(e)−MSE)
under H0(B), where n(a,b) = mini,j{nij}, and
PB(e) =
1
ab
a∑
i=1
b∑
j=1
e¯2ij·.
We have
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TB(e) = n(a, b)
√
ab(PB(e)−MSE)
=
n(a, b)√
ab
a∑
i=1
b∑
j=1
[
e¯2ij· −
cij∑
k=1
(eijk − e¯ij·)2
cij(cij − 1)
]
=
n(a, b)√
ab
a∑
i=1
b∑
j=1
cij∑
k 6=k′
eijkeijk′
cij(cij − 1) .
It is clear that E[TB(e)] = 0, and as b → ∞,
V ar[TB(e)] =
n2(a, b)
ab
V ar
[
a∑
i=1
b∑
j=1
cij∑
k 6=k′
eijkeijk′
cij(cij − 1)
]
=
2n2(a, b)
ab
a∑
i=1
b∑
j=1
σ4ij
cij(cij − 1)
< ∞.
We will use Lyapounov’s theorem to obtain the asymptotic distribution of T1A(e). Lya-
pounov’s condition will be satisfied if
L(b) =
b∑
j=1
E
∣∣∣∣∣n(a, b)√ab
a∑
i=1
cij∑
k 6=k′
eijkeijk′
cij(cij − 1)
∣∣∣∣∣
4
→ 0.
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L(b)
=
b∑
j=1
E
∣∣∣∣∣n(a, b)√ab
a∑
i=1
cij∑
k 6=k′
eijkeijk′
cij(cij − 1)
∣∣∣∣∣
4
=
b∑
j=1
n4(a, b)
(ab)2
a∑
i,i1,i2,i3
cij∑
k 6=k′
ci1j∑
k1 6=k′1
ci2j∑
k2 6=k′2
ci3j∑
k3 6=k′3
E(eijkeijk′ei1jk1ei1jk′1ei2jk2ei2jk′2ei3jk3ei3jk′3)
cij(cij − 1)ci1j(ci1j − 1)ci2j(ci2j − 1)ci3j(ci3j − 1)
= O(
b∑
j=1
n4(a, b)
(ab)2
a∑
i,i1
cij∑
k 6=k′
ci1j∑
k1 6=k′1
E(e2ijk)E(e
2
ijk′)E(e
2
i1jk1
)E(e2i1jk′1
)
c2ij(cij − 1)2c2i1j(ci1j − 1)2
)
= O(
n4(a, b)
a2b2
b∑
j=1
(
a∑
i=1
σ4ij
cij(cij − 1))
2)
= O(b−1).
This completes the proof.
4.4 Main results based on ranks
In this section, we use the overall (mid-)ranks (Rijk) of the original observations to test
hypotheses. We denote H(x) = N−1Σi,jnijFij(x) and Yijk = H(Xijk), the average distribution
function, and denote Hˆ the average of the left and right continuous version of the edf and
Zijk = Hˆ(Xijk).
Then, we have
Rijk = NHˆ(Xijk) + 0.5.
Theorem 4.4.1. For testing H0(A): Ai = 0 for i=1,...,a, let QR(A) be the statistic given
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in (4.2.1) with X∗ijk = Rijk. If Xijk has the finite fourth moment, then under H0(A),
QR(A)
d→ χ2a−1
holds for all ni ≥ 2, i=1, ..., I.
The proof is similar to that of theorem 3.4.1 in Wang (2004).
Theorem 4.4.2. For testing H0(B): all Bj = 0 when a is fixed and b is large. Let FR(B)
be the statistics FX∗(B) with X
∗
ijk = Rijk. As b→∞,
√
ab(FR(B)− 1)√
τB/σ2
d→ N(0, 1),
where τB and σ
2 are defined in Theorem 3.2 with evaluation at Yijk.
ProofWe denote MSTB(Y), MSTB(Z) and MSTB(R) the MSTB evaluated on Y, Z and
R respectively. Note that MSTB(R)/N
2 = MSTB(Z). By lemma A.3 and A.4, it suffices to
obtain the asymptotic distribution of
T (Z − E(Y )) = n(a, b)
√
ab(PB(Z − E(Y ))−MSE(Z)).
We will show that T(Z - E(Y)) – T(Y – E(Y)) = op(1) for
T (Y − E(Y ))√
τB/σ2
d→ N(0, 1)
by theorem (4.3.2). The proof is similar to Lemma A.4 after the expand of T(Z - E(Y)) and
T(Y – E(Y)) as in proof of theorem (4.3.2).
Appendix
Lemma A.1 Under the settings and assumptions of Theorem (4.3.2), we have
n(a, b)(MSE - σ2) → 0 in probability, where n(a,b) = mini,j{nij}.
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Proof Note that
E(MSE) = E(
1
ab
a∑
i=1
b∑
j=1
S2ij,X
cij
) = σ2,
and
(ab)2Var(MSE) =
a∑
i=1
b∑
j=1
1
c2ij(cij − 1)2
Var
(
cij − 1
cij
cij∑
k=1
e2ijk −
1
cij
cij∑
k 6=k′
eijkeijk′
)
=
a∑
i=1
b∑
j=1
1
c4ij
[
cij∑
k=1
(E(e4ijk)− σ4ij) +
2cij
cij − 1σ
4
ij
]
=
a∑
i=1
b∑
j=1
1
c4ij
[
cij∑
k=1
δ4ij −
cij(cij − 3)
cij − 1 σ
4
ij
]
≤
a∑
i=1
b∑
j=1
1
c4ij
cij∑
k=1
δ4ij.
(cij > 3)
Thus
Var[n(a, b)MSE] ≤ 1
(ab)2
a∑
i=1
b∑
j=1
n2(a, b)
n4ij
nij∑
k=1
δ4ij → 0
as b→∞. Therefore, n(a, b)(MSE - σ2) → 0 in probability.
Lemma A.2 Define
PB(e) =
1
ab
a∑
i=1
b∑
j=1
e˜2ij·
Under the settings and assumptions of Theorem 3.2, and under H0(B), we have
T ∗B(e) = n(a, b)
√
ab(MSTB − PB(e)) P→ 0
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as b→∞, where n(a,b) = mini,j{cij}.
Proof Under H0(B),
MSTB =
1
a(b− 1)
a∑
i=1
b∑
j=1
(e˜ij· − e˜i··)2
=
1
a(b− 1)
a∑
i=1
(
b− 1
b
b∑
j=1
e˜ij· − 1
b
b∑
j 6=j′
e˜ij·e˜ij′·
)
=
1
ab
a∑
i=1
b∑
j=1
e˜2ij· −
1
ab(b− 1)
a∑
i=1
b∑
j 6=j′
e˜ij·e˜ij′·.
Thus, we have
T ∗B(e) = n(a, b)
√
ab
(
− 1
ab(b− 1)
a∑
i=1
b∑
j 6=j′
e˜ij·e˜ij′·
)
= − n(a, b)√
ab(b− 1)
a∑
i=1
b∑
j 6=j′
e˜ij·e˜ij′·.
It follows that
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E[T ∗B(e)]
2 =
n2(a, b)
ab(b− 1)2E
[
a∑
i=1
b∑
j 6=j′
e˜ij·e˜ij′·
]2
=
2n2(a, b)
ab(b− 1)2
a∑
i=1
b∑
j 6=j′
E[e˜2ij·e˜
2
ij′·]
=
2n2(a, b)
ab(b− 1)2
a∑
i=1
b∑
j 6=j′
σ2ij
cij
σ2ij′
cij′
≤ 2n
2(a, b)
ab(b− 1)
a∑
i=1
b∑
j=1
σ4ij
cij
= O(b−1).
Therefore,
T ∗B(e) = n(a, b)
√
ab(MSTB − PB(e)) P→ 0
as b → ∞.
Lemma A.3 Under the settings and assumptions of Theorem 4.2, we have
n(a, b)(MSE/N2 - σ2) → 0 in probability as b → ∞, where n(a,b) = mini,j{nij} and a and
cij remain fixed.
Proof For details, refer to the proof of Lemma 3.7.8 in Wang (2004).
Lemma A.4 Let PB(Z – E(Y)) be defined as PB(E) in lemma A.2 with eijk replaced by
Zijk – E(Yijk). Then under H0(B) and under the settings and assumptions of Theorem 4.2,
as b → ∞, we have
T ∗B(Z − E(Y )) = n(a, b)
√
ab(MSTB(Z)− PB(Z − E(Y ))) P→ 0
as b→∞, where n(a,b) = mini,j{cij} ≥ 2.
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Proof By lemma A.2, TB*(Y - E(Y)) = op(1) under HB(0). Therefore, it suffices to show
that DZY = TB*(Z - E(Y)) - TB*(Y - E(Y)) = op(1). Note that E(Z) = E(Y). Using the
similar decompositions as in lemma A.2, under HB(0) we have
T ∗B(Y − E(Y )) = n(a, b)
√
ab
[
− 1
ab(b− 1)
a∑
i=1
b∑
j 6=j′
(y¯ij· − p¯ij·)(y¯ij′· − p¯ij′·)
]
= − n(a, b)√
ab(b− 1)
a∑
i=1
b∑
j 6=j′
(y¯ij·y¯ij′· − y¯ij′·p¯ij· − y¯ij′·p¯ij′· + p¯ij·p¯ij′·),
and
T ∗B(Z − E(Y )) = n(a, b)
√
ab
[
− 1
ab(b− 1)
a∑
i=1
b∑
j 6=j′
(z¯ij· − p¯ij·)(z¯ij′· − p¯ij′·)
]
= − n(a, b)√
ab(b− 1)
a∑
i=1
b∑
j 6=j′
(z¯ij·z¯ij′· − z¯ij′·p¯ij· − z¯ij′·p¯ij′· + p¯ij·p¯ij′·).
Then we have DZY = D1 + D2, where
D1 = − n(a, b)√
ab(b− 1)
a∑
i=1
b∑
j 6=j′
(z¯ij· − y¯ij·)(z¯ij′· − y¯ij′·),
and
D2 = − 2n(a, b)√
ab(b− 1)
a∑
i=1
b∑
j 6=j′
(z¯ij· − y¯ij·)(y¯ij′· − p¯ij′·)
= − 2n(a, b)√
ab(b− 1)
a∑
i=1
b∑
j 6=j′
∑
k,k′
(z¯ijk − y¯ijk)(y¯ij′k′ − p¯ij′k′)
cijcij′
.
Because
sup
x
(Hˆ(x)−H(x)) = Op(N−1/2),
we have
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D1 = Op(
√
abn(a, b)/N) = op(1).
Note E(D2) = 0 for E(zijk) = E(yijk).
E(D2)
2 =
4n(a, b)2
ab(b− 1)2
a∑
i=1
b∑
j 6=j′
∑
k,k′
(z¯ijk − y¯ijk)2(y¯ij′k′ − p¯ij′k′)2
c2ijc
2
ij′
≤ 4n(a, b)
2
ab(b− 1)2
a∑
i=1
b∑
j 6=j′
∑
k,k′
1
c2ijc
2
ij′
=
4n(a, b)2
ab(b− 1)2
a∑
i=1
b∑
j 6=j′
1
cijcij′
≤ 4
b− 1
= op(1).
This completes the proof.
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Chapter 5
Summary and future studies
5.1 Summary of the current study
In recent years, high throughput technology have made available a great deal of biological
data to the researchers. The technology has been increasingly applied to more complicated
design such as time course study or nested design. The scientific community is in great
need of statistical tools to analyze such high dimensional data. We attempted to provide
a set of statistics for main effect tests for which traditional methodology is not successful.
Robust statistics have been obtained for high dimensional data with heteroscadastic within
subject correlation and unbalanced design. The asymptotic properties were provided as
well. Comprehensive simulation studies have been conducted to test our methods in various
conditions. In all conditions, our proposed methods provided satisfactory type I error rate.
Power analysis were conducted to compare the approaches to linear mixed-effects model
(LME) and generalized estimating equations (GEE). To allow the simulated data to closely
represent real data, we used bootstrap to generate data based on applications from array
CGH and expression microarray. The proposed methods were very sensitive with statistical
testing power superior to that of LME and GEE in all tests. Our methods were applied to two
recent longitudinal researches, Wilms’ tumor aCGH study and IL-2 responsive microarray
study. Comparing the literature reports, we provided results that were statistically more
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justified and biologically more interpretable. It is promising to extend the methodology to
a broader area of biological applications.
5.2 Future studies
Similar to the proposed methods, statistical methodology could be implemented and devel-
oped to a wide range of high dimensional data applications. We mainly consider three areas
for future studies.
5.2.1 Spatially correlated image data
In Chapter 2, we focused on analysis longitudinal array CGH data. An important fea-
ture about array CGH is that probes are spatially correlated that adjacent probes tend
to be deleted or amplified together. Similar spatial correlation is also observed in other
image technology such as Magnetic Resonance Imaging (MRI) and Geographic Information
Systems (GIS) imaging. Although most of current analyses of aCGH data assumed inde-
pendence between probes (Weir et al. (2007); Sabatti and Lange (2008)), a few attempts
have been made to consider the correlation. Fridlyand et al. (2004) used a hidden Markov
model for the sequence of probes. However, it has to assume the correlation is exponentially
distributed and the measures are log-normal distributed. Tibshirani and Wang (2008) pro-
posed fused LASSO technique to constrain the copy number difference between neighboring
probes. We implemented their method, but found it impossible to be applied to arrays with
more than 100K probes due to the computation cost.
Wang et al. (2008) proposed a non-parametric clustering method for functional data
whose time series satisfy an α−mixing condition. As the spatial sequence of probes bears
similar correlation property to that of time series data, it is desirable to develop method-
ology for longitudinal aCGH study based on their techniques with proper consideration of
correlations between time points.
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5.2.2 Genetic interaction and gene networking
It is essential to elucidate gene-gene interaction for understanding how the basic biological
activities of an organism are regulated by its genome. It has been a active research area
to investigating genetic interaction and gene networking with high throughput technology
(Brem et al. (2005); Zhong and Sternberg (2006)). In Chapter 3, we applied our test
statistics to gene set enrichment analysis (GSEA) and detected activated gene groups. The
selected genes within the same group are good candidates for investigating gene networking.
Furthermore, our test statistics are potentially useful for test-based gene clustering and
classification (Liao and Akritas (2007)).
5.2.3 High dimensional data integration
Nowadays, microarray or array CGH data are often collected from multiple centers or are
acquired from various sources. It is important to control the batch effects between sources
before data analysis. Furthermore, the multiple centers often use different platforms or ver-
sions of chips. Technically it is hard to integrate the data into a unified format (Irizarry et al.
(2005)). In Chapter 4, we provided test statistics for nested design with high dimensional
variables. They are intended to be used for high dimensional data integration. Simulation
and real data anlaysis need be conducted to verify our methods.
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Appendix A
R codes for data analysis
In this Appendix, we provide the R functions used for the simulation study and for the real
data analysis. They are listed in the order of the chapters.
A.1 R functions for longitudinal aCGH study
For all the functions presented in this section, there are two input parameters. One is for the
input data, named Data, d, or sim.data. The other is a vector of the number of replications
for each probe, and it is named n or ni in the following functions.
The input data should be a data matrix. Each row represents a time point, and each
column represents a probe. Let Xijk denotes the copy number of the ith probe, the jth time
point, and the kth replicate. The input data matrix should be in the following format.

x111 x112 · · x211 x212 · · xa1na
x121 x122 · · x221 x222 · · xa2na
· · · · · · · · ·
x1J1 x1J2 · · x2J1 x2J2 · · xaJna

where a is the number of probes, J is the number of time points, and na is the number
of replications of the ath probe.
The vector of the numbers of the replications is in the format of {n1, n2, · · ·, na}, where
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ni is the number of replications for the ith probe.
For the functions used by NPT, the output value is the statistic calculated by NPT. For
the functions of LME and GEE, a P value is reported.
A.1.1 R function for the test of the probe effect by NPT
# calculate the test statistic of the SNP effect for unbalanced data
calcStat.CN <- function(Data, n){
b <- nrow(Data)
a <- length(n)
X<-Data
VQ <- 0
MSE <- 0
for (i in 1:a) {
if (i==1) start <- 1 else {
start <- sum(n[1:(i-1)])+1
}
end <- sum(n[1:i])
temp <- X[,start:end]
temp.1 <- cbind(temp[,-1], temp[,1])
Xd <- temp-temp.1 # paired difference X_{ijk}-X_{ijk+1}
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Xd.mult1 <- kronecker(Xd, rep(1,b))
Xd.mult2 <- kronecker(rep(1,b), Xd)
Xd.prod1 <- Xd.mult1 * Xd.mult2
Xd.mult3 <- kronecker(rep(1,b^2), Xd.prod1)
Xd.mult4 <- kronecker(cbind(Xd.prod1[,-c(1,2)],
Xd.prod1[,c(1,2)]), rep(1, b^2))
Xd.prod2 <- Xd.mult3 * Xd.mult4
VQ <- VQ + sum(Xd.prod2)/(2*n[i]^2*(n[i]-1))
# MSE
Mean.1 <- apply(temp, 1, mean) #mean of row
Xm.d <- temp - Mean.1
Xmd.mult1 <- kronecker(Xm.d,rep(1,b))
Xmd.mult2 <- kronecker(rep(1,b),Xm.d)
Xmd.prod <- Xmd.mult1 * Xmd.mult2
MSE <- MSE + sum(Xmd.prod)/(n[i]*(n[i]-1))
}
TauA <- VQ /(a*b^2)
MSE <- MSE/(a*b)
ind <- rep(1:a, n)
Mean.B <- NULL # average over replication n, b*a matrix
for (i in 1:b) {
Mean.B <- rbind(Mean.B, tapply(X[i,], ind, mean))
}
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Mean.A <- apply(Mean.B, 2, mean)
A <- Mean.A - mean(Mean.A)
MST <- b / (a-1) * sum(A * A)
Stat <- sqrt(a) * (MST - MSE) / sqrt(TauA)
Stat
}
A.1.2 R function for the test of the time effect by NPT
# calculate the chi-sq statistic of time effect
# the unbalnaced design
calcStat.CN <- function(d, n.i){
I <- length(n.i)
J <- nrow(d)
L <- rbind(t(rep(1, J-1)), -diag(J-1))
#calculate means
id.i <- rep(1:I, n.i)
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calcMeanij <- function(vd) tapply(vd, id.i, mean)
mean.ij<-t(apply(d, 1, calcMeanij))
mean.j <- apply(mean.ij,1,mean)
#calculate eta
data.d <-d - t(apply(mean.ij, 1, rep, times=n.i)) # x_ijk - mean.ij
d1 <- kronecker(data.d, rep(1,J))
d2 <- kronecker(rep(1,J), data.d)
d.sq <- d1*d2
d.sq.ij <- t(apply(d.sq, 1, calcMeanij)/(n.i-1))
d.sq.j <- matrix(apply(d.sq.ij, 1, mean), J, J) # matrix of length J^2
eta <- t(L) %*% d.sq.j %*% L /I
Stat <- t(mean.j) %*% L %*% solve(eta) %*% t(L) %*% mean.j
Stat
}
A.1.3 R function for the test of the probe and time interaction
by NPT
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# calculate the test statistic of interaction effect for unbalanced data
calcStat.CN <- function(sim.data, n){
b <- nrow(sim.data)
a <- length(n)
X<-sim.data
# variance matrix V1 -- sum(\sigma^2_{i,jj1)) for any j, j1
V1 <- 0
V2 <- 0
V3 <- 0
MSE <- 0
for (i in 1:a) {
if (i==1) start <- 1 else {
start <- sum(n[1:(i-1)])+1
}
end <- sum(n[1:i])
temp <- X[,start:end]
temp.1 <- cbind(temp[,-1], temp[,1])
Xd <- temp-temp.1 # paired difference X_{ijk}-X_{ijk+1}
Xd.mult1 <- kronecker(Xd, rep(1,b))
Xd.mult2 <- kronecker(rep(1,b), Xd)
Xd.prod <- Xd.mult1 * Xd.mult2
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V.mult1 <- kronecker(rep(1,b^2), Xd.prod)
V.mult2 <- kronecker(cbind(Xd.prod[,-c(1,2)], Xd.prod[,c(1,2)]),
rep(1, b^2))
V.prod <- V.mult1 * V.mult2
#sigma^2 matrix
# sigma.sq <- matrix(apply(Xd.prod, 1, mean)/2, J)
# V1 <- V1 + sum(sigma.sq^2)/(n[i]*(n[i]-1))
V1.id <- c(TRUE, rep(c(rep(FALSE, b^2), TRUE), b^2-1))
V1 <- V1 + sum(V.prod[V1.id,])/(4*n[i]^2*(n[i]-1))
# V2 <- V2 + sum(sigma.sq %*% sigma.sq)/(J^2*n[i]*(n[i]-1))
V2 <- V2 + sum(V.prod)/(4*b^2*n[i]^2*(n[i]-1))
V3.id <- c(rep(c(rep(TRUE, b), rep(FALSE, b^2-b)), b-1), rep(TRUE, b),
rep(c(rep(FALSE, b), rep(c(rep(FALSE, b^2-b),
rep(TRUE, b)), b)), b-1))
V3 <- V3 + sum(V.prod[V3.id,])/(2*b*n[i]^2*(n[i]-1))
# MSE
Mean.1 <- apply(temp, 1, mean) #mean of row
Xm.d <- temp - Mean.1
Xmd.mult1 <- kronecker(Xm.d,rep(1,b))
Xmd.mult2 <- kronecker(rep(1,b),Xm.d)
Xmd.prod <- Xmd.mult1 * Xmd.mult2
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MSE <- MSE + sum(Xm.d*Xm.d)/(a*(b-1)*n[i]*(n[i]-1))
- sum(Xmd.prod)/(a*b*(b-1)*n[i]*(n[i]-1))
}
TauA <- 2* (V1 + V2 - V3) /(a*(b-1)^2)
# MSE <- MSE/(a*b)
ind <- rep(1:a, n)
Mean.AB <- NULL # average over replication n, b*a matrix
for (i in 1:b) {
Mean.AB <- rbind(Mean.AB, tapply(X[i,], ind, mean))
}
Mean.A <- t(matrix(rep(apply(Mean.AB, 2, mean), b), ncol=b))
Mean.B <- matrix(rep(apply(Mean.AB, 1, mean), a), nrow=b)
Mean <- mean(Mean.A)
AB <- Mean.AB - Mean.A - Mean.B + Mean
MST <- 1 / ((a-1)*(b-1)) * sum(AB * AB)
Stat <- sqrt(a) * (MST - MSE) / sqrt(TauA)
Stat
}
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A.1.4 Sample codes for LME and GEE calculations
We present two example functions for LME and GEE. They are used for the test of the
probe and the time interaction. For the tests of the main effects, the codes need only to be
slightly changed for the effect of interest.
## LME for the probe and time interactions
library(nlme)
calcStat.LME <- function(sim.data, n) {
I <- length(n)
J <- nrow(sim.data)
Time <- as.vector(row(sim.data))
SNP <- as.vector(t(matrix(rep(rep(1:I, n), J), ncol=J)))
Sub <- as.vector(col(sim.data))
CN <- as.vector(sim.data)
X <- cbind(SNP, Time, Sub, CN)
X <- data.matrix(X)
gls.o=gls(CN~SNP+Time+SNP*Time, data=data.frame(X),
corr=corSymm(form=~1|Sub))
anova(gls.o, type="marginal")$"p-value"[4]
}
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## GEE for the probe and time interaction.
library(geepack)
calcStat.GEE <- function(sim.data, n) {
I <- length(n)
J <- nrow(sim.data)
Time <- as.vector(row(sim.data))
SNP <- as.vector(t(matrix(rep(rep(1:I, n), J), ncol=J)))
Sub <- as.vector(col(sim.data))
CN <- as.vector(sim.data)
X <- cbind(SNP, Time, Sub, CN)
#X <- data.matrix(X)
family <- "gaussian" #"poisson"
gee.o=try(geese(CN~SNP+Time+SNP*Time, id=Sub,
data=data.frame(X), family=family), T)
if (!is(gee.o, "try-error")) geePvalue=c(summary(gee.o)$mean[4,4],
1) else geePvalue=c(0,0)
geePvalue # pvalue for the trt effect
}
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A.2 R functions for longitudinal microarray study with
treatment groups
For all the functions presented in this section, there are two input parameters. One is for
the input data, named Data or d. The other is a vector of the number of replications for
each probe, and it is named n or nik in the following functions.
The input data should be a data matrix. Each row represents a time point, and each
column represents a gene. Let Xijkl denotes the copy number of the ith treatment group,
the jth time point, and the kth gene, and the lth replicate. In the example of two treatment
groups, the input data matrix should be in the following format.

x1111 x1112 · · x1121 x1122 · · x11KniKx2111 x2112 · · x2121 x2122 · · x21KniK
x1211 x1212 · · x1221 x1222 · · x12KniKx2211 x2212 · · x2221 x2222 · · x22KniK
· · · · · · · · · · · · · · · · ·
x1J11 x1J12 · · x1J21 x1J22 · · x1JKniKx2J11 x2J12 · · x2J21 x2J22 · · x2JKniK

where K is the number of genes, J is the number of time points, and nik is the number
of replications of the kth probe in the ith treatment group.
The vector of the numbers of the replications is in the format of {n11, n12, ···, n1K , n21, n22, ··
·, n2K}, where nik is the number of replications for the kth gene in the ith treatment group.
For the functions used by NPT, the output value is the statistic calculated by NPT. For
the functions of LME and GEE, a P value is reported.
In Chapter 3, we only considered the cases with 2 treatment groups for it is the most
common. So in the sample codes, we assume two treatments group (I = 2).
A.2.1 R function for the test of the treatment effect by NPT
# calculate the test statistic of treatment effect.
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calcStat.CN <- function(Data, n.ik){
I <- 2
J <- nrow(Data)
K <- length(n.ik)/2
#calculate means
id.ik <- rep(1:(I*K),n.ik)
mean.ijk<-NULL
for (i in 1:J) {
mean.ijk <- rbind(mean.ijk, tapply(Data[i,],id.ik,mean))
}
# mean.ijk <- apply(Data, 1, tapply, INDEX=id.ik, FUN=mean)
mean.ik <- apply(mean.ijk,2,mean)
id.i<-rep(1:I, rep(K,I))
mean.i <- tapply(mean.ik, id.i, mean)
#calculate eta
Data.d <-Data - t(apply(mean.ijk, 1, rep, times=n.ik))
d1 <- kronecker(Data.d, rep(1,J))
d2 <- kronecker(rep(1,J), Data.d)
d.sq <- d1*d2
d.sq.ijk <- NULL
for (i in 1:J^2) {
d.sq.ijk <- rbind(d.sq.ijk, tapply(d.sq[i,], id.ik, sum))
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}d.sq.ijk <- t(t(d.sq.ijk)/(n.ik*(n.ik-1)))
eta <- sum(d.sq.ijk)/J^2/K^2 #eta1+eta2
Stat <- (mean.i[1]-mean.i[2])^2/eta
Stat
}
A.2.2 R function for the test of the time effect by NPT
# calculate the chi-sq statistic of time effect.
calcStat.CN <- function(d, n.ik){
I <- 2
J <- nrow(d)
K <- length(n.ik)/2
L <- rbind(t(rep(1, J-1)), -diag(J-1))
#calculate means
ind.ijk <- rep(1:(2*K), n.ik)
ind.jk <- rep(1:K, 2)
mean.ijk <- NULL # average over replication n, J*(2K) matrix
for (j in 1:J) {
mean.ijk <- rbind(mean.ijk, tapply(d[j,], ind.ijk, mean))
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}mean.jk <- NULL # average over replication n, J*K matrix
for (j in 1:J) {
mean.jk <- rbind(mean.jk, tapply(mean.ijk[j,], ind.jk, mean))
}
mean.j <- apply(mean.jk,1,mean) # J*1 vector
#calculate eta=LVL’
data.d <-d - t(apply(mean.ijk, 1, rep, times=n.ik))
d1 <- kronecker(data.d, rep(1,J))
d2 <- kronecker(rep(1,J), data.d)
d.sq <- d1*d2
d.sq.jk <- NULL
for (j in 1:J^2) {
d.sq.ijk <- tapply(d.sq[j,], ind.ijk, mean)/(n.ik-1)
d.sq.jk <- rbind(d.sq.jk, tapply(d.sq.ijk, ind.jk, mean))
}
d.sq.j <- matrix(apply(d.sq.jk, 1, mean), J, J)
eta <- t(L) %*% d.sq.j %*% L /I /K
Stat <- t(mean.j) %*% L %*% solve(eta) %*% t(L) %*% mean.j
Stat
}
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A.2.3 R function for the test of the gene effect by NPT
# calculate the test statistic of gene effect for unbalanced data
calcStat.CN <- function(d, n.ik){
I <- 2
J <- nrow(d)
K <- length(n.ik)/2
n <- n.ik[1:K]
X <- list(d[, 1:sum(n)], d[, (sum(n)+1):ncol(d)])
V1 <- 0
V2 <- 0
MSE <- 0
for (k in 1:K) { # for each gene
if (k==1) start <- 1 else {
start <- sum(n[1:(k-1)])+1
}
end <- sum(n[1:k])
sigma <- list(NULL, NULL) # sigma estimation for 2 trts
for (i in 1:I) { # for each trt
temp <- X[[i]][,start:end]
temp.1 <- cbind(temp[,-1], temp[,1])
Xd <- temp-temp.1 # paired difference X_{l}-X_{l+1}
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Xd.mult1 <- kronecker(Xd, rep(1,J))
Xd.mult2 <- kronecker(rep(1,J), Xd)
sigma[[i]] <- Xd.mult1 * Xd.mult2 / 2
Xd.mult3 <- kronecker(rep(1,J^2), sigma[[i]])
Xd.mult4 <- kronecker(cbind(sigma[[i]][,-c(1,2)],
sigma[[i]][,c(1,2)]), rep(1, J^2))
Xd.prod2 <- Xd.mult3 * Xd.mult4
V2 <- V2 + sum(Xd.prod2)/(n[k]^2*(n[k]-1))
# MSE
Mean.1 <- apply(temp, 1, mean) #mean of row
Xm.d <- temp - Mean.1
Xmd.mult1 <- kronecker(Xm.d,rep(1,J))
Xmd.mult2 <- kronecker(rep(1,J),Xm.d)
Xmd.prod <- Xmd.mult1 * Xmd.mult2
MSE <- MSE + sum(Xmd.prod)/(n[k]*(n[k]-1))
}
Xd.prod3 <- kronecker(sigma[[1]], rep(1, J^2)) * Xd.mult3
V1 <- V1 + 2 * sum(Xd.prod3) / n[k]^3
}
TauA <- 2*(V1 + V2) /(I^2*J^2*K)
MSE <- MSE/(I*J*K)
# MST
ind <- rep(1:(2*K), n.ik)
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Mean.K <- NULL
for (j in 1:J) {
Mean.K <- rbind(Mean.K, tapply(d[j,], ind, mean))
}
Mean.J <- apply(Mean.K, 2, mean) #1*2K matrix
ind.i <- rep(1:K, 2)
Mean.I <- tapply(Mean.J, ind.i, mean) # 1*K matrix
A <- Mean.I - mean(Mean.I)
MST <- I*J / (K-1) * sum(A * A)
Stat <- sqrt(K) * (MST - MSE) / sqrt(TauA)
Stat
}
A.2.4 R function for the test of the treatment and time interac-
tion by NPT
# calculate the chi-sq statistic of trt and time interaction.
calcStat.CN <- function(d, n.ik){
I <- 2
J <- nrow(d)
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K <- length(n.ik)/2
L <- rbind(t(rep(1, I*J-1)), -diag(I*J-1))
#calculate means
ind.ijk <- rep(1:(2*K), n.ik)
# ind.jk <- rep(1:K, 2)
ind.ij <- c(rep(1,K), rep(2,K))
mean.ijk <- NULL # average over replication n, J*(2K) matrix
for (j in 1:J) {
mean.ijk <- rbind(mean.ijk, tapply(d[j,], ind.ijk, mean))
}
mean.ij <- NULL # average over trts, J*I matrix
for (j in 1:J) {
mean.ij <- rbind(mean.ij, tapply(mean.ijk[j,], ind.ij, mean))
}
mean.ij.vec <- as.vector(mean.ij)
mean.j <- apply(mean.ij,1,mean) # J*1 vector
#calculate eta=LVL’
data.d <-d - t(apply(mean.ijk, 1, rep, times=n.ik))
d1 <- kronecker(data.d, rep(1,J))
d2 <- kronecker(rep(1,J), data.d)
d.sq <- d1*d2 # (J^2)*(IK)
d.sq.ij <- NULL # (J^2)*I
for (j in 1:J^2) {
d.sq.ijk <- tapply(d.sq[j,], ind.ijk, mean)/(n.ik-1)
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d.sq.ij <- rbind(d.sq.ij, tapply(d.sq.ijk, ind.ij, mean))
}
# d.sq.j <- matrix(apply(d.sq.jk, 1, mean), J, J) # J*J matrix
d.sq.i <- diag(I*J)
for (i in 1:I) {
d.sq.i[((i-1)*J+1):(i*J), ((i-1)*J+1):(i*J)] <-
matrix(d.sq.ij[,i], nrow=J)
}
eta <- t(L) %*% d.sq.i %*% L /K # (IJ)*(IJ)
Stat <- t(mean.ij.vec) %*% L %*% solve(eta)
%*% t(L) %*% mean.ij.vec
Stat
}
A.2.5 R function for the test of the treatment and gene interac-
tion by NPT
# calculate the test statistic of interaction effect of trt and gene
# for unbalanced data with unstructured correlation
calcStat.CN <- function(d, n.ik){
I <- 2
J <- nrow(d)
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K <- length(n.ik)/2
n <- n.ik[1:K]
X <- list(d[, 1:sum(n)], d[, (sum(n)+1):ncol(d)])
V1 <- 0
V2 <- 0
MSE <- 0
for (k in 1:K) { # for each gene
if (k==1) start <- 1 else {
start <- sum(n[1:(k-1)])+1
}
end <- sum(n[1:k])
sigma <- list(NULL, NULL) # sigma estimation for 2 trts
for (i in 1:I) { # for each trt
temp <- X[[i]][,start:end]
temp.1 <- cbind(temp[,-1], temp[,1])
Xd <- temp-temp.1 # paired difference X_{l}-X_{l+1}
Xd.mult1 <- kronecker(Xd, rep(1,J))
Xd.mult2 <- kronecker(rep(1,J), Xd)
sigma[[i]] <- Xd.mult1 * Xd.mult2 / 2
Xd.mult3 <- kronecker(rep(1,J^2), sigma[[i]])
Xd.mult4 <- kronecker(cbind(sigma[[i]][,-c(1,2)],
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sigma[[i]][,c(1,2)]), rep(1, J^2))
Xd.prod2 <- Xd.mult3 * Xd.mult4
V2 <- V2 + sum(Xd.prod2)/(n[k]^2*(n[k]-1))
# MSE
Mean.1 <- apply(temp, 1, mean) #mean of row
Xm.d <- temp - Mean.1
Xmd.mult1 <- kronecker(Xm.d,rep(1,J))
Xmd.mult2 <- kronecker(rep(1,J),Xm.d)
Xmd.prod <- Xmd.mult1 * Xmd.mult2
MSE <- MSE + sum(Xmd.prod)/(n[k]*(n[k]-1))
}
Xd.prod3 <- kronecker(sigma[[1]], rep(1, J^2)) * Xd.mult3
V1 <- V1 + 2 * sum(Xd.prod3) / n[k]^3
}
TauA <- 2*(V1/(I-1)^2 + V2) /(I^2*J^2*K)
MSE <- MSE/(I*J*K)
# MST
ind.ijk <- rep(1:(2*K), n.ik)
ind.i <- c(rep(1,K), rep(2,K))
ind.k <- rep(1:K, 2)
Mean.ijk <- NULL
for (j in 1:J) {
Mean.ijk <- rbind(Mean.ijk, tapply(d[j,], ind.ijk, mean))
}
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Mean.ik <- apply(Mean.ijk, 2, mean)
Mean.i <- tapply(Mean.ik, ind.i, mean)
Mean.k <- tapply(Mean.ik, ind.k, mean)
Mean <- mean(Mean.k)
A <- Mean.ik - rep(Mean.i, rep(K,I)) - rep(Mean.k, I) + Mean
MST <- J /((I-1) * (K-1)) * sum(A * A)
Stat <- sqrt(K) * (MST - MSE) / sqrt(TauA)
Stat
}
A.2.6 R function for the test of the gene and time interaction by
NPT
# calculate the test statistic of interaction effect of time
# and gene for unbalanced data with unstructured correlation
calcStat.CN <- function(d, n.ik){
I <- 2
J <- nrow(d)
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K <- length(n.ik)/2
n <- n.ik[1:K]
X <- list(d[, 1:sum(n)], d[, (sum(n)+1):ncol(d)])
V1 <- 0
V2 <- 0
V3 <- 0
MSE <- 0
for (k in 1:K) { # for each gene
if (k==1) start <- 1 else {
start <- sum(n[1:(k-1)])+1
}
end <- sum(n[1:k])
for (i in 1:I) { # for each trt
temp <- X[[i]][,start:end]
temp.1 <- cbind(temp[,-1], temp[,1])
Xd <- temp-temp.1 # paired difference X_{l}-X_{l+1}
Xd.mult1 <- kronecker(Xd, rep(1,J))
Xd.mult2 <- kronecker(rep(1,J), Xd)
Xd.prod <- Xd.mult1 * Xd.mult2
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V.mult1 <- kronecker(rep(1,J^2), Xd.prod)
V.mult2 <- kronecker(cbind(Xd.prod[,-c(1,2)],
Xd.prod[,c(1,2)]), rep(1, J^2))
V.prod <- V.mult1 * V.mult2
V1.id <- c(TRUE, rep(c(rep(FALSE, J^2), TRUE), J^2-1))
V1 <- V1 + sum(V.prod[V1.id,])/(4*n[k]^2*(n[k]-1))
V2 <- V2 + sum(V.prod)/(4*J^2*n[k]^2*(n[k]-1))
V3.id <- c(rep(c(rep(TRUE, J), rep(FALSE, J^2-J)), J-1),
rep(TRUE, J), rep(c(rep(FALSE, J), rep(c(rep(FALSE,
J^2-J), rep(TRUE, J)), J)), J-1))
V3 <- V3 + sum(V.prod[V3.id,])/(2*J*n[k]^2*(n[k]-1))
# MSE
Mean.1 <- apply(temp, 1, mean) #mean of row
Xm.d <- temp - Mean.1
Xmd.prod1 <- Xm.d*Xm.d
Xmd.mult1 <- kronecker(Xm.d,rep(1,J))
Xmd.mult2 <- kronecker(rep(1,J),Xm.d)
Xmd.prod2 <- Xmd.mult1 * Xmd.mult2
MSE <- MSE + sum(Xmd.prod1)/(n[k]*(n[k]-1))
- sum(Xmd.prod2)/(J*n[k]*(n[k]-1))
}
}
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TauA <- 2* (V1 + V2 - V3) /(I*K*(J-1)^2)
MSE <- MSE/(I*K*(J-1))
# MST
ind.ijk <- rep(1:(2*K), n.ik)
ind.jk <- rep(1:K, 2)
Mean.jk <- NULL
for (j in 1:J) {
Mean.ijk <- tapply(d[j,], ind.ijk, mean)
Mean.jk <- rbind(Mean.jk, tapply(Mean.ijk, ind.jk, mean))
}
Mean.j <- apply(Mean.jk, 1, mean)
Mean.k <- apply(Mean.jk, 2, mean)
Mean <- mean(Mean.k)
A <- Mean.jk - Mean.j - kronecker(t(Mean.k), rep(1,J)) + Mean
MST <- I /((J-1) * (K-1)) * sum(A * A)
Stat <- sqrt(K) * (MST - MSE) / sqrt(TauA)
Stat
}
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A.2.7 Sample codes for LME and GEE calculations
We present two example functions for LME and GEE. They are used for the test of the gene
and the time interaction. For the tests of the main effects and other interactions, the codes
need only to be slightly changed for the effect of interest.
## LME for the gene and time interactions
library(nlme)
calcStat.LME <- function(Data, n) {
I <- 2
J <- nrow(Data)
K <- length(n)/2
Trt <- as.vector(col(Data))
Trt[Trt<=sum(n)/2] <- 1
Trt[Trt>sum(n)/2] <- 2
Time <- as.vector(row(Data))
Gene <- as.vector(t(matrix(rep(c(rep(1:K, n[1:K]),
rep(1:K, n[(K+1):(2*K)])), J), ncol=J)))
Sub <- as.vector(col(Data))
Exp <- as.vector(Data)
X <- cbind(Trt, Gene, Time, Sub, Exp)
X <- data.matrix(X)
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gls.o=gls(Exp~Trt+Gene+Time+Time*Gene,
data=data.frame(X), corr=corSymm(form=~1|Sub))
anova(gls.o, type="marginal")$"p-value"[5]
}
## GEE for the gene and time interaction.
library(geepack)
calcStat.GEE <- function(Data, n) {
I <- 2
J <- nrow(Data)
K <- length(n)/2
Trt <- as.vector(col(Data))
Trt[Trt<=sum(n)/2] <- 1
Trt[Trt>sum(n)/2] <- 2
Time <- as.vector(row(Data))
Gene <- as.vector(t(matrix(rep(c(rep(1:K, n[1:K]),
rep(1:K, n[(K+1):(2*K)])), J), ncol=J)))
Sub <- as.vector(col(Data))
Exp <- as.vector(Data)
X <- cbind(Trt, Gene, Time, Sub, Exp)
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family <- "gaussian" #"poisson"
gee.o=try(geese(Exp~Trt+Gene+Time+Time*Gene, id=Sub,
data=data.frame(X), family=family), T)
if (!is(gee.o, "try-error")) geePvalue=c(summary(
gee.o)$mean[5,4],1) else geePvalue=c(0,0)
geePvalue # pvalue for the trt effect
}
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